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Abstract
The gene PAX6 is located on chromosome 11 (1 lpl3) and encodes a transcription factor (PAX6)
that is expressed early in development. The PAX6 protein is expressed in the developing eye,
regions of the brain, central nervous system (CNS), nasal epithelium and pancreas. PAX6 is best
known for its role in eye development with heterozygous mutations causing congenital ocular
malformations. However, it must be remembered that PAX6 has multiple functions in the brain
including specification of neuronal subtypes and axon guidance.
There is growing understanding of the role of PAX6 as a transcription factor during
development, and many of its DNA targets have recently been defined. However, almost nothing
is known about the proteins with which PAX6 interacts.
In the initial stage of my research I identified a conserved region consisting of the final 32 amino
acids of the PST (proline, serine and threonine rich) domain of PAX6. Based on sequence
homology and secondary structure predictions I classed this region as a novel domain, the 'C
terminal domain'. Next I used the yeast 2-hybrid system to investigate possible PAX6 protein
interactions. By screening a mouse brain cDNA library with the C terminal domain and whole
PST domain, I identified three novel and interesting interactors, Homer3, Dncll and Triml 1.
I re-confirmed these interactions in a pairwise manner using the yeast 2-hybrid system, and I
showed that the C terminal domain was vital for the interactions between PAX6 and Homer3 or
Dncll. Furthermore, certain C terminal mutations that are known to cause ocular malformations
in patients are also sufficient to reduce or abolish these interactions. I attempted to further
characterise the interactions by co-immunoprecipitation. However, this was not possible due to
technical difficulties.
Although speculative at present, the finding that PAX6 may interact with Homer3 (a component
of the post synaptic density) and Dncll (a subunit of the motor protein dynein) alludes to an
interesting new role for PAX6 in neurogenesis.
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1.1 PAX6 - A brief gene outline.
PAX6 has been identified as a master control gene for eye development and is located on
chromosome 11 (llpl3). The gene comprises 15 exons that span 28kb and this is illustrated in
Figure 1.1 (Glaser et al., 1992; Xu et al., 1999b). The PAX6 gene was first identified by
positional cloning as a candidate aniridia gene (Ton et al., 1991). PAX6 is expressed early in
development not only in the eye, but also in regions of the brain, the developing central nervous
system, nasal epithelium and the pancreas (Prosser and van Heyningen, 1998).
nh
0 12 3 4
PO I
5 5a 6 7 8 91011 12 13
->•
2kb
Figure 1.1 Genomic Structure ofPAX6.
Genomic organisation of the PAX6 gene. PAX6 is located on chromosome llpl3, and in this
diagram the PAX6 exons are shown as boxes. The diagram also shows 3 alternative promoters of
PAX6, which are labelled PO, PI and Pa. The major PAX6 start codon is contained at the end of
exon 4 and the stop codon is at the start of exon 13 (remainder of exon 13 coloured red to
illustrate the 3' untranslated region).
1.1.1 Alternative promoters.
Two promoters, PO and PI, of mouse Pax6 have been identified (as illustrated in Figure 1.1) that
direct the expression of different transcripts to different regions of the developing eye. PO
transcripts are found in the lens placode and corneal and conjunctival epithelia, whereas PI
transcripts are found in the lens placode, optic vesicle and the central nervous system (Xu et al.,
1999b). PO is regulated by upstream regulatory elements, one of which directs expression of PO
transcripts to pancreatic cells (4.6kb upstream of PO, U1 Figure 1.2), the other directing
expression to ectodermally derived eye structures, namely the lens, cornea, and conjunctival
epithelia (3.6kb upstream of PO, U2 Figure 1.2) (Williams et al., 1998; Kammandel et al., 1999).
The PI promoter directs expression of its transcripts to the optic vesicle, central nervous system
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(Xu et al., 1999b) and to the developing nasal epithelium (Plaza et al., 1995b); however, an
upstream regulatory element, in a 5kb fragment between promoters PO and PI (U3 Figure 1.2),
has been shown to direct expression of PI transcripts more specifically to regions of the brain
(dorsal telencephalon and hindbrain) and the spinal cord (Kammandel et al., 1999). It has also
been demonstrated in quail Pax6 that there is a temporal as well as spatial difference between the
transcripts produced from promoters PO and PI, with PI transcripts being detected before PO
transcripts specifically during neuroretinal development (Plaza et al., 1995b).
An enhancer element (U4, Figure 1.2) and potential promoter (Pa, Figure 1.1) was also
described in quail and mouse Pax6 that is located in intron 4 (Plaza et al., 1995a; Plaza et al.,
1995b; Kammandel et al., 1999) and directs expression of Pax6 to the neural ectoderm derived
structures, neural retina, the pigmented retina layer and the iris (Kammandel et al., 1999; Xu et
al., 1999b). More recently it has been shown that this highly conserved enhancer element
specifically mediates the formation of a distal1"811 to proximal'011 gradient of PAX6 (see 1.5.1) in
these regions (Baumer et al., 2002).
1.1.2 3' Regulatory elements involved in PAX6 expression.
It has also been proposed that 3' regulatory elements are involved in the expression of PAX6.
Two aniridia pedigrees are associated with chromosomal rearrangements 85-185kb distal to the
3'end of PAX6 with no mutation to the PAX6 transcription unit. It was proposed that these
disruptions were most probably due to a position effect, which disrupted the normal
chromosomal environment and obstructed PAX6 expression (Fantes et al., 1995). More
specifically 2 further examples of aniridia were shown where small deletions more than llkb
from the 3'end of PAX6 deleted 3' regulatory elements (D1 Figure 1.2) that were required for
PAX6 expression (Lauderdale et al., 2000).
All these chromosomal rearrangements and deletions actually occur in the final intron of another
gene called ELP4 (see Figure 1.2). However, it was reported that heterozygous loss of this gene
does not reproduce the aniridia phenotype seen in the original patients and so the heterozygous
loss of ELP4 alone is not the causative factor in these patients (Kleinjan et al., 2002). However,
PAX6 could have distant regulatory elements in the unrelated ELP4 gene as this has been
described previously for the alpha globin (Flint et al., 2001) and human growth hormone gene
clusters (Bonifer, 1999). Further to this point it has been convincingly shown that there is a
complex regulatory region (termed the downstream regulatory region or DRR by the author)
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about 130kb downstream of the PAX6 poly (A) addition site (DRR, Figure 1.2), which contains
regulatory elements that have been proven to direct reporter gene expression to distinct subsets
















Figure 1.2 The PAX6 and ELP4 loci and regulatory elements ofPAX6.
A. This shows the genomic organisation of the PAX6 gene (exons 0-13, as in Figure 1.1) and the
ELP4 gene (exons 1-10 from right to left).
B. This shows an enlarged diagram of the PAX6 and ELP4 genes as in A, however, this time the
upstream (U1-U3) and downstream {Dl, DRR) regulatory elements have been indicated. U1 and
U2 are 4.6kb and 3.6kb upstream of the exon 0, respectively. U3 is situated between exons 0 and
1; U4 is situated between exons 4 and 5. The downstream regulatory elements D1 and DRR are
1 lkb and 130kb downstream of the 3' end of PAX6 respectively.
The replicated function between the upstream (see 1.1.1) and downstream regulatory elements
(see Figure 1.2) has led to the tentative proposal that a DNA looping model may explain the long
range control of PAX6 gene expression (Kleinjan et al., 2001).
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1.2 The Pax protein family.
The first identified paired domain containing protein was encoded by the Drosophila
segmentation gene paired. Subsequently a multigene family of paired box containing genes (Pax
genes) was identified in mammals based on sequence homology to the highly conserved paired
domain of paired (Prosser and van Heyningen, 1998; Chi and Epstein, 2002). As already
mentioned (see 1.1) human PAX6 was first identified by positional cloning as a candidate
aniridia gene (Ton et al., 1991).
There are 9 members of the Pax (Paired-box") family in mammals (see Table 1.1 for a summary
of PAX 1-9) and these have been divided into 4 subsets due to sequence conservation, genomic
structure and conserved function (Chi and Epstein, 2002). The defining feature of all Pax
proteins is that they contain a 128 amino acid DNA binding domain termed the paired domain
(PD), which has been conserved over evolution (Walther and Gruss, 1991). The Pax protein
family is a group of transcription factors that have important functions in early development.
Mutations in the genes that encode these evolutionarily conserved proteins result in acute
developmental defects (see Table 1.2) in organisms ranging from flies, to mice and humans (Chi
and Epstein, 2002).
1.2.1 Evolution and conservation of PAX6.
It was initially thought that the evolution of the eyes in vertebrates and the structurally different
insect compound eye had different origins; however, with the function of PAX6 being
illuminated in eye development there is now more support for the hypothesis that eyes have
arisen once in evolution (Gehring and Ikeo, 1999), Heterozygous mutations in the PAX6 gene
were shown to cause similar phenotypes in mouse and humans: the Small eye phenotype in mice
(Hill et al., 1991) and aniridia in humans (see 1.7 for more detail). The murine and human PAX6
proteins are virtually identical in amino acid sequence and only differ by one amino acid in the
alternative splice form +5a (Glaser et al., 1992) (see 1.3.2). A PAX6 homolog was also identified
in Drosophila that transpired to be the previously described gene eyeless. This gene showed high
sequence homology to the mouse and human proteins in the paired and homeodomains and
mutation in the gene again lead to eye defects (Quiring et al., 1994). This finding that PAX6 is
required for the formation of the eye in both vertebrates and invertebrates has led to the proposal
that it is a master control gene that initiates eye development (Quiring et al., 1994).
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1.2.2 Ectopic expression studies.
The proposal of a monophyletic origin of the eye, notwithstanding the considerable divergence
in eye morphology, has been backed up even further by ectopic expression studies. The targeted
expression of the eyeless gene in various imaginal discs of Drosophila have shown that this is
sufficient to produce ectopic eye structures on wings, legs and antennae (Haider et al., 1995).
Furthermore, it has been shown that squid (Loligo opalescens) Pax6 which has significant
differences in sequence outside the paired domain and homeodomain, is also sufficient to
produce ectopic eye structures when expressed in Drosophila imaginal discs (Tomarev et al.,
1997). The ascidian Phallusia mammillata is an organism that is characteristic of the ancestor
from which vertebrates may have arisen and it contains a single photosensitive ocellus, which
corresponds to a primeval eye structure. It is interesting to note that this urochordate PAX6 is
also capable of inducing ectopic eye structures when expressed in Drosophila imaginal discs
(Glardon et al., 1997). It has also been shown that Pax6 is able to direct the formation of small
but fully differentiated ectopic eyes in the vertebrate Xenopus laevis (Chow et al., 1999). The
combined information of ectopic expression studies has cemented the evolutionary conserved
role of PAX6 to direct eye morphogenesis.
1.2.3 PAX6 DNA binding motifs and their distribution in the genome.
A consensus DNA binding sequence that is bound by the paired domain of all Pax proteins was
originally revealed from detailed studies of Pax5 (Czerny and Busslinger, 1995). It was further
shown that Pax6 binds to a subset of Pax5 DNA binding sites (Czerny and Busslinger, 1995).
The Pax6 paired domain characteristically binds to a 16-20 base pair sequence
((ANN)TTCACGCA/TTc/fANTG/xA/cN('1/'(•)) whereas the homeodomain has been shown to
recognise a short DNA sequence (TAAT) (Zhou et al., 2002). Zhou et al. screened single-copy
human genomic DNA libraries using cyclic amplification of protein binding sequences and
electrophoretic mobility shift assays (Zhou et al., 2000; Zhou et al., 2002). These studies
revealed that certain Pax6 binding sites occurred in sequences of the repetitive rodent B1
elements or the primate Alu elements; however, the functional significance of this observation is
unclear. It has been shown that the paired domain and the homedomain can both function
independently or together to regulate different genes (Zhou et al., 2002). It has also been shown
that the +5a PAX6 isoform has a novel binding site on DNA that is not bound by the -5a PAX6
isoform. This novel +5a PAX6 binding site contains 2 copies of an imperfect 11 base pair repeat:
ATGCTCAGTGA I ATGTTCATTGA (Epstein et al., 1994). It is difficult therefore to illustrate
a genome wide distribution of PAX6 DNA binding motifs as although a consensus sequence has
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been described, other DNA binding sites have been identified that do not share any similarity to
this paired domain consensus binding site (Zhou et al., 2002).






Thought that these 2 members have both distinct and overlapping
functions in the development of the skeleton.
2
PAX2 PD 1 H
Pax2 is expressed in the developing kidney, optic stalk and regions of
the brain and CNS. In kidney Pax2 induces WTI expression, however,
Pax2 expression is repressed by WTI.
PAX5 PD 1 H
Involved in B cell development and regulating transcription of B cell
specific genes. Interaction of Sox4 and Pax5 possibly regulates B cell
specific gene expression.
PAX8 PD 1 H Involved in directly regulating thyroid specific genes
3
PAX4 PD HD
Involved in specifying pancreatic cell types and regulating
transcription of pancreatic hormone genes.
PAX6 PD HD
Main function in developing eye but also involved in specifying
glucagon-producing a cells in the pancreas. Interaction of Sox2 and
Pax6 regulates crystallin in the developing lens.
4
PAX3 PD HD
Involved in formation of the heart as well as intestinal ganglia
formation and development of skeletal muscle. Interaction of Sox 10
and Pax3 regulates c-RET and MITF in the neural crest.
PAX7 PD HD
Thought to specify muscle satellite cells that can be triggered to
differentiate into new muscle.
Table 1.1 The Pax gene family.
Overview of the 9 members of the Pax gene family, arranging them into their 4 subgroups. All
contain a paired domain (PD), and 4 contain a homeodomain (HD). 3 proteins contain only the
PD and the first helix of the HD (1 H). There is also a brief description of the important
functions of each member of the Pax family but these are by no means exhaustive (Chi and
Epstein, 2002).
Page 7
PAX6 protein-protein interactions Introduction
Disease Phenotype in mice Disease Phenotype in human
Paxl
Paxl mutations cause the undulated
mutation that show a phenotype similar
to a severe form of spina bifida (Balling
etal., 1988).
Mutation in the PAX1 paired domain found in a patient
with spina bifida, a neural tube defect caused as the spine
doesn't close during development (Hoi et al., 1996).
Pax2
Human phenotype similar to Krd
(Kidney, renal defects) mutant mice, that
have mutations in Pax2 and other genes
(Keller et al., 1994).
Mutations in PAX2 cause kidneys to develop abnormally.
Patients also exhibit an eye phenotype such as optic nerve
or retinal dysplasia (Devriendt et al., 1998).
Pax3
Pax3 mutations cause the splotch
mutation that show white spotting on the
belly and back and have nervous system
defects (Mancino et al., 1992).
Mutations in PAX3 cause Waardenburg's Syndrome I/III
that produce fused digits, limb abnormalities,
anophthalmia and hearing and ear defects (Hoth et al.,
1993). Also PAX3 FKHR fusion, see PAX7.
Pax5 -
A translocation alters PAX5 transcription that may
contribute to large cell lymphoma (Busslinger et al., 1996).
Pax6
Pax6 mutations cause the small eye
mutation in mice that have various eye,
nose and brain defects (Hill et al., 1991).
Aniridia is the classical disease associated with PAX6
mutations, see section 1.7 for more information.
Pax7 -
A translocation causing the fusion of PAX7 to FKHR
(forkhead), produces the paediatric soft tissue cancer
alveolar rhabdomyosarcoma, a fast growing highly
malignant tumour, which affects the muscles of the
extremities or trunk (Whang-Peng et al., 1992).
Pax8 -
Mutations in the paired domain of PAX8 cause thyroid
dysgenesis in hypothyroidism (Macchia et al., 1998).
Pax9
Pax9 loss in caudal portion of Danforth's
Short tail mutant cause fewer caudal
vertebrae (Neubuser et al., 1995).
Mutations in PAX9 cause oligodontia, in which 6 or more
of the teeth are missing (Stockton et al., 2000).
Table 1.2 Pax mutations and related disease phenotypes in mice and men.
This table illustrates the disease phenotypes that have been linked to mutations in the Pax genes
in both mice and men. No disease phenotypes linked to Pax4 mutations, therefore, not included.
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1.3 The PAX6 protein.
The transcriptional start site for the PAX6 protein is located at the 3' end of exon 4. The PAX6
protein is coded from this start site in exon 4 up to the stop codon in exon 13 and there is an
alternative spliceoform (5a) between exons 5 and 6. The arrangement of the PAX6 protein






lOObp Paired Domain Homeodomain PST Domain CT Domain
Figure 1.3 Structure of the PAX6 cDNA.
This illustrates the PAX6 cDNA with the exon boundaries marked. PAX6 has 2 main isoforms
and the +5a isoform has an additional 14 amino acids that is also shown (Glaser et al., 1992).
The domain structure of PAX6 is also indicated, illustrating the paired domain, homeodomain,
PST domain and CT (C terminal) domain as differently coloured regions of the cDNA map.
1.3.1 Composition and domains of PAX6.
The two major isoforms of PAX6, -5a and +5a (see 1.3.2), are 422 and 436 amino acids proteins
that are composed of 3 main domains including a paired domain at the N terminus, a
homeodomain and a proline, serine and threonine (PST) rich region (Ton et al., 1991; Glaser et
al., 1992) (see Figure 1.4). The paired domain (128 amino acid domain) is a highly conserved
DNA binding region that is composed of 2 subdomains, each of which contains 3 a-helices in a
helix-turn-helix motif (Xu et al., 1995; Xu et al., 1999a). Both of the subdomains of the paired
domain bind to individual consensus DNA sequences. The homeodomain (61 amino acid
domain) is another DNA binding region and is also composed of 3 a-helices in a helix-turn-helix
motif (Wilson et al., 1995). These two DNA binding domains are highly conserved through
evolution, illustrated by only a single amino acid change in both domains between PAX6 of
human and zebrafish (Glaser et al., 1992). The PST rich region (final 145 amino acid region)
acts as a transcriptional activator (Glaser et al., 1994), which together with the occurrence of the
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2 specific DNA binding domains, lends support to the idea that PAX6 is a transcription factor.
There is now a good deal of functional evidence to support this (see 1.6.2).
Figure 1.4 Diagrammatic representation of the PAX6 protein.
This cartoon illustrates how PAX6 is bound to DNA by the DNA binding regions of the protein;
NTS and CTS refer to the 2 subdomains of the paired domain and HD refers to the
homeodomain. The PST (proline, serine, threonine rich region) region is also illustrated and the
very C terminal region (CT) is shown as a separate domain.
1.3.2 Isoforms - PAX6 +/- 5a.
The PAX6 +5a isoform has an additional 14 amino acids inserted into the N terminal subdomain
(NTS) of the paired domain. These added amino acids are inserted into the most conserved
region of the paired domain (Walther and Gruss, 1991). It has been reported that the addition of
these extra amino acids is sufficient to alter the binding characteristics of the paired domain by
allowing the DNA recognition to occur through the C terminal subdomain (CTS) of the paired
domain rather than the NTS (Epstein et al., 1994). This has the knock-on effect that the
transactivation ability through the CTS of the PAX6 +5a isoform is enhanced. This finding has
led to the hypothesis that exon 5a might act as a switch that selects and specifies target genes
(Azuma et al., 1999). Not only do the +/- 5a isoforms of PAX6 have specific binding
characteristics and specific functions during development, but also the specific ratio of +/- 5a
PAX6 transcripts is very important in eye development. This is highlighted by 2 different
mutations which are sufficient to cause unusual eye phenotypes: a mutation in the exon 5a splice
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acceptor site, which increases the +5a isoform and decreases the -5a isoform (Epstein et al.,
1994); and a missense mutation (V54D) in the alternative +5a exon which has the reciprocal
effect (Azuma et al., 1999).
The specific role of the PAX6 +5a isoform is still unclear; however the fact that this splice
variant is only found in vertebrates could mean that it may contribute to the formation of a more
complex eye structure. Exon 5a null mice have been generated and these develop with iris
hypoplasia and defects of the cornea, lens and retina (Singh et al., 2002). Conversely, transgenic
mice that over express the PAX6 +5a isoform have also been shown to develop eye anomalies
(Duncan et al., 2000), increasing support for the necessity of a tightly controlled ratio of +/- 5a
PAX6 isoforms in the developing eye. The requirement of the +5a isoform in iris development
has led to the hypothesis that perhaps it was the evolution of this isoform that has led to more
advanced features of the vertebrate eye, such as the contractile iris (Singh et al., 2002).
However, the +5a isoform is only expressed at low levels in the developing eye but its
expression is up-regulated after birth and so this suggests that the +5a isoform may play a role in
the differentiation and maintenance of the adult eye structures (Singh et al., 2002).
1.3.3 -PD PAX6 isoform.
It has been shown in 3 different reports that another PAX6 protein isoform (termed -PD PAX6)
can be formed that is lacking the paired domain. It was shown that the Caenorhabditis elegans
Pax6 locus was capable of encoding a protein which is lacking the paired domain (Chisholm and
Horvitz, 1995). It was identified that this -PD Pax6 was expressed from a promoter in the intron
before exon 8, between the paired domain and homeodomain (Zhang and Emmons, 1995). The
-PD Pax6 protein was shown to be expressed in C. elegans with antibodies designed against the
homeodomain, and this expression was both nuclear and cytoplasmic (Zhang et al., 1998).
Two identical -PD Pax6 isoforms have also been identified in mouse eye and brain RNA by a
modified RT-PCR technique (Gorlov and Saunders, 2002). These isoforms are missing exons
2-7 and are proposed to be generated from the 2 different Pax6 promoters P0 and PI (see Figure
1.1), which generate differently spliced isoforms but ultimately encode identical 221 amino acids
proteins that are lacking the paired domain of Pax6 (Gorlov and Saunders, 2002).
Isoforms identified by RT-PCR must be treated with some suspicion as it still remains to be
shown whether these isoforms will ever be translated into protein in vivo. However, another
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study investigating protein isoforms of PAX6, but this time in quail neuroretina cells, has
revealed a similar isoform lacking the paired domain (Carriere et al., 1993). This -PD Pax6
isoform has been shown to be expressed in avian neuroretina cells by antibodies raised against
the homeodomain and PST domains of Pax6 (Carriere et al., 1993). Unlike the better
characterised isoforms of PAX6 (+/- 5a) which are localised solely in the nucleus, it has been
shown the -PD PAX6 isoform is nuclear (due to a conserved nuclear localisation signal in exon
8) but with a significant cytoplasmic localisation (Carriere et al., 1995).
These combined results certainly suggest that there may well be a PAX6 isoform that is lacking
the N terminal 201 amino acids that encompass the paired domain and that this isoform is also
partially localised in the cytoplasm.
1.3.4 Two speculative PAX6 splice variants.
Other splice variants have been reported, however, the validity of these is uncertain. One such
isoform is meant to produce PAX6 that contains exon 5a, but using an alternative 5' splice site
for exon 6, whereby only 15bp of exon 6 would be included in this isoform (Gronskov et al.,
1999). Although this isoform has been identified from human cerebellum and lymphoblastoid
cells from patients, there is still doubt about its functional significance as it has only been
identified by RT-PCR. The second isoform was isolated by the same authors (Gronskov et al.,
2001) and produces PAX6 that skips exon 12 which causes a shift in the read frame of the
transcript and so if translated would produce a protein that was 55 amino acids longer than the
'normal' PAX6 isoform. Once again it has been shown by RT-PCR that this transcript is
produced in human foetal brain cells and lymphoblastoid cell lines. Therefore, both these
isoforms may be present as RNA in very small quantities in cells; however they may never be
translated into protein and never contribute to the functioning of PAX6.
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1.4 Development of structures that express PAX6.
This section summarises the development of the eye and the brain so that in section 1.5, which
describes the expression pattern of PAX6 in these structures, it will be possible to clearly
visualise the expression pattern.
1.4.1 Development of the eye.
Eye development begins at the end of gastrulation (the process where the germ layers are formed
and the basic body plan is established) when the forebrain neural fold forms a pair of shallow
grooves called the optic sulci. Each optic sulcus then enlarges to form optic grooves and as the
neural folds fuse these grooves are pushed outwards (see Figure 1.5). The optic sulci grow
towards the surface ectoderm to form optic vesicles while the proximal end of the optic vesicle
narrows to form the optic stalk, which connects to the brain cavity.
Figure 1.5 Various developmental sections through a human forebrain.
This figure shows transverse sections through a human forebrain at 3 stages of developments: 22






Thickening of the surface ectoderm in the region apposed to the extended optic vesicle forms the
lens placode. Both the lens placode and the optic vesicle invaginate at this stage and form the
lens vesicle and optic cup respectively (see Figure 1.6). The lens vesicle contained within the
optic cup will eventually become the solid lens of the eye. The inner and outer layers of the optic
cup give rise to the thicker neural retina and thin pigmented retina respectively (Cvekl and
Piatigorsky, 19%).
The invagination that forms the lens vesicle and optic cup also occurs on the surface of the optic
stalk forming a linear groove called the choroidal fissure. This choroidal fissure allows the
Page 13
PAX6 protein-protein interactions Introduction
developing lens and retina to be supplied with blood by the hyaloid artery. Ultimately the edges
of the choroidal fissure will fuse, enclosing the hyaloid artery and vein as well as axons from the





Figure 1.6 Formation of lens placode and lens vesicle in a human eye.
This figure illustrates the thickening of the surface ectoderm to form the lens placode (A, B) and
its subsequent invagination to initially form the lens pit and then the lens vesicle (C, D). This
figure also illustrates the invagination of the optic vesicle to form the optic cup (B to D). Each
panel (A to D) represents a consecutive developmental stage (30 to 32 days) (Larsen, 1993).
Following the formation of the main eye structures a layer of mesenchyme surrounds the optic
cup. This mesenchyme in turn will form the two layers that surround the eye, the thin inner
choroid and the fibrous outer sclera. These mesenchymal layers also form over the developing
lens; however, at this region the 2 layers are separated by a space called the anterior chamber.
The external wall of this chamber along with surface ectoderm will form the cornea, whereas the
inner wall overlying the lens will eventually develop into the pupil and vacuolisation will form
the posterior chamber. Finally, the rim of the optic cup and the overlying choroid will develop
into the iris and the ciliary body (Larsen, 1993). The anatomy of the mature eye is illustrated in
Figure 1.7.
Figure 1.7 Normal Eye.
This diagram illustrates a vertical section
through a normal eye, with the key structural
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1.4.2 Development of the brain.
The 3 main divisions of the developing human brain, forebrain (prosencephalon), midbrain
(mesencephalon) and hindbrain (rhombencephalon) are apparent as thickened regions of the
neural tube even before the start of neurulation (4 weeks gestation). Neurulation is the name
given to the conversion of the neural plate into the neural tube. First a crease (neural groove)
appears down the centre of the neural plate that is used to hinge the folding of the thick neural
folds (see Figure 1.8).
Figure 1.8 Neurulation.
Ectoderm in the dorsal midline thickens forming the neural plate. The edges of the neural plate
roll toward each other to form the neural folds. The neural folds then meet dorsally forming the
neural tube & overlying ectoderm. The neural tube will develop into the central nervous system
(CNS, light blue) and the neural crest will develop into the peripheral nervous system (PNS,
dark blue). Figure taken from www.lsic.ucla.edu:8027/.
The edges of the neural folds then fuse, first near the middle of the embryo and then proceeding
rostrally (towards head) and caudally (towards tail), to form the neural tube (see Figure 1.8 and
1.9). The rostral portion of the neural tube folds at 3 points (labeled a-c, see Figure 1.9) whilst
continuing to expand.
During the fifth week of brain development the forebrain is further subdivided into the
telencephalon and diencephalon and the hindbrain is divided into the metencephalon and
myelencephalon (see Table 1.3).
Neural plate Neural fold
Notochord
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Figure 1.9 Summary of human brain development.
The neural tube begins to close at 3 weeks of gestation. By week 4 the presumptive major
regions of the brain can be recognised, including the forebrain, midbrain, hindbrain, and optic
vesicle (see section 1.4.1 for eye development). Flexing of the brain occurs at 3 points (labeled
a-c in 7 week panel). Expansion and flexing of the brain then continues, with ridges of the adult
brain apparent by six months (Ariniello, 2002).














































Table 1.3 Illustration of regions of the adult human brain.
This table illustrates the regions of the adult brain that develop from different embryonic brain
structures (highlighted in red). Pictures taken from http://faculty.washineton.edu/chudler
lnsdivide.html.
Page 16
PAX6 protein-protein interactions Introduction
In brain development neurons are generated in an inside out manner to produce a highly
organised structure of 6 neuronal layers. Each layer is composed of specialised neurons that have
specific phenotypes and synaptic connections (Rakic and Lombroso, 1998). The neurons are
originally produced from dividing progenitors in the ventricular zone and then migrate along the
fibers of radial glial cells to settle and differentiate in the cortical plate (see Figure 1.10). Each
subsequent set of migrating neurons will follow the same route by way of the previously formed
neurons. Hence the inside out pattern of development in which the deepest cortical layers are

















Figure 1.10 Development of the cerebral cortex.
A, This shows a cross-section of the occipital lobe of a developing primate brain, showing the
pattern of radial glial cells that extend from the inner (ventricle) to outer (pial) surface of the
brain. B, This magnified region illustrates the migration of the neurons from their birth place in
the ventricular zone through the intermediate (or mantle) zone to their destination at the interface
between the marginal zone and the developing cortical plate. C, This shows a single migrating
neuron using a glial fibre as a guiding scaffold (Rakic and Lombroso, 1998).
After the neurons are correctly positioned they form distinct axonal connections with related
regions of the cortex. The generation of specific brain regions has been suggested to be caused
by the expression of certain genes and this is beginning to be clarified, for example the
reciprocal gradient of Emx2 and Pax6 expression in the developing brain (see Figure 1.14) is
thought to be involved in brain arealisation (Bishop et al., 2000). The 4 main regions of the
human brain and more specific regions of the forebrain, midbrain and hindbrain can be seen
illustrated in Figure 1.11.
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Figure 1.11 Regions of the
human brain.
This illustration shows the
important regions of a human
brain. A, This shows the 4
main sections of the cerebral
cortex: the occipital lobe, the
temporal lobe, the parietal lobe
and the frontal lobe. B, This
shows a cross-section of the
brain, illustrating the major
internal structures in the
forebrain (1), midbrain (2) and
hindbrain (3) (Ariniello, 2002).
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1.5 Where is PAX6 expressed?
The PAX6 gene is expressed early in development, mainly in the developing eye but also in
regions of the brain, central nervous system (CNS), nasal epithelium and pancreas (Prosser and
van Heyningen, 1998). Although it has been shown that Pax6 is expressed in the developing
olfactory bulb and in a small subset of cells in the developing pancreas, I will concentrate on the
Pax6 expression pattern in the developing eye and brain, which is more pertinent to my project.
1.5.1 In the developing eye.
PAX6 is expressed in all the major structures of the developing eye. The majority of the
developmental studies that investigate the expression of the Pax6 gene have used mouse
embryos as a model system as they represent a more readily available resource than human
samples. However, the expression pattern of PAX6 that has been studied in human tissues has
been shown to be interchangeable with the mouse Pax6 expression pattern.
In the developing mouse eye, Pax6 is first detected at day 8 of gestation in the optic sulcus and
then in the resultant optic vesicle and optic stalk (Walther and Gruss, 1991). The overlying
surface ectoderm also expresses Pax6, particularly in the thickening region, the lens placode.
Between days 10-15 of gestation Pax6 is also expressed in the optic cup, more specifically in the
inner layer of the optic cup (the developing neural retina), the lens and the cornea (Walther and
Gruss, 1991). In the newly formed optic cup (at 10.5 days of gestation in mice) a distalhlgh to
proximal10"1 gradient of Pax6 expression is produced in the developing neuroretina, which is
specifically mediated by the Pax6 activated, conserved intronic enhancer a (Baumer et al.,
2002). It has been proposed that the peak of this a initiated Pax6 expression, at the anterior rim
of the optic cup, corresponds to the future iris epithelium (Baumer et al., 2002).
At early stages of development PAX6 is expressed in the entire developing retina; however, at
later stages of development this expression pattern is restricted to the ganglion cell layer and the
inner and outer portions of the inner nuclear layer, which will differentiate into amacrine and
horizontal cells (Ton et al., 1991). A picture illustrating the expression of PAX6 at this stage of
human eye development is shown in Figure 1.12.
One must be careful when drawing conclusions from the RNA expression pattern of a gene, as it
does not always follow that the expression pattern of the RNA will be mimicked by the
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expression pattern of the translated protein. However, in the case of PAX6 it has been shown
that the protein expression mimics the RNA expression in the developing eye (Nishina et al.,
1999). The early expression of PAX6 in human eye sections has been shown by anti-PAX6
antibody staining (Nishina et al., 1999) to resemble the in situ hybridisation findings of PAX6
expression in mice (Walther and Gruss, 1991) and a 49 day old human eye (see Figure 1.12).
Figure 1.12 PAX6 RNA expression in the human eye.
This picture shows the PAX6 RNA expression (as determined by in situ hybridisation) in a
human eye at 7 weeks of gestation. PAX6 expression can be seen in the optic vesicle and the
overlying ectoderm as well as in the pigmented and neuronal retina (Ton et al., 1991).
1.5.2 In the developing brain.
PAX6 has also been shown to be expressed in the brain. However, this expression pattern is
extremely complex. Pax6 expression, as in the eye, begins at day 8 of gestation in the
developing mouse in the neuroepithelium of the forebrain and hindbrain, and is then followed by
expression along the length of the neural tube (Glardon et al., 1997).
During brain development (days 10.5-18.5 of gestation) expression of Pax6 extends from the
telencephalon into the diencephalon (the 2 main regions of the forebrain) but never penetrates
the boundary of midbrain (Walther and Gruss, 1991). A high level of Pax6 expression persists in
the developing ventral thalamus (Stoykova et al., 1996) from 10.5 to 18.5 days of gestation,
however, a much lower Pax6 expression level is seen in the developing dorsal thalamus which is
undetectable at 15.5 days of gestation (Walther and Gruss, 1991). This suggests that a gradient
of Pax6 is establish in this region, as in the neuroretina in the eye. Delayed Pax6 expression,
from 15.5 to 18.5 days of gestation, also occurs in the developing metencephalon (Walther and
Gruss, 1991).
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Figure 1.13 Expression ofPax6 in developing mouse embryo.
Pax6 expression can be seen in the developing forebrain and hindbrain as well as along the
length of the developing neural tube. Pax6 expression can also be seen in the developing
olfactory structures and in the eye (Picture provided by P. Rashbass).
Pax6 expression is detected at 13.5 days of gestation in the ventricular zone and this extends to
the subventricular zone at 16.5 days of gestation (Caric et al., 1997). The cells generated from
these mitotically active regions then migrate from this inner region of the telencephalon to the
cortical plate along radial glial cells (see Figure 1.10), which also express Pax6 (Heins et al.,
2002).
Pax6 has also been shown to be expressed in a high rostrolateral to low caudomedial gradient
which is complemented by an opposing gradient of Emx2 (Bishop et al., 2002).
Figure 1.14 Pax6 and Emx2 expression in neocortex.
The predicted expression of Pax6 and Emx2 in
opposing directions in the developing neocortex. It is
thought that this reciprocal expression is required to
define specific regions of the brain. Diagrams represent
dorsal views of the mouse neocortex. C, Caudal; L,
Lateral; M, Medial; R, Rostral (Bishop et al., 2002).
It has been shown that the complementary function of Emx2 and Pax6 specifies area identity in
the neocortex (Bishop et al., 2002).
Emx2 Pax6
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1.6 Function of the PAX6 protein.
I have already explained that the PAX6 protein is thought to be a transcription factor and I have
outlined the development of the brain and eye, the two main structures in which PAX6 is
expressed. Our knowledge of the role of PAX6 in patterning the developing brain has expanded
over recent years. PAX6 is involved in regionalisation of the brain (briefly mentioned in section
1.5.2) and also in cell migration (Talamillo et al., 2003) and axon guidance (Mastick et al.,
1997) in forebrain development.
However, PAX6 is best known for its conserved role in eye development and therefore the main
area of research into the functioning of PAX6 has been in the developing eye. This section is
intended to highlight some specific details of how PAX6 functions at the molecular level in the
development of the eye.
1.6.1 Regulators of Pax6 expression in the eye.
Pax2 has been shown to bind to the regulatory region between exons 4 and 5 of Pax6 (U4 in
Figure 1.2) and this down regulates expression, whereas the binding of Pax6 to an upstream
regulatory region in Pax2 also down regulates expression (Schwarz et al., 2000). Conversely,
Pax6 has been shown to be able to stimulate its own expression by binding to the same
regulatory region (Schwarz et al., 2000; Baumer et al., 2002). As PAX2 is specifically expressed
in the optic stalk and PAX6 is expressed in the developing retina, and missense mutations of
PAX6 lead to optic nerve malformation (Azuma et al., 2003), then it is possible that the
overlapping expression of PAX2 and PAX6 set up an optic cup/optic stalk border during
development. This hypothesis is backed up by information from the cyclops mutant in zebrafish
(Macdonald et al., 1995). This mutant has fused eyes and this is due to the fact that Pax6
expression is expanded from the developing retina into the normal expression area of Pax2 (the
presumptive optic stalk) and Pax2 expression is almost absent. Therefore, Pax6 expression
encroaches on the normal Pax2 expression area and the Pax2/Pax6 boundary is altered.
As has been alluded to several times already it is known that PAX6 is able to regulate its own
expression during development. I have already commented that binding of Pax6 to a regulatory
region between exons 4 and 5 (U4 see Figure 1.2) specifically directs expression of further Pax6
transcripts in a gradient in the developing neuroretina (Baumer et al., 2002). However, Pax6 has
also been shown to bind to the enhancer element upstream of the P0 promoter (U2 see Figure
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1.2) in combination with the transcription factors Sox2 and Sox3 (Aota et al., 2003). It is
postulated that the positive autoregulation of Pax6 may be adjusted by this interaction with Sox2
and Sox3.
The regulation of PAX6 expression in lens development also seems to be under the control of the
homeoproteins Meisl and Meis2. It has been shown that these proteins bind to the specific lens
enhancer element (U2 see Figure 1.2) and increased Meis2 has been shown to increase the
expression levels of PAX6 in the lens (Zhang et al., 2002). Specific levels of Pax6 expression
are also required in the developing lens to regulate expression of the homeobox gene Six3, and
Six3 also binds to the lens specific enhancer of Pax6 (U2 see Figure 1.2) to activate Pax6
expression (Goudreau et al., 2002).
Therefore, it can be seen that not only is the regulation of PAX6 finely controlled in the
developing eye, but that this controlled expression of PAX6 will also influence other genes and
proteins (see 1.6.2 and 1.6.3).
1.6.2 Genes regulated by the PAX6 protein.
It has already been mentioned that the binding of PAX6 protein to specific PAX6 regulatory
elements specifically stimulates expression of the gene (Schwarz et al., 2000; Baumer et al.,
2002; Aota et al., 2003). However, the Pax6 protein has also been reported to directly activate
other genes that are involved in eye development. As already mentioned Pax6 regulates
activation of Six3 in a dose dependant manner in the developing lens, so the more PAX6, the
more Six3 expression (Goudreau et al., 2002). Consistent with the function of the Pax6 protein in
the developing lens, it also regulates expression of different crystallin genes (Cvekl and
Piatigorsky, 1996) and Maf genes (Sakai et al., 2001). Pax6 also controls the activation of bHLH
factors such as Ngn2, which are required in the developing retina to produce the correct cell
types from retinal progenitor cells (Marquardt et al., 2001).
It is thought that Foxe3 expression is activated by a threshold amount of Pax6 in the developing
lens (Dimanlig et al., 2001). Also the Necab gene is thought to be a downstream target of Pax6,
and be involved in retina development (Bernier et al., 2001). Although the expression of both
these genes has been shown to be absent in mutant mice, a direct interaction with Pax6 has not
been confirmed and so these predictions are still speculative.
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Pax6 not only stimulates gene expression, but it also represses gene expression as has already
been described (see 1.6.1) with the example that Pax6 represses Pax2 expression (Schwarz et al.,
2000). Pax6 has also been shown to repress expression of a fi-crystallin gene by blocking an
activation domain in its promoter (Duncan et al., 1998). The dual roles of Pax6 as a repressor
and activator further the information that Pax6 is responsible for regulating a complex spatial
and temporal pattern of gene expression in the developing eye.
1.6.3 PAX6 protein-protein interactions.
As has just been shown PAX6 is highly regulated; not only is the expression of PAX6 restricted
to specific areas of the developing embryo, but also this has subsequent effects on the regulation
of other genes. However, it is important to remember that the specific regulation of genes by the
PAX6 protein is not just accounted for by the highly controlled expression pattern of PAX6 or
its specific DNA binding domains. It is becoming apparent that transcription factors do not act in
isolation but are dependent on interactions with other proteins to carry out their function
(Oikawa and Yamada, 2003; Westerman et al., 2003). These interactions, which are themselves
dependant on temporal and spatial expression, introduce more specificity into the regulatory
function of PAX6. To date three protein-protein interactions of PAX6 have been described: the
specific interaction of Sox2 and Pax6; the interaction of mDia and Pax6; and the interaction of
Maf proteins and Pax6.
As SOX2 has a spatially and temporarily controlled expression pattern in the developing eye and
central nervous system and gene mutations have been reported in patients with anophthalmia, a
severe structural eye malformation (Fantes et al., 2003) it is plausible to hypothesise that the
interaction of Sox2 and Pax6 is vital in certain stages of development. Specifically, it has been
postulated that lens development is initiated by the binding of a Sox2/Pax6 complex onto a lens
specific (6-crystallin) enhancer element in chicks (Kamachi et al., 2001). This example
substantiates the hypothesis that the Sox2/Pax6 interaction creates a specific combination of
DNA binding domains that will bind to a corresponding combination of binding sites in the
enhancer region (Kamachi et al., 2000).
Therefore, one could envisage a scenario by which PAX6 interacts with many different proteins
to allow binding to various enhancer elements to specifically regulate its function during
development.
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It has been found from a yeast 2-hybrid screen using mDia as bait that Pax6 interacts with this
protein (Tominaga et al., 2002). It has been proposed that mDia binds across the homeodomain
of Pax6 in the nucleus of cerebellar granule cells, which causes Pax6 to dissociate from DNA
and translocate to the cytoplasm (Tominaga et al., 2002). In this way it has been shown that the
transcriptional activity of Pax6 is reduced due to the binding of mDia, and this is responsible for
neurite elongation and branching in the cerebellar granule cells. Therefore, it has been suggested
that mDia regulates axon pathfinding and Pax6 activated gene transcription and that this could
potentially provide a mechanism of how early neuronal development is modulated due to its
interaction with Pax6 (Tominaga et al., 2002).
Furthermore, it has been shown that Pax6 and Maf proteins interact in pull down experiments in
vitro and that not only does Pax6 regulate expression of the pancreatic hormone gene, glucagon,
but also the transactivation of this gene is increased by the combined binding to its promoter of
both the Pax6 and Maf proteins (Planque et al., 2001).
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Regulates activation of Six3 in a
dose dependant manner in the Goudreau et al., (2002)
developing lens.
Regulates different crystallin
genes in the developing lens.
Activates gene expression of c-
Maf in lens development.
Controls the activation of Ngn2 in
the developing retina
Cvekl and Piatigorsky, (1996)
Sakai et al., (2001)
Marquardt et al., (2001)
Pax6 speculated to activate Foxe3
Dimanlig et al., (2001)
expression in the lens.
Pax6 proposed to regulate Necab








Sox2/Pax6 complex binds to a lens
Kamachi et al., (2001)
Tominaga et al., (2002)
specific enhancer element.
mDia binds to Pax6 in cerebellar
granule cells.
Maf binds to Pax6 causing
increased transactivation of the Planque et al., (2001)
glucagon gene.
Table 1.4 Summary of gene regulation by the PAX6 protein.
This table summarises the genes that are regulated by the PAX6 protein (see 1.6.2), and these
have been split into 2 categories depending on whether there is direct or indirect evidence for
PAX6 regulation. Known protein-protein interactions are also shown (see 1.6.3).
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1.7 Mutations of PAX6.
Classically, mutation of PAX6 was associated with a congenital eye malformation, aniridia
(Greek for absence of the iris, see Figure 1.15), that is a rare, bilateral, panophthalmic disorder,
characterised by iris hypoplasia (Ton et al., 1991; Jordan et al., 1992). Aniridia can also be
associated with corneal, lens, optic nerve, and retinal manifestations as well as foveal and optic
nerve hypoplasia, which cause a reduction in visual acuity and congenital sensory nystagmus.
Vision may also deteriorate as patients age due to the onset of cataracts, glaucoma, and corneal
opacification (Taken from www.emedicine.com).
Figure 1.15 Illustration of aniridia.
Only a very small region of iris tissue remains at the bottom of
the eye. The pupil of the eye is brightly illuminated as light is
being reflected off the retina (Hanson and Van Heyningen,
1995).
Although aniridia is the most common eye disease phenotype associated with mutations in
PAX6, other diseases such as Peters anomaly, ectopia pupillae and foveal hypoplasia are also
associated with PAX6 mutations (see Figure 1.16).
Figure 1.16 Eye diseases associated
with PAX6 mutations.
Illustration of eye diseases other than
aniridia associated with PAX 6
mutations: A, shows ectopia pupillae,
with the pupil offset towards the nose;
B, illustrates Peters anomaly showing
central corneal opacification; C and D
illustrate foveal hypoplasia, with C,
showing a normal retina and D,
illustrates the disease showing a poorly
formed fovea with abnormal
vascularisation.
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Peters anomaly is a rare form of anterior segment dysgenesis in which abnormal cleavage of the
anterior chamber occurs (causing adhesions between the cornea, iris and/or the lens) and is
characterised by central or paracentral corneal opacifications (Taken from www.emedicine.com).
Ectopia pupillae is a congenital eye malformation in which the pupils are offset from their
central position, normally towards the nose (Hanson et al., 1999). The fovea is the region of the
retina that contains a single layer of cones with no overlapping blood vessels and has the greatest
visual acuity. In foveal hypoplasia, the fovea is underdeveloped and there is vascularisation
through the vestigial fovea (Azuma et al., 1996).
Heterozygous mutations in PAX6 are the genetic cause for the previously described congenital
eye malformations (Prosser and van Heyningen, 1998) and it is thought that most of these
mutations result in non-functional alleles (see 1.7.1). Homozygous mutations cause far more
severe phenotypes. Two cases have been described: One in which the patient died at 37 weeks
gestation and was completely lacking eyes, nose and adrenal gland, although it was only
presumed that this phenotype was caused by a homozygous PAX6 mutation (Hodgson and
Saunders, 1980); and a patient that was a compound heterozygote that developed with no eyes,
an underdeveloped brain and central nervous system abnormalities and died 8 days after birth
(Glaser etal., 1994).
1.7.1 Overview of PAX6 mutants and the database.
As I have already mentioned heterozygous mutations of PAX6 cause eye disease phenotypes,
however just as there is a lot of variation in the disease phenotype there is also a wide range of
genotypic mutations that cause these diseases. The entire spectrum of mutations that occur in the
PAX6 gene are collated in the PAX6 Allelic Variant Database (http://pax6.hgu.mrc.ac.uk/). There
are 292 mutations recorded in this database and 275 of these are mutations within the coding
region of PAX6, which cause disease phenotypes. The variety of different types of mutation that
lead to these 275 pathological mutations can be seen in Figure 1.17.
It has also been noted that certain positions in the PAX6 gene are 'mutation hotspots' which
include mutations that affect the PAX6 stop codon and the mutations R203X (14 cases), R240X
(17 cases) and R317X (12 cases) (Chao et al., 2003). Although there are far more mutations of
PAX6 than are mentioned here, I am going to concentrate more on the different types of
mutation, i.e. missense or null mutations, with specific reference to any interesting or relevant
mutations.
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■ In-frame insertion or deletion
□ Frame-shifting insertion or deletion
Figure 1.17 PAX6 mutations.
This pie chart illustrates the frequency of the different types of pathological mutations that occur
within the PAX6 coding region. Anti-termination mutations refer specifically to mutations that
change the stop codon to a coding codon (Hanson, 2003).
1.7.2 Null Mutations.
Classically aniridia was associated with a complete deletion of one allele of the PAX6 gene due
to the hemizygous deletion of 11 p 13 that typifies the WAGR syndrome (Wilms tumour, aniridia,
genitourinary malformations and mental retardation) (Ton et al., 1991). This led to the
hypothesis that aniridia was caused by haploinsufficiency of PAX6 and that loss of function of
one allele meant that insufficient wild type protein was produced to elicit normal eye
development (Martha et al., 1994). It has since been shown that intragenic mutations of PAX6
also cause eye disease phenotypes and 71% of these introduce a premature termination codon
(PTC) due to either frameshift, nonsense or splice mutations. This was initially envisaged to
result in the formation of truncated PAX6 proteins (see 1.7.4) although more recently it has been
suggested that mutations that produce a mRNA containing a premature stop codon may never be
translated into protein due to the function of nonsense-mediated decay (Vincent et al., 2003).
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1.7.3 Missense Mutations.
Missense mutations are most commonly associated with atypical aniridia or uncommon
phenotypes (Vincent et al., 2003) and seem to be underrepresented in the mutational spectrum of
PAX6 mutations. It has been suggested that a reason for this might be that missense mutations
might segregate with highly diverse or non-ocular phenotypes (Hanson et al., 1999). Therefore,
missense mutations may well be associated with phenotypes rather different from aniridia due to
the production of a protein with altered rather than a loss of function (Axton et al., 1997).
1.7.4 Haploinsufficiency and nonsense-mediated mRNA decay.
As discussed in section 1.7.2 haploinsufficiency has been suggested as the explanation for the
heterozygous phenotype that causes aniridia, meaning that the mutated PAX6 allele produces
inactive protein and that the normal PAX6 allele cannot make sufficient wild type protein to
sustain normal eye development (Martha et al., 1994). As the PAX6 mutation database expanded
it was seen that the majority (71%) of PAX6 mutations resulted in the addition of a premature
termination codon (PTC). Most of these mutants introduced a PTC before the PST domain,
which would theoretically form proteins that are unlikely to have any function (Martha et al.,
1994) and fitting a haploinsufficient cause of aniridia. However, transcripts that added a PTC
into the PST domain (see Figure 1.3 for position of the PST domain), if translated, would
represent proteins that contained intact DNA binding domains devoid of the transactivating PST
domain. These truncated PAX6 proteins have been shown to bind more strongly than full length
PAX6 to PAX6 DNA-binding sites (Singh et al., 1998) and also to show a reduced
transactivation ability (Singh et al., 1998; Tang et al., 1998). This fuelled an alternate hypothesis
that suggested that the truncated protein, devoid of the transactivating PST domain would exert a
dominant negative effect by competing for PAX6 DNA binding sites and interrupt the normal
functioning of PAX6 to activate downstream genes. This fitted with the information obtained by
Singh et al., (1998) and was backed up by further in vivo evidence, which showed that the
formation of endogenous and ectopic eyes in Xenopus laevis were suppressed by the
introduction of a dominant negative mutant (Chow et al., 1999).
Although dominant negative effects have been reported for truncated PAX6 proteins (Singh et
al., 1998) it must be stressed that this hypothesis is still questionable. The highly contrived
experiments that support the dominant negative effect avoid a fundamental control mechanism,
nonsense-mediated mRNA decay (NMD). This is a mechanism employed by cells to selectively
destroy mRNAs that contain premature stop codons, so that only full-length proteins are
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produced (Maquat and Carmichael, 2001; Byers, 2002). When investigating mutations that cause
premature termination codons, or frame-shift mutations that produce proteins with novel
properties, proof of the mRNA stability and protein production must be demonstrated before
conclusions are drawn as to the detrimental effect of the mutant protein. The experiments
supporting dominant negative mutants overlooked this vital point and so the results illustrated an
unnatural occurrence. This is supported by the phenotype of mutations that create premature stop
codons in the PST domain in vivo, which seem to suggest haploinsufficiency (Vincent et ai.,
2003) as all 44 cases of patients with PST domain mutations show aniridia or closely related eye
phenotypes. If the normal function of PAX6 is almost completely blocked then severe
phenotypes, more akin to homozygotes, should be seen. Therefore, it is likely that NMD
prevents these proteins from being formed.
For the majority of mutations of PAX6, the explanation for disease phenotypes will be loss of
function of one allele causing haploinsufficiency. However, certain mutations actually cause
read through of the normal stop codon of PAX6 (termed run-on mutations).
1.7.5 Run-on Mutations.
Run-on mutations that cause read through of the normal stop codon into the 3' untranslated
region (UTR) of PAX6 are known to cause aniridia. mRNAs that contain run-on mutations
would not be expected to be degraded by nonsense-mediated decay because they don't introduce
a premature stop codon. Furthermore, it has been reported that nonsense-mediated decay does
not act within the final exon of a gene (Byers, 2002) so it is expected that run-on mutations will
produce elongated PAX6 protein. The C terminal region of the PST domain of PAX6 has been
shown to be highly conserved between species (see 1.8) and altering the C terminal amino acid
can interfere with the binding capabilities of the homeodomain (Singh et al., 2001). Therefore,
these elongated PAX6 proteins may interfere with the normal functioning of the C terminal
region and so instigate a novel function, although existing patient phenotypes associated with
this type of mutation, suggest that the elongated PAX6 protein will have a partial or complete
loss of function.
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1.7.6 C terminal mutations.
21% of the PAX6 mutations occur in the coding region of the PST domain; however, more
specifically mutations do occur in a C terminal region of the PST domain of PAX6 (to be
defined in more detail in section 1.8), which are capable of causing eye malformations. These
mutations can be as subtle as the insertion or changing of a single nucleotide, or the deletion of
10 nucleotides from the terminal region of the PST domain of PAX6 (see Figure 1.18).
A single nucleotide change from A to G at position 1627 causes a glutamine to arginine amino
acid substitution in the last codon (422) of PAX6. This missense mutation (Q422R, see Figure
1.18) was reported in two patients both of whom were shown to have ocular anterior segment
malformations (Azuma and Yamada, 1998; Singh et al., 2001). One patient developed mild
aniridia characterised by uveal ectropion which is an invasion of the cornea by the conjunctival
epithelium (Azuma and Yamada, 1998) and the other patient has more classical aniridia with
associated foveal hypoplasia (see Figure 1.16) (Singh et al., 2001).
Another specific C terminal mutation has been reported in a patient (WHEDA, see figure 1.18)
suffering from aniridia in which there is a 10 base pair deletion in exon 13 of PAX6. This
deletion occurs just before the stop codon in PAX6, causing read through and generating an
almost normal PAX6 protein (missing last 5 amino acids) but with an elongated C terminal end
that extends 103 amino acids into the 3' untranslated region (Heyman et al., 1999). It is
interesting to note that not only does this patient have an abnormal eye phenotype, aniridia, but
they also have an unusual neurobehavioural phenotype, namely impaired social understanding
and verbal inhibition, that may be a consequence of this mutation.
A C terminal mutation (X423L) has been reported in 11 patients suffering from aniridia (Baum
et al., 1999; Singh et al., 2001; Sisodiya et al., 2001; Chao et al., 2003). The X423L mutation
(see Figure 1.18) causes a single T nucleotide insertion into the stop codon, which changes it to a
leucine and so forms a full length PAX6 protein but with an elongated C terminal end that
extends for a further 35 amino acids into the 3' untranslated region. In addition to aniridia one
patient, REMAR, was also missing the anterior commissure (AC), a region in the brain involved
in communication between the brain hemispheres. This patient was also reported to have a
severe defect in olfactory function although with an apparently normal olfactory bulb which
indicates a possible defect in neuronal patterning in this region (Sisodiya et al., 2001). Further
evidence for defects in neuronal development due to this mutation came from the discovery that
the nephew of REMAR had epilepsy and both the nephew and the sister of REMAR had a rare
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brain disorder, polymicrogyria (PMG), that is thought to arise from the disruption of neuronal
migration (Mitchell et al., 2003). Another patient was also shown to have brain asymmetry as
identified by a computer tomography scan which manifested itself as autistic-type behaviour
(Chao et al., 2003), which is similar to the phenotype of the 1615dell0 (WHEDA) PAX6
mutation that also results in an elongated protein. However, it must be remembered that the
autistic-type behaviour has only been reported in 1 patient out of 11 with the X423L mutation
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Figure 1.18 Schematic of C terminal PAX6 mutations.
This shows the 3 C terminal PAX6 mutants: Q422R; WHEDA (1615del 10); and REMAR
(X423L). The normal C terminal PAX6 nucleotide and PAX6 amino acid sequences are
illustrated at the top of this figure. The A to G nucleotide substitution and the resulting Q422R
amino acid change is illustrated in yellow. The lObp deletion of the WHEDA mutant and
subsequent altered reading frame and elongated protein is illustrated in red. The substitution of
the stop codon by a leucine due to the insertion of a T nucleotide into the stop codon and the
subsequent elongated protein of the REMAR mutant is illustrated in blue.
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1.8 Importance of C terminal motif.
1.8.1 Known homology studies.
It has been noted in a previous study that there is a region at the C terminus of the PST domain
which shows very high sequence conservation between vertebrates, sea urchin (Paracentrotus
lividus) and squid (Loligo opalescens) when the whole PAX6 protein sequence is used as a




Figure 1.19 A conserved C motif in the C terminus of PAX6.
This shows a sequence comparison of the conserved motif found at the C terminus of the PAX6
protein in vertebrates, Paracentrotus lividus and Loligo opalescens. Dots represent identical
amino acids, dashes represent introduced gaps and the asterisks represent the stop codon
(Glardon et al., 1997).
This level of amino acid conservation suggests that the C terminal region of the PST domain is
very important for the normal function of PAX6. The mutations described in section 1.7.6 all
occur in this region and provide additional evidence for the functional importance of this part of
the protein. However, at present this region of the PST domain is uncharacterised in terms of
structure and function. Therefore, this set up the founding principles behind my PhD which were
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1.9 Objectives.
1.9.1 Define the C terminal region using bioinformatics.
My main goal is to investigate the C terminal end of PAX6. However, as I have already
mentioned this region is currently uncharacterised and so the first question that needs to be
answered is "How should the C terminal region be defined?" This will be undertaken using
bioinformatic programmes such as BLAST, which will be used to search for homology between
the PST regions of PAX6 in human and other species, and JPRED, which will be used to
investigate secondary structure in the C terminal region.
1.9.2 Create a series of clones for functional investigations.
On successful definition of the C terminal domain I will make clones that correspond to the C
terminal domain, full length PAX6, and truncated forms of PAX6. I will also clone mutant
copies of each construct that include the Q422R mutation, already mentioned. In addition I will
make clones containing the 2 mutations that produce an elongated C terminal end of PAX6
(WHEDA and REMAR). Each peptide will be cloned into pDBLeu, a yeast 2-hybrid vector.
1.9.3 Identify interacting proteins using the yeast 2-hybrid system.
On successful completion of my cloning the next step will be to use the pDBLeu clones to
investigate interactions with other proteins. This will be done by using the yeast 2-hybrid system
to screen a mouse brain cDNA library.
1.9.4 Reconfirmation of the interactions.
The interactions identified from the yeast 2-hybrid screen would first be reconfirmed in the yeast
2-hybrid system by using pairwise interactions rather than library screening. Then I will try and
finally reconfirm the interactions using an alternative method to the yeast 2-hybrid system, such
as co-immunoprecipitation of tissue culture cells using tagged protein(s).
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2.1.1 BLAST (Basic Local Alignment Search Tool).
This is a program that searches for patches of similarity between inputted sequences and
databases. BLASTP was used to identify regions of high conservation between PAX6 amino
acid sequences and protein sequence databases (SPTR and TrEMBL). BLASTP searches were
performed using the UK HGMP resource centre web page (http://menu.hgmp.mrc.ac.uk/cgi-
bin/blasf). Default settings were used for the searches except that the 'mask biased regions' filter
was not used. This option filters out low compositional complexity regions. In the PAX6 PST
region (used in the first BLAST search) it masks the region rich in proline, serine and threonine,
preventing alignments in the PST domain. Hence by removing this filtering from the BLAST
search it allows position-by-position alignment of the whole sequence.
BLASTN was also used (through http://www.ncbi.nlm.nih.gov/blast/') to find similar nucleotide
sequences between query sequences, obtained from the sequencing of interactors pulled out of
the yeast 2-hybrid screen, and nucleotide databases. Again default settings were used for this
program.
BLAST2 Sequences (http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.htmn. another BLAST
program was used to produces the alignment of two given sequences using the BLAST engine
for local alignment. This program was mainly used in the comparison of human and mouse
sequences of the 3 interesting interactors identified from the yeast 2-hybrid screens.
Program Use
BLASTP Protein sequence used to search protein databases.
BLASTN Nucleotide sequence used to search NCBI nucleotide databases.
BLAST 2 Performs a comparison between 2 sequences (nucleotide or protein) using the
BLAST algorithm.
Table 2.1 Differences between BLAST programs.
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2.1.2 CLUSTAL.
This is a program that performs multiple alignments of various PAX6 protein sequences. PAX6
sequences from different organisms, which were identified by BLAST searches on the PAX6 C
terminus, were fetched from protein databases and compiled into a multiple sequence file. This
multiple sequence file was then run through CLUSTAL to produce an alignment. The
CLUSTAL alignment was run via the following web page http://www.hgmp.mrc.ac.uk
/Registered/Option/clustal.html whereas protein sequences were retrieved from databases using a
program called FETCH http://menu.hgmp.mrc.ac.uk/cgi-bin/fetchsequence.
2.1.3 JPRED.
This program predicts secondary structure for a protein sequence by combining a number of
different prediction methods to form a consensus. The secondary structure prediction was carried
out using the web page http://jura.ebi.ac.uk:8888 and the default settings were used for this
program. (More detail of the specific use of this program will be explained in subsequent results
sections).
2.1.4 Autoassembler™ 1.4.0.
This is a Mac based sequence analysis and manipulation program that was used to analyse
sequencing results (see 2.7.3). This program was mainly used to compare sequencing results and
also to produce alignments between similar stretches of sequence. This was particularly helpful
when manipulating the sequence information of interesting interactors as it was easy to tell that
certain isolated clones coded for the same protein.
2.1.5 EMBOSS (European Molecular Biology Open Software Suite).
A web interface to EMBOSS fhttp://www.hgmp.mrc.ac.uk/Registered/Webapp/emboss-w2h')
was used to access sequence analysis software tools. Frequently used components were: Remap,
which displays a sequence with protein translation and restriction sites indicated; Pepstats, which
accurately calculates protein statistics such as molecular weight from protein sequence; and
Matcher, which can compare 2 sequences and identify gaps or changes.
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2.1.6 NCBI (National Centre for Biotechnology Information).
This website ('http://www.ncbi.nlm.nih.gov/Entrez') was used to access many databases, which
are outlined in the following table.
Database
Nucleotide (Genbank)





Search for nucleotide sequences.
Investigate human genes and inherited diseases.
Search for protein sequences.
Search for biomedical literature.
Investigate gene-oriented clusters of transcript
sequences.
Table 2.2 Summary of NCBI databases.
2.2 DNA techniques.
2.2.1 Small scale preparation (miniprep) of plasmid DNA (QIAprep®).
Buffer PI (Resuspension Buffer) 50mM Tris-Cl, pH 8.0;
lOmM EDTA;
lOOpg/ml RNase A
Buffer P2 (Lysis Buffer) 0.2M NaOH,
1% w/v SDS
Buffer N3 (Neutralization Buffer) Recipe is proprietary and unavailable
Buffer PE (Wash Buffer) Recipe is proprietary and unavailable
Buffer EB lOmM Tris-Cl, pH 8.5
The following protocol is as outlined in the QIAprep Miniprep Handbook. All the centrifugation
steps are 12 OOOxg at room temperature.
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A single colony was used to inoculate 3ml of LB-broth, containing the appropriate selective
antibiotic, and was incubated overnight at 37°C with vigorous shaking (200rpm). From this
culture a 1.5ml aliquot was transferred into a 1.5ml microcentrifuge tube (Eppendorf™) and the
cells were pelleted by centrifugation at 12 OOOxg for lmin. The supernatant was discarded and
the pelleted bacterial cells were resuspended by vortexing in 250pl of Buffer PI. 250ul of Buffer
P2 was then added to the resuspended cells and the tube gently inverted 6 times. This lysis
reaction was not allowed to proceed for more than 5mins, then 350pl of ice-cold neutralising
Buffer N3 was added and the tube immediately inverted 6 times. The mixture was centrifuged
for lOmins, then the supernatant was pipetted into a preassembled QIAprep spin column in a 2ml
collection tube. The plasmid DNA was bound to the column by centrifuging the supernatant
through it for lmin. The column was then washed by adding 750pi of Buffer PE and centrifuged
for lmin. The flow through was then discarded and the column completely dried by centrifuging
for a further lmin. The plasmid DNA was then eluted into a clean eppendorf by adding 50pl of
Buffer EB into the centre of the QIAprep column, allowing it to stand for lmin and then
centrifuging for lmin. This eppendorf was then labelled and stored at -20°C.
2.2.2 Plasmid Purification (QIAGEN Plasmid Midi Protocol).
Buffer PI (Resuspension Buffer) 50mM Tris-Cl, pH 8.0;
lOmM EDTA;
lOOpg/ml RNase A
Buffer P2 (Lysis Buffer) 0.2M NaOH, l%w/v SDS
Buffer P3 (Neutralization Buffer) 3M Potassium acetate pH 5.5
Buffer QBT (Equilibration Buffer) 750mM NaCl;
50mM MOPS, pH 7;
15% Isopropanol;
0.15% Triton® X-100
Buffer QC (Wash Buffer) 1M NaCl;
50mM MOPS, pH 7
15% Isopropanol
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Buffer QF (Elution Buffer) 1.25M NaCl;
50mM Tris-Cl, pH 8.5;
15% Isopropanol
Buffer EB lOmM Tris-Cl, pH 8.5
The following protocol is as outlined in the QIAGEN® Plasmid Purification Handbook.
A single colony was picked from a freshly streaked selective plate and used to inoculate a 'day
culture' of 5ml LB-broth, containing the appropriate selective antibiotic. This 'day culture' was
incubated at 37°C for ~8hrs with vigorous shaking (200rpm). The 'day culture' was then diluted
1 in 1000 into 30ml of selective LB-broth and grown at 37°C overnight with vigorous shaking
(200rpm). The bacterial cells were then harvested by centrifugation at 6000xg for 15mins at 4°C
and the resulting pellet was resuspended in 4ml of Buffer PI by vortexing. The resuspended cell
pellet was then lysed, for 5mins at room temperature, by adding 4ml of Buffer P2. Then 4ml of
ice-cold Buffer P3 was added, mixed by inverting 6 times and incubated for 15mins on ice, to
allow precipitation of unwanted genomic DNA, protein, cell debris and SDS. This mixture was
then centrifuged at 20 OOOxg for 30mins at 4°C. Whilst this centrifugation step took place, a
QIAGEN-tip 100 was equilibrated by applying 4ml of Buffer QBT and allowing the column to
empty by gravity flow. The resulting supernatant from the centrifuged mixture was filtered
through a '597.5 Folded Filter' (Schleicher & Scuell), and then applied to the equilibrated
QIAGEN-tip and allowed to enter the resin by gravity flow. The QIAGEN-tip was then washed
twice with 10ml of Buffer QC and then the DNA was eluted with 5ml of Buffer QF into a glass
tube (Corex). The DNA was precipitated by adding 3.5ml of room temperature isopropanol to
the eluted DNA and then the precipitated DNA pelleted by centrifuging at 15 OOOxg for 30mins
at 4°C. The supernatant was then carefully decanted and the pellet washed with 2ml of room
temperature 70% ethanol. Again the DNA was pelleted by centrifugation at 15 OOOxg for lOmins
at 4°C and the supernatant discarded. The pellet was allowed to air-dry for 5mins and then the
DNA was redissolved in 200pl of Buffer EB. The resulting DNA was transferred to a clean
eppendorf, which was then labelled and stored at -20°C
Page 41
PAX6 protein-protein interactions Materials and Methods
2.2.3 Spectrophotometric quantitation of DNA.
The concentration of DNA was determined by spectrophotometric measurement at 260nm
(OD260) using a UV Spectrophotometer (Ultrospec 3000, Pharmacia Biotech). The
spectrophotometer was set to zero with dH20 and the optical density (OD) of a 1:200 dilution of
DNA determined. This reading was then used to calculate the DNA concentration. An OD of 1 is
equivalent to approximately 50pg/ml of double stranded DNA, 40pg/ml for single stranded
DNA and 20pg/ml for single-stranded oligonucleotides. The DNA purity was determined by
taking a further reading at 280nm; anything with an OD260/OD280 ratio of around 1.8 was
considered acceptable. The formula required for calculating the concentration of genomic DNA
is shown below.
(OD260)(50/zg/m/)(Dilution factor [D])DNA concentration ag/wl = -
1000
2.2.4 Restriction enzyme digestion of DNA.
Restriction endonuclease digestions were performed under the appropriate conditions as
recommended by the manufacturer (Roche), and with the buffers supplied with the enzymes.
For diagnostic digests of miniprep DNA (see 2.2.1) 5pl of DNA (~2.5pg) was digested with 10
units of enzyme, in a total reaction volume of 20pl (made up with sterile water) and incubated at
the optimal enzyme temperature (typically 37°C) for 1 hour.
For cloning strategies that required preparation of a vector fragment cut with a single enzyme,
5pg of genomic DNA was digested with 50 units of enzyme, in a total reaction volume of 60pi
and incubated at the optimal enzyme temperature for 2 hours. If a double digest was required
then 2 approaches were taken. If both enzymes worked effectively in the same reaction buffer
then 50 units of each enzyme were combined with the DNA in a total reaction volume of 120pl
and incubated at the optimal enzyme temperature for 2 hours. However, if the enzymes work in
incompatible buffers then the DNA is digested, as for a single digest, and then the buffer
conditions altered by adding suitable amounts of 500mM Tris and 500mM NaCl to mimic the
preferred buffer conditions of the second enzyme. Once the buffer condition had been adjusted
then 50 units of the second enzyme were added, the total reaction volume adjusted to 120pl and
the digest incubated at the optimal temperature for a further 2 hours.
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For cloning strategies that required preparation of an insert fragment, the restriction digest
conditions were exactly the same as for preparing a vector fragment, however, lOpg of DNA
were digested instead of 5pg.
2.2.5 5' dephosphorylation - HK™ Thermolabile Phosphatase.
////Phosphatase (Epicentre Technologies) catalyses the dephosphorylation of protruding 5'-ends
of DNA. This was used when trying to clone fragments into vector that had only been digested
with a single restriction enzyme, to reduce self-ligation of the cut vector and allow insertion of
the fragment. CaCl2 was added to the 60pi vector digest to a final concentration of 5mM and
incubated at 30°C for 5mins before the HK phosphatase was added. 5 units of HK phosphatase
was then added and the reaction incubated at 30°C for 1 hour to dephosphorylate the DNA, and
then at 65°C for 15mins to inactivate the HK phosphatase.
The QIAquick PCR purification kit (Qiagen) was used to remove restriction enzyme and
restriction enzyme buffer from digested vector (see 2.2.4), as these may have interfered with
subsequent ligation reactions. To each vector restriction digest reaction, 5 volumes of Buffer
PB* was added to 1 volume of the reaction and mixed thoroughly before loading directly onto a
QIAquick spin column. The cut DNA was bound to the column by centrifugation at 12 OOOxg
for lmin, whilst the other reaction components passed through and were discarded. The DNA
bound to the column was washed by adding 750pl of buffer PE followed by brief centrifugation
and discarding the flow through. The columns were then dried by brief centrifugation. The cut
DNA was eluted in 50pl of buffer EB, which was collected from the column into a fresh 1.5ml
eppendorf during the final centrifugation.
2.2.6 QIAquick™ PCR Purification Kit.
*For components of QIAquick kit refer to the manufacturer.
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Ethidium bromide (Bio-Rad) lOmg/ml in dH20
Store in darkness at room temperature (RT).
Tris-borate (TBE)




DNA was visualised and size fractionated by agarose gel electrophoresis. The gels were
prepared to concentrations ranging from 0.8 to 2% agarose (w/v) in the appropriate volume of
0.5x TBE buffer. The higher percentage gels were used to visualise low molecular weight DNA,
and to compare small size differences. The low percentage gels were used to visualise high
molecular weight DNA and to differentiate large size differences. The concentration of agarose
was increased up to 4% to optimise resolution of smaller fragments such as PCR products, and
in these cases NuSieve® GTG agarose (BioWhittaker Molecular Applications) was employed.
Ethidium bromide was added at a concentration of 0.5pg/ml to molten agarose before each gel
was poured. Once the gel had set it was submerged under buffer and DNA samples, combined
with one-fifth volume Orange-G loading buffer, were loaded into the wells alongside an
appropriate size marker. DNA size markers were HindlU cut bacteriophage X (Gibco BRL, now
Invitrogen) or HaeIII cut (|>X174 (Promega) or DNA Molecular Weight Marker XVII (500bp
ladder, Roche), depending on the size range of interest. The samples were then electrophoresed
through the gel at 100 volts, until the DNA had run a sufficient distance. The DNA was then
visualised by viewing under ultra violet light (on a transilluminator) and the image captured
using the UVIdoc gel documentation system, produced by UVItec.
2.2.8 Recovery of DNA from agarose gels (QIAEX II).
The following protocol is as outlined in the QIAEX II Handbook and all solutions are as
provided in the kit. All the centrifugation steps are 10 OOOxg at room temperature.
DNA was recovered from agarose using the QIAEX II Agarose Gel Extraction Kit (QIAGEN).
DNA was first electrophoreticaily separated (see 2.2.7) and the target band was excised using a
clean scalpel blade while briefly visualised by short wave UV transillumination. The excised
band was weighed and 3 volumes of Buffer QX1 was added to 1 volume of gel for DNA
fragments of lOObp to 4kb (for DNA fragments larger than 4kb an additional 2 volumes of dH20
was also added). The QIAEX II beads were vortexed for 30secs, and then either lOpl or 30pl
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QIAEX II beads was added to the sample. If the sample contained less than 2pg of DNA then
lOpl of beads were added; alternatively if the sample contained more than 2pg of DNA then
30pl of beads were added. The sample was incubated at 50°C for lOmins, mixing every 2mins,
to solubilise the agarose as well as allow the QIAEX II beads to bind the DNA. The sample was
then centrifuged for 30secs and the supernatant was carefully removed and discarded. The
pelleted QIAEX II beads were then washed once in 500pl of Buffer QX1 and then twice in
500pl of wash Buffer PE. After each wash the sample was centrifuged for 30secs and the
supernatant was discarded. After the final wash step the pellet was left to air dry for 15mins until
the pellet became white and then it was resuspended in 20pl of elution Buffer EB (lOmM
Tris-HCl, pH 8.5). The sample was incubated at room temperature for 5mins and then
centrifuged for 30secs to remove the QIAEX II beads. The eluted DNA was pipetted into a clean
eppendorf and stored at -20°C
2.2.9 Estimation of DNA concentration.
l-5pl of gel isolated DNA was made up to lOpl with 5x Orange G loading buffer and dH20 and
loaded onto an agarose gel (see 2.2.7). After a short period of electrophoresis the relative
amounts of vector and fragment DNA were estimated by comparison to 0.5pg of a relevant
DNA size marker (see 2.2.7) under ultraviolet light visualisation.
Once digested with the appropriate restriction enzymes, and modified when necessary, DNA
fragments were ligated together in lOpl reactions. A 3-fold molar excess of insert DNA: vector
DNA was used for cloning experiments. Reactions were performed in lx T4 DNA ligase buffer
containing 1 unit of T4 DNA ligase at 4°C overnight. A vector only control and a vector only
without T4 DNA ligase control were always set up to combat against incomplete restriction
enzyme cutting. The completed ligation reactions were then stored at -20°C prior to
transformation (see 2.6.1).
2.2.10 Ligation of DNA.
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2.3 RNA techniques.
2.3.1 Tri Reagent™ preparation of RNA.
RNA was isolated from the cell lines H36CE2 and mv+ (see Table 2.8) using the Tri Reagent
(Sigma) following the manufacturers protocol. All centrifugation was at 12 OOOxg at 4°C. In
brief, a T75 flask of each cell type was grown until fully confluent (see 2.9.1) and 1ml of Tri
Reagent was added directly to the flask to Iyse the cells. The cell debris was then removed by
spinning for lOmins and the supernatant was then combined with 200pl of chloroform. This
mixture was then vortexed for 15secs, allowed to settle at room temperature for 5mins before
spinning for a further 15mins. The upper aqueous phase contained the RNA and was transferred
to a fresh eppendorf where it was combined with 500pl of isopropanol and stood at room
temperature for lOmins. The mixture was then spun for lOmins and the RNA pellet washed with
lml of 75% ethanol. The pellet was air dried for 5mins and then resuspended in 50pl of nuclease
free water (Promega) and then stored in aliquots at -70°C. The RNA concentration was
determined as for DNA (see 2.2.3) but by using this different formula:
(OD260)(33^/m/)(Dilution factor [D])RNA concentration ug/ul = —
1000
2.4 The polymerase chain reaction (PCR).
2.4.1 Oligonucleotide primer design.
Oligonucleotide primers were designed by eye and were between 17-21 bases in length. The
software available on the Sigma-Genosys website (http://www.sigma-genosys.co.uk/index
2.html) was used to check primer melting point and self-complementarity. Oligonucleotide
primers were purchased from Sigma-Genosys UK Ltd. and were supplied as lyophilised
products at a synthesis concentration of 0.3pM. The details of why different oligonucleotide
primers were designed and their specific use in construct cloning will be discussed in more detail
in the relevant results sections.
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2.4.2 Polymerase chain reaction.
PCRs were carried out in a MJ Research Peltier Thermal Cycler (PTC-225 Gradient Cycler) in
0.5ml tubes, in a total reaction volume of 50ptl made up with sterile dH20. The reaction mix
contained lx Mg-free Ampli7ag polymerase buffer (Perkin Elmer), 1.5mM MgCl2, 200pM
dNTPs (Pharmacia), 0.25uM each primer, 2.5 units of Ampli7ag polymerase (Perkin Elmer) and
lOng template DNA. After an initial denaturation step of 95°C for 30secs, the PCR conditions
were 32 cycles of 94°C for 30secs, the appropriate primer annealing temperature for 30secs, and
primer extension at 72°C for 30secs, and then a final extension stage at 72°C for 2mins. Details
of the specific PCR primers used to generate various fragments can be seen in Table 2.3, which
also gives details of the specific annealing temperature for primer pairs and very brief details of
the use for each primer pair. The PCR products were always checked by running one tenth of the
PCR reaction volume on an agarose gel. If the correct PCR product had been generated then it
was stored at -20°C until used (see 2.4.8).
2.4.3 First strand cDNA synthesis.
First strand cDNA was amplified from the relevant RNA. The RNA for WHEDA and REMAR
PAX6 mutations had previously been prepared by Kathy Williamson from immortalised
leukocyte cell lines from patients and I was instructed that 2pl of RNA would be sufficient to
prepare first strand cDNA. RNA from lens epithelium cell lines had been prepared using the Tri
Reagent method (Sigma), the extracted RNA had been quantified (see 2.3.1), and 2pg was used
to prepare first strand cDNA. To the RNA lOOpmol of random hexamer primers (pdN6), lOmM
DTT and lpl RNase inhibitor were added and made up to 14pl with nuclease free H20. The
sample was then incubated at 70°C for 5mins. For each RNA sample 2 reactions were set up. In
one (+AMV), the RNA was transcribed, whereas in the other, control sample, no reverse
transcriptase was added (-AMV). To each reaction lx Reaction Buffer, ImM dNTPs and either
20 units AMV (Avian Myeloblastosis Virus) Reverse Transcriptase or H20 were added and
incubated at 42°C for one hour and then 75°C for 8mins. The cDNA obtained was either placed
on ice and used immediately for PCR, or stored at -20°C until use.
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2.4.4 RT-PCR.
Each PCR contained lx PCR Buffer*, 0.25pM forward and reverse primers, 200pM dNTPs*,
2.5 units of HotStar7ag™ DNA Polymerase* and 5pl of either the +AMV or -AMV cDNAs
(see 2.4.3), in a total volume of lOOpl. Primer sequences, annealing temperatures, and details of
the use of each primer can be seen in Table 2.4. The PCR conditions were an initial denaturation
step of 95°C for 15secs, followed by 35 cycles of 94°C for 30secs, the appropriate primer
annealing temperature for 30secs, and primer extension at 72°C for lmin, and then a final
extension stage at 72°C for lOmins. The resulting PCR products were then visualised by running
one tenth of the PCR volume on an agarose gel.
* These reagents were from the HotStarTa^ DNA Polymerase Kit (Qiagen).
2.4.5 Nested RT-PCR to generate WHEDA and REMAR PAX6 mutants.
First strand cDNA was amplified from the relevant patient RNA (see 2.4.3). Nested PCR was
then performed using a mix of AmpliTag (Perkin Elmer) and Pfu (Stratagene) polymerase (9:1
unit ratio) to increase fidelity of the resulting fragment. The first set of PCR primers had been
designed by Kathy Williamson (MRC HGU) to encompass exons 12 and 13 of PAX6 (see 9fwd
and 13rvs in Table 2.3). The second set of PCR primers were either ST004 and ST013 or ST015
and ST031 (see Table 2.3) and this generated specific fragments of mutated PAX6. The nested
PCRs were setup as for normal PCR although the enzyme used was different. 1 unit of the
AmpliTaq/Pfu mix was used per PCR and the PCR conditions were an initial denaturation step
of 95°C for 30secs, and then 30 cycles of 94°C for lmin, the appropriate primer annealing
temperature for lmin, and primer extension at 72°C for lmin, and then a final extension stage at
72°C for lOmins. As a control the nested PCRs were also set up using 2.5 units of Ampli7ag to
check that the primers worked. Again the PCR products were always checked by running them
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2.4.6 Touchdown PCR.
The PCR is set up as for the RT-PCR, except that 200ng of template DNA was added to the
reaction instead of +/- AMV cDNA (see 2.4.4). The primer sequences, melting temperatures
(mp) and the details of the use of each primer can be seen in Table 2.5. The touchdown PCR was
used to amplify MatchMaker Co-IP constructs as this type of PCR uses a cycling program with
varying annealing temperatures that increases the specificity of the PCR product. The PCR
conditions were an initial denaturation step of 95°C for 15mins, followed by 94°C for 30secs,
70°C for 30secs and 72°C for 1 or 2mins* which was repeated for 10 cycles with the annealing
temperature reducing by 1°C each cycle so that a final 20 cycles of 94°C for 30secs, 60°C for
30secs and 72°C for l/2mins could be performed. A final extension stage at 72°C for lOmins
was also included. The resulting PCR products were then visualised by running one tenth of the
PCR volume on an agarose gel (see 2.2.7).
* The extension time at 72°C was variable between 1 and 2mins due to the size of insert to be
PCR'd. An extension time of lmin was used to generate PCR products of up to lkilobase in
length. To generate larger PCR products the extension time was increased by approximately
lmin per kb DNA.
2.4.7 Poly(A) Reaction.
Pfu polymerase (Stratagene) exhibits a low error rate, making it the ideal choice for high-fidelity
PCR amplification. However, PCR products that were generated using this proof reading
polymerase were blunt ended, and so terminal deoxyadenosine needed to be added, in order that
these PCR products could be inserted into the pGEM®-T cloning system. 5ng of PCR product,
lx Ampli7ag buffer, 0.2mM dATP and 5 units of Ampli7a^ polymerase (Perkin Elmer) were
incubated, in a total volume of lOpl, for 30mins at 70°C. The poly(A) PCR product was then













































































































































































































Table 2.5 PCR primers for adding the T7 promoters and epitope tags.
This table outlines the PCR primers that were designed to add a T7 promoter (purple box) and a
eMyc epitope tag (blue box) for pDBLeu constructs or an HA epitope tag (orange box) for
pPC86 constructs.
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2.4.8 pGEM-T cloning strategy for PCR products (Promega).





The pGEM-T vector system was used as a convenient way of cloning PCR products. The single
3'-T overhang at the insertion site, which is added to this vector, is pivotal in producing a highly
efficient PCR cloning system. Certain thermostable polymerases that were used, such as
AmpWTaq (Perkin Elmer) and HotStar7ag (Qiagen), add a single deoxyadenosine to the 3'-end
of the amplified fragments, which is able to ligate to the 3'-T overhang of the vector system.
However, some PCR reactions that were performed required the use of a proofreading
polymerase such as Pfu (Stratagene, see 2.4.5), which does not add 3'A's to the generated PCR
product. Therefore, this has to be done artificially utilising a Poly(A) reaction (see 2.4.7), so that
these PCR fragment can still be cloned using the pGEM-T system.
Once the PCR products have been generated so that they contain 3'A's then they can be cloned
into the pGEM-T vector. The appropriate amount of PCR product (insert) to be included in the
ligation reaction, was calculated using the following reaction:
The concentration of PCR product was estimated by running a tenth of the total volume of PCR
product on an agarose gel (see 2.2.9). Then the correct amount of PCR product was added to
25ng of pGEM-T vector, lx rapid ligation buffer and 3 units of T4 DNA ligase, made up to a
total volume of lOpl with dH20. The ligation was then incubated overnight at 4°C and then
transformed into Library Efficiency™ DH5cx™ Competent Cells (see 2.6.2) for blue/white
screening.
ng of vector x kb size of insert
x (3 : l) insert: vector molar ratio = ng of insertkb size of vector
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2.5 Construct Cloning.
This section of the methods is by no means meant to explain the details of the cloning steps that
were required to generate the constructs that I have used as part of my PhD. More detailed
information of the specific cloning strategies can be seen in the construct cloning results chapter
(Chapter 4).
2.5.1 GATEWAY Cloning.
Tris-EDTA (TE) Buffer, pH 8.0 lOmM Tris-HCl, pH 8.0,
ImM EDTA,
Sterilise by autoclaving
The GATEWAY cloning system (Invitrogen) was used to make Homer3, Trimll and Dncll
coupled to an N-terminal GST molecule. DNA of the appropriate pPC86 clones were cloned into
the GATEWAY entry vector, pENTR3c. The LR Recombination Reaction was then used to
transfer the appropriate pPC86 derived fragments from the pENTR3c clones into a GATEWAY
destination vector pDEST™27.
lpl of pENTR3c clone miniprep DNA was combined with 300ng pDEST27, lx LR Clonase™
Reaction Buffer and made up to 18pl with TE buffer pH 8. The LR Clonase Enzyme Mix was
then thawed on ice and 2pl added to each reaction and mixed. After incubating at 25°C for lhr,
lpl of Proteinase K was added to each reaction and incubated for lOmins at 37°C. 1 pi of the LR
recombination reaction was then transformed into 50pl Library Efficiency DH5cx Cells (see
2.6.2).
2.5.2 Oligonucleotide annealing to make pDBLeu_ASNT-TTST.
This method was used to make a pDBLeu_ASNT_normal construct that was lacking the C
terminal region of PAX6. A synthetic linker was created from 2 annealed oligos (see Table 2.6),
which were designed to generate the complete PAX6 clone without the C terminal domain.
Details of this cloning procedure will be covered in more detail in the relevant results section.
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Primer Name Sequence
ST018(5'->3') TAT GCA GAC ACA CAT GAA CAG TCA GCC AAT GGG CAC CTC GGG CTA GC
ST032 (3'-»5') A CGT CTG TGT GTA CTT GTC AGT CGG TTA CCC GTC GAG CCC GAT CGC CGG
NdeI site Notl site
Table 2.6 Linker addition oligonucleotide pair used in cloning of pDBLeu_ASNT-TTST.
Bases corresponding to Ndel and Notl restriction sites are coloured in red. An artificial stop
codon (TAG) was also designed into the linker.
The oligos were ordered from Sigma-Genosys at 0.05pmol scale, with a 5' phosphate and PAGE
purified, and were received as a lyophilised powder. Both complementary oligonucleotides were
then resuspended at the same molar concentration of lOOpmol/pl, using lx T4 DNA ligase
buffer. Then equal volumes (50pl) of both complementary oligos were mixed in a 1.5ml
eppendorf tube, which was placed in a standard heatblock at 95°C. The heatblock was then
removed from the apparatus and allowed to cool to 25°C (~45-60mins). The annealed oligos
were then stored at 4°C until ready to use.
2.5.3 IMAGE clone for Homer3.
The Homer3 clones that were isolated from the yeast 2-hybrid screen were found to be missing
the N terminal 72 amino acids of the published sequence. Therefore, it was decided that it would
be interesting to investigate whether full length Homer3 protein behaved differently. Therefore,
the Homer3 image clone (IMAGE ID: 3602414) was ordered from the UK Human Genome
Mapping Project Resource Centre website (http://www.hgmp.mrc.ac.uk/geneservice/reagents
/products/image/index.shtmD. The IMAGE clone arrived streaked on LB agar containing
50pg/ml ampicillin, and as suggested, the clone was restreaked as soon as possible onto the same
medium and incubated overnight at 37°C to obtain single colonies. Then 10 isolated colonies of
this restreak were grown up overnight at 37°C in the media suggested by HGMP (LB broth +
Mg2+ containing 50pg/ml ampicillin and 8% glycerol for subsequent freezing at -70°C). These
colonies were then frozen on dry ice for 30mins and then transferred to a -70°C freezer for
storage. A single loop of this glycerol stock was then used to seed a miniprep culture and the
Homer3 DNA was prepared using the Qiagen Miniprep Kit (see 2.2.1).
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2.6 Transformation of bacterial cells with DNA.
Antibiotic Selection - Ampicillin 50mg/ml Ampicillin in dH20,
Filter sterilise,
Store at -20°C.
Ampicillin used at 50pg/ml,
Antibiotic Selection - Kanamycin 25mg/ml Kanamycin in dH20,
Filter sterilise,
Store at -20°C.
Kanamycin used at 25pg/ml
Isopropyl-P-D-thiogalactopyranoside lOOmM in dFFO
(IPTG) Filter sterilize to 0.22 microns,
Store at -20°C




pH to 7.2 with NaOH.
Sterilise by autoclaving.
Luria-Bertani (LB)-broth 1% w/v Bacto-tryptone,
0.5% Bacto-yeast extract,
0.5% w/v NaCl,
pH to 7.2 with NaOH.
Sterilise by autoclaving.





pH to 7.2 with NaOH, sterilise by autoclaving.
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SOC Replacement Medium 0.4% Glucose in LB-broth + Mg2+,
Mixture filter sterilised.
5-Bromo-4-chloro-3-indolyl-|3-D-
ga lac topyranos ide (X-gal)
20mg/ml in Dimethylformamide
Store in darkness at -20°C.




Allow the IPTG and X-Gal to diffuse into the
agar for at least 30mins.
Library Efficiency DH5a Competent Cells (Invitrogen) and XLl-Blue Subcloning-Grade
Competent Cells (Stratagene) were transformed with DNA by heat shock, according to the
manufacturer's instructions. Aliquots of competent cells were stored at -70°C prior to use.
2.6.1 XL1-Blue Subcloning-Grade Competent Cells.
These cells were used for 'general-purpose' transformations and for subcloning steps. Sufficient
eppendorf tubes for the required number of transformations were prechilled on ice. An aliquot of
competent cells was thawed on ice and 50-100pl dispensed into each tube. Next either lOng of
supercoiled plasmid DNA or 5% of the volume of cells for ligation reactions (e.g. for 50pl cells
add 2.5pl of ligation reaction), was added to each tube, swirled to mix and the tubes left on ice
for 20mins. Also for every transformation that was performed a positive control was always
included; O.lng of the pUCl8 control plasmid was added to a 50-lOOpl aliquot of cells. After
incubation on ice the cells were then heat-pulsed in a 42°C water bath for exactly 45secs
followed by incubation on ice for 2mins. 0.9ml of SOC replacement medium were added and the
tubes incubated with shaking at 37°C for 1 hour. 10pl and 200pl aliquots of the transformation
mix were plated onto fresh LB-agar plates containing the appropriate selection media and
cultured at 37°C overnight.
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2.6.2 Library Efficiency DH5a Competent Cells.
These cells were used when blue/white screening was required (e.g. when using pGEM-T
cloning of PCR generated fragments, see 2.4.8). Sufficient eppendorf tubes for the required
number of transformations were prechilled on ice. An aliquot of competent cells was thawed on
ice and 50pl dispensed into each tube. Next 2.5pl (5% of the volume of cells) of the pGEM-T
ligation reaction was added to each tube, swirled to mix and the tubes left on ice for 30mins.
Also for every transformation that was performed a positive control was always included; 500pg
of the pUC19 control plasmid was added to a 50pl aliquot of cells. After incubation on ice the
cells were then heat-pulsed in a 37°C water bath for exactly 20secs followed by incubation on
ice for 2mins. 0.9ml of SOC replacement medium were added and the tubes incubated with
shaking at 37°C for 1 hour. 5pl and 200pl aliquots of the transformation mix were plated onto
fresh X-Gal LB-agar plates and cultured at 37°C overnight.
2.6.3 ElectroMAX™ DH1 OB™ Cells.
Isolated DNA of positive interactors was electroporated into ElectroMAX DH10B cells
(GibcoBRL) using the following protocol. I pi of DNA (c. 50ng) was added to the 40pl aliquot
of competent cells and cooled on ice for 5mins. A lOpg pUC19 positive control was also
included in every transformation to estimate transformation efficiency. The gene-pulser
apparatus was then set to a capacitance of 25pF, voltage of 2.5kV and impedence of 100Q. The
cells were then placed in a chilled 0.2ml electroporation cuvette and pulsed with a time constant
of 4.5msec. The cuvette was removed from the gene pulser and 1ml of SOC replacement
medium was immediately mixed with the cells; they were then cultured at 37°C for one hour.
The cells were then spun down at 10 OOOxg, the cell pellet resuspended in 150pl of SOC
replacement medium and this was then plated onto fresh LB-agar plates containing 50pg/ml of
ampicillin and cultured at 37°C for 16 hours. This will selectively isolate the pPC86-Y plasmid,
which is ampicillin resistant, and not the pDBLeu-X plasmid.
2.6.4 Restreaking bacterial colonies.
Short-term storage of bacterial transformants is achieved by restreaking positive colonies on LB
agar plates containing the correct antibiotic selection. Transformants can be stored by this
method for up to 4 weeks at 4°C.
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A single positive clone is streaked onto an LB agar plate containing the correct antibiotic
selection and the plate is incubated overnight at 37°C. The resulting plate of single colonies can
then be stored at 4°C.
2.6.5 Glycerol stocks of bacterial colonies.
Glycerol Solution 15% Glycerol in LB-broth + Mg2+,
Long-term storage of bacterial transformants is attained by resuspending an aliquot of grown up
cells in 15% glycerol in selective media. These transformants can be stored indefinitely at -70°C.
A 1ml aliquot of overnight bacterial culture is centrifuged at 10 OOOxg for lmin. The cell pellet
is resuspended in 1ml glycerol solution and then flash frozen on dry ice for 30mins. The frozen
glycerol stock is then transferred to -70°C.
2.7 Sequencing.
DNA was sequenced using the BigDye™ terminator sequencing kit (PE Applied Biosystems),
which is a variation of the Sanger end terminator sequencing technique (Sanger et al., 1977).
2.7.1 ABI Prism® BigDye Terminator Cycle Sequencing Kit.
Termination Ready Reaction Mix Dye terminators:





(dATP, dCTP, dITP, dUTP)
Ampli7arjr DNA polymerase, FS,
with thermally stable pyrophosphatase
MgCl2
Tris-HCl buffer, pH 9.0
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The sequencing reactions were set up in 0.5ml PCR tubes and contained: 3.2pmol of sequencing
primer, approximately 750ng of template DNA, 4pl of BigDye terminator ready reaction mix
and deionised water to a total reaction volume of 20pl. Each reaction was mixed well and
collected by brief centrifugation. The sequencing process was carried out on a MJ Research
Peltier Thermal Cycler (PTC-225 Gradient Cycler), and comprised of 25 cycles of 96°C for
30secs, 47°C for 15secs (this melting temperature varies for different sequencing primers - see
Table 2.7) and 60°C for 4mins. The sequencing products were then purified.
2.7.2 Purification of BigDye sequencing products.
The sequencing reactions were purified using Edge Gel Filtration Cartridges (Edge BioSystems).
The Edge Gel Filtration Cartridges were prepared by spinning for 2mins at 750xg and then
placing in a fresh 1.5ml eppendorf. The sequencing reaction was then applied to the centre of the
packed column, the cap closed and spun for 2mins at 750xg. The eluate was then dried for
15mins in a DNA Speed Vac® (Savant) set at medium drying rate. These dried samples were
then stored at -20°C until sequenced by the sequencing service.
2.7.3 Sequencing Service.
Sequencing gels were run either by Angie Fawkes or Alison Condie on an ABI 3100 Capillary
Sequence Analyser. The resulting sequence traces were then analysed using either the Chromas
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2.8 Yeast 2-hybrid System.
The yeast 2-hybrid work was carried out using the ProQuest™ Two-Hybrid System (Gibco
BRL). The system was used to investigate possible interactions between the proteins encoded by
a mouse brain cDNA library (Gibco BRL) and the protein generated by the construct
pDBLeu_TTST_norm or pDBLeu_ASNT_norm, which correspond to the wild type C terminal
domain of PAX6, and the PST region of PAX6 respectively, in the yeast 2-hybrid vector
pDBLeu.
2.8.1 ProQuest Two-Hybrid Mouse Brain cDNA Library.
The cDNA library was used to prepare double-stranded plasmid DNA that was used with the
ProQuest Two-Hybrid System. The Gibco BRL protocol for the amplification and preparation of
plasmid DNA from an amplified cDNA library was followed exactly and the resulting DNA was
stored at -20°C in I pg/ul aliquots.
2.8.2 Small-scale preparation of competent MaV203 cells.
Tris-EDTA (TE) Solution (lOx) lOOmM Tris-HCl pH 7.5,
lOmM EDTA,
Sterilise by autoclaving
Lithium Acetate (LiAc) Solution (lOx) 1M Lithium acetate,
Sterilise by autoclaving.
TE/LiAc Solution (1 x) 10% v/v lOx TE,
10% v/v lOx LiAc,
Make fresh and store on ice.
YPAD broth 1 % w/v Bacto-yeast extract,
2% w/v Bacto-peptone,
2% w/v Glucose,
0.01% w/v Adenine sulphate,
pH to 6 with HC1,
Sterilise by autoclaving.
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YPAD Agar 2% w/v Bacto-agar,
non-autoclaved YPAD medium,
pH to 6 with HC1,
Sterilise by autoclaving.
MaV203 cells were streaked out from the glycerol stock (supplied in Gibco BRL Two-Hybrid
System Kit) onto a YPAD plate and grown for 48 hours at 30°C. Several of the resulting single
colonies were then resuspended in 50pl of dH20 and spread in a circle into the middle of a fresh
YPAD plate, which was then grown overnight at 30°C. The resulting circle of cells was then
resuspended in 5ml dH20 and the optical density at 600nm was determined. A sufficient amount
of this cell suspension was added to 100ml YPAD broth in a 500ml flask to produce a final
ODgoo of 0.1. The MaV203 culture was then incubated at 30°C with shaking (250rpm) for 4-5
hours until the OD^o reached 0.4. The 100ml culture was split into 2x 50ml aliquots and the
yeast cells of each aliquot were then pelleted by spinning at 3000xg for 5mins at room
temperature. The cell pellet was then resuspended in 20ml dH20 and spun for a further 5mins at
3000xg at room temperature. The resulting pellet was washed in 10ml of lx TE/LiAc solution
and spun for a further 5mins at 3000xg. The final cell pellet was then suspended in 175pl of lx
TE/LiAc solution and the two aliquots were pooled. This protocol produced enough MaV203
cells for 7 yeast transformations (see 2.8.3).
2.8.3 Small-scale yeast transformation.
Amino Acid Mix 2g of each of the following:
Adenine sulphate, alanine, arginine, aspartic acid,
asparagine, cysteine, glutamic acid, glutamine,
glycine, isoleucine, lysine, methionine,
phenylalanine, proline, serine, threonine, tyrosine,
valine.
PEG/LiAc Solution 10% v/v lOx TE,
10% v/v lOx LiAc,
80% v/v 50% PEG-3350,
Make fresh and store on ice.
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SC Agar 0.705% w/v Difco™ Yeast Nitrogen Base w/o
amino acids,
0.142% w/v Amino Acid Mix,
pH to 5.9 with NaOH,
2% w/v Bacto-agar,
Autoclave to sterilise and melt agar.




Added to autoclaved SC Agar, mixed and poured.
SC-Leu-Trp Agar Plates 2% w/v Glucose,
0.16mM Uracil,
0.8mM Histidine,
Added to autoclaved SC Agar, mixed and poured.
Sonicated Salmon Sperm 50pi Sonicated salmon sperm (lOmg/ml),
Boiled for 5mins,
Incubate on ice until used.
For each transformation 50pi of MaV203 cells were combined with 5pl of freshly boiled carrier
DNA (sonicated salmon sperm) and lOOng of each plasmid DNA in an autoclaved 1.5ml
eppendorf. This was mixed gently by pipetting up and down and then 300pl of PEG/LiAc
solution was added, mixed and then incubated at 30°C for 30mins. The yeast cells were then
'heat-shocked' for 15mins at 42°C, centrifuged at 7000xg for 30secs and the cell pellet was
resuspended in 500pl of dH20. To obtain well-separated colonies, lOpI and 200pl of the
suspension was spread over the appropriate SC agar selection plates (SC-Leu plates for single
transformants or SC-Leu-Trp for double transformants). The plates were incubated at 30°C for
48-72 hours until colonies appeared.
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2.8.4 Determining the optimum 3AT concentration needed for library
screening.
HIS3 is a reporter gene that is used as the first selection for possible interacting proteins. The
enzyme produced by this reporter gene (imidazole glycerol phosphate dehydratase) is inhibited
by 3-amino-l, 2, 4-triazole (3AT) in a dose-dependent manner. In order for the library screening
to be a success any background growth, due to self-activation of the HIS3 reporter by
pDBLeu-X, has to be eliminated so that only positive interactors will be seen. Therefore,
following the protocol outlined by the ProQuest 2-Hybrid System (Gibco BRL, pages 16-17),
pDBLeu_TTST_norm and pDBLeu_ASNT_norm were titrated against 3AT. It was found that
7.5mM 3AT was needed to eliminate basal levels of HIS3 reporter gene expression for
pDBLeu_TTST_norm and lOmM 3AT was needed for pDBLeu_ASNT_norm.
2.8.5 Screening the cDNA library for possible interactions with pDBLeu
constructs.
SC-Leu-Trp-His + 3AT Agar Plates 2% w/v Glucose,
0.16mM Uracil,
7.5 or lOmM 3-Amino-l,2,4-Triazole (3AT),
Added to autoclaved SC Agar and incubated at
50°C for 30mins before pouring into plates.
PAX6 constructs and the mouse brain cDNA library were co-transformed into library efficiency
MaV203 competent cells (Gibco BRL) using the method in the ProQuest 2-Hybrid protocol
(Gibco BRL). Firstly, 2x 250pl aliquots of cells were each combined with 7.5pg of DNA
binding domain vector (pDBLeu) containing a test gene (i.e. pDBLeu_TTST_norm or
pDBLeu_ASNT_norm) and 7.5pg of activation domain vector (pPC86) containing the cDNA
library (see 2.8.1) in a 1.5ml eppendorf. Each eppendorf of cells and DNA was combined with
1.5ml of the supplied PEG/LiAc solution and incubated at 30°C for 30mins. Then 88pl of
DMSO were added to each tube and the cells were heat shocked for 20mins at 42°C. The
transformed cells were then pelleted at 640xg for 5mins and each cell pellet was resuspended in
8ml of 0.9% NaCl. To ensure that sufficient cells were transformed to represent the cDNA
library several dilutions (ranging from 1:50 to 1:1500) of the transformed cells were plated onto
10cm SC-Leu-Trp plates and incubated at 30°C for 3-4 days. The remainder of the transformed
cells were then plated in 400pl aliquots onto 40x 15cm SC-Leu-Trp-His+3AT plates and
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incubated at 30°C for 3 days (correct concentrations of 3AT determined in 2.8.4). In tandem
with this library screen a control transformation was also included to ensure that the
transformation worked correctly. This control involved combining 25pl cells with 1 jxg of
pMAB12 and pMAB37 DNA and incubating with 180pl PEG/LiAC at 30°C for 30mins. Then
10.8pl of DMSO were added and the cells were heat shocked for 20mins at 42°C. The cells were
then pelleted as before and resuspended in 1ml 0.9% NaCl. Then 1:100 and 1:1000 dilutions of
the transformed cells were plated onto 10cm SC-Leu-Trp plates and incubated at 30°C for 3
days.
After the 3 days incubation at 30°C, both the screen plates and the control plates were replica
cleaned, using velvet and then returned to 30°C for further incubation. The development of HISS
positive colonies was then recorded for up to a week at which time HIS3 positive colonies were
stored as described in 2.8.6.
2.8.6 Storing HIS3 positive transformants.




In SC media (SC Agar without Bacto-agar).
Before testing HIS3 positive transformants further, it was vital that these colonies were stored so
that re-testing could be accomplished. This was done using this derived technique. A single
colony that grew on the SC-Leu-Trp-His+3AT plate was dissolved in 50pl of dH20 and then
spread on a quadrant of an SC-Leu-Trp plate and grown at 30°C for 3 days. This whole quadrant
was then scraped off the plate and dissolved in 1ml of yeast freeze solution and stored at -80°C.
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2.8.7 Confirming HIS3 positive transformants using 3 reporter genes.
SC-Leu-Trp-Ura Agar Plates 2% w/v Glucose,
0.8mM Histidine,
Added to autoclaved SC Agar, mixed and poured.
SC-Leu-Trp + 5FOA Agar Plates 2% w/v Glucose,
0.16mM Uracil,
0.8mM Histidine,
0.2% w/v 5-Fluoroorotic acid (5FOA),
Added to autoclaved SC Agar and incubated at
50°C for 30mins before pouring into plates.
The resulting colonies were further tested to confirm whether any interaction was positive using
3 reporter genes (HIS3, URA3 and lacZ) that have been integrated into the yeast genome.
Technical information for this can be found in the ProQuest 2-Hybrid system manual (Gibco
BRL, pages 19-22).
H1S3: As already mentioned positive interaction means that growth will occur on plates
lacking histidine. As before plates contained the optimal concentration of 3AT to eliminate
background growth.
URA3\ As with HIS3, a positive interaction will allow growth on plates lacking uracil. This
tests for high-level activation of the URA3 reporter gene and so will identify strong interactions.
However, the URA3 reporter gene can be used for additional confirmation of positive
interactions as the induction of URA3 causes 5-fluoroorotic acid (5FOA) to be converted into
toxic 5-fluorouracil. Therefore, the growth of the cells containing interacting proteins will be
inhibited on plates containing 5FOA. In contrast this tests for low-level activation of the URA3
reporter gene and is therefore able to test for weak interactions.
LacZ\ Interacting proteins will activate the lacZ reporter gene, which will cause X-Gal
(5-bromo-4-chloro-3-indolyl-(VD-gaIactopyranoside) to turn blue in a (Tgal assay.
For this method, HIS3 positive transformants were prepared as single colonies from the stored
glycerol stocks, by restreaking the glycerol onto an SC-Leu-Trp plate quadrant and incubating it
at 30°C for 3 days. Single colonies were then picked and plated in quadruplicate onto a single
plate called a 'master plate' (see Figure 2.1). This master plate also included the 5 supplied yeast
control strains (A-E), which were plated in duplicate and also the relevant pDBLeu-X + pPC86
negative control, which was also plated in duplicate.
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Negative control.








Figure 2.1 Yeast 2-Hybrid master control plate layout
The master plate was incubated at 30°C for 24 hours. The master plate was then replica plated,
using velvet, onto the following plates, in the order listed: YPAD containing a Hybond™-N
nylon membrane (Amersham pharmacia biotech); SC-Leu-Trp-Ura; SC-Leu-Trp-His + 3AT
(replica cleaned); SC-Leu-Trp + 5F0A (replica cleaned). These plates were incubated at 30°C
for 24 hours and then the YPAD plate was used in an X-Gal assay (see 2.8.8) and the remaining
plates were replica cleaned and then further incubated at 30°C for a further 48 hours. The
resulting phenotypes of the potential positives were then compared to the Yeast Control Strains





Store in darkness at -20°C.
Z Buffer 60mM Anhydrous di-sodium hydrogen
orthophosphate (Na2HP04),
40mM Anhydrous sodium phosphate (NaH2P04),
lOmM Potassium chloride (KC1),
ImM Anhydrous magnesium sulphate (MgS04),
Adjust to pH 7.0 and autoclave.
Z/X-Gal Reaction Buffer lOOpl X-Gal (lOOmg/ml),
60pl (1-mercaptoethanol,
10ml Z buffer,
This is enough for one membrane.
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As described in the previous section (see 2.8.7) the master plate had been replica plated directly
onto a Hybond-N nylon membrane and incubated for between 18-24 hours at 30°C. Two round
125mm Whatman 541 filter papers were stacked in a 15cm Petri dish and saturated with 8ml of
the Z/X-Gal Reaction Buffer. Any air bubbles were removed as well as any excess reaction
buffer. The Hybond-N membrane was flash frozen for 30secs in liquid nitrogen to permeabilise
the colonies, and then left to thaw at room temperature. The membrane filter was then
transferred to the prepared 15cm Petri dish, colony-side up and incubated at 37°C (Parafilm was
wrapped around the Petri dish to minimise the smell of (3-mercaptoethanol). The appearance of
the blue colour was monitored over 24 hours and then finally scored after 24 hours according to
the rate at which the colonies turned blue: strong interactors show blue colour within 1 hour (e.g.
Yeast Control Strain E); weak interactors show blue colour within 24 hours (e.g. Yeast Control
Strain B). The appearance of blue colonies in yeast cells transformed with only one of the yeast
expression plasmids would indicate that the expressed fusion protein auto-activates the system.
2.8.9 Plasmid DNA extraction from Yeast.
SC-Leu-Trp media 2% w/v Glucose,
0.16mM Uracil,
0.8mM Histidine,
In SC media (SC Agar without Bacto-agar).
Plasmid DNA isolated from yeast is typically not suitable for restriction analysis or sequencing.
Therefore, plasmid DNA was first isolated from yeast, and then introduced into E. coli by
electroporation (see 2.6.3). Then the resulting transformants were miniprepped (see 2.2.1), and
this DNA was suitable for restriction analysis and sequencing.
The method used for the isolation of plasmid DNA from yeast was as described in the ProQuest
2-Hybrid System manual (Gibco BRL, pages 41-42). For this method single colonies were
needed and so the glycerol stock (see 2.8.6) was streaked out onto a quadrant of an SC-Leu-Trp
plate and incubated at 30°C for 3 days. A single colony was then suspended in 1ml of
SC-Leu-Trp media and incubated at 30°C with shaking for 24 hours. The resulting culture was
spun at 14 OOOxg for 30secs and the yeast cell pellet was suspended in 100pi of freshly prepared
3% sodium dodecyl sulphate (SDS), 0.2M sodium hydroxide (NaOH). This was incubated at
room temperature for 15mins and then 500pl of IxTE, 60pl of 3M sodium acetate and 600ul of
phenol: chloroform: isoamyl alcohol (25:24:1, Fluka) were added in series mixing after each
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addition. The resulting mixture was then vortexed at full speed for 2mins and then centrifuged at
14 OOOxg for 2mins. The upper aqueous phase was transferred to a new 1.5ml eppendorf and
another 600(d of phenol: chloroform: isoamyl alcohol was added, vortexed and spun as before.
The upper aqueous phase was once again transferred to a fresh 1.5ml eppendorf and 650pl of
cold isopropanol was added, mixed and incubated at -20°C for 20mins. The tube was then
centrifuged for 5mins at 14 OOOxg, the supernatant carefully discarded, and the pellet washed in
lOOpl of 70% ethanol. After spinning for a further 5mins at 14 OOOxg and removing the
supernatant the pellet was suspended in lOpl of lxTE and stored at -20°C until used to
electroporate ElectroMAX DH10B cells (see 2.6.3).
2.9 Cell Culture.
DMEM - Full media 90% (v/v) DMEM (Dulbecco's Modified Eagle
Medium),




Store at 4°C but warm to 37°C before use.
DMEM - No antibiotics 90% (v/v) DMEM (Dulbecco's Modified Eagle
Medium),
10% (v/v) FCS (Foetal Calf Serum),
2mM Glutamine,
Store at 4°C but warm to 37°C before use.
Freeze Buffer 10% (v/v) DMSO,
90% (v/v) FCS, Store at -20°C.
Trypsin: Versene (T:V) 1:1 Trypsin: Versene,
Store at 4°C but warm to 37°C before use.
V3 Media 1:3 Versene: PBS
Store at 4°C but warm to 37°C before use.
Page 70
PAX6 protein-protein interactions Materials and Methods
2.9.1 Growth of cell lines in vitro.
An Envair Class II Microbiological Safety Cabinet provided the sterile environment for tissue
culture. Cells were grown in T75 tissue-culture flasks with filter caps (CellStar®) in DMEM full
medium at 37°C with 5% carbon dioxide. The 2 cell lines that were commonly used are outlined
in Table 2.8. Adherent cell layers were routinely passaged at subconfluency, normally every 2-3
days
Cell Line Info Supplied by
mv+
H36CE2
Mouse lens epithelium cell line
Human lens epithelium cell line
Veronica van Heyningen.
Veronica van Heyningen.
Table 2.8 Cell line information.
2.9.2 Passage of surface-adherent cells.
The growth medium was aspirated from the flask and the cells were washed once in 12ml of V3
media. Then 12ml of T:V was added to the cells and the flask was incubated at 37°C until the
cells had begun to dissociate from the flask, typically 10-15mins. The detached cells were then
re-seeded at a suitable density, typically 1:10 or 1:20, into a fresh T75 flask containing 30ml
pre-warmed DMEM full media. The flask was then returned to the 37°C incubator.
2.9.3 Preparation and recovery of cell stocks.
For long-term storage cells were stored in liquid nitrogen. The cells were first treated as if they
were to be normally passaged. However, once the cells had been detached from the flask, they
were transferred to a falcon tube and the volume made up to 50ml with DMEM full medium.
The cell suspension was then centrifuged for 3mins at 750xg. The supernatant was carefully
removed and the cell pellet was resuspended in 9ml of Freeze Buffer. 1ml of cell suspension per
vial was aliquoted into NUNC™ cryotubes (Nalge Nunc International) and the cells slow-frozen
at -70°C before transferring to liquid nitrogen the next day. To recover the cells, a cryotube was
removed from liquid nitrogen, defrosted, and in a safety cabinet, used to seed a T75 flask
containing 30ml of pre-warmed DMEM full medium. Following overnight incubation at 37°C
the medium was replaced with fresh medium and these cells were then treated as normal.
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2.9.4 Determining cell number.
To aid the reproducibility of the transfection method (see 2.9.5) the number of cells per ml was
determined by using a haemocytometer. Cells were detached from the flask according to the
passage protocol (see 2.9.2) and irrespective of the total volume in which the cells had been
resuspended, the number of cells xlO4 present in 1ml was represented by the number of cells
counted under the microscope within the 5x5 square grid of the haemocytometer. The following
equation was then used to calculate the volume of cell solution required to give a specific
number of cells per well:
Cells to be added („1> = Sped"C Ce" "enS"y x 1000
Cell number per ml
To a 6 well microtitre plate, 3ml of antibiotic free DMEM media was added per well. Then cells
were added at the relevant cell density, which was typically between 1-6 x 105 cells per well.
The cells were then incubated at 37°C overnight.
2.9.5 Transfecting cells using Lipofectamine™ 2000.
The transfection of tissue culture cells requires that the cells be seeded at a specific cell density
24 hours before transfection so that specific cell confluency can be achieved. The Lipofectamine
2000 (Invitrogen) transfection protocol advised that cells should be 90-95% confluent at the time
of transfection. However, due to the very high growth rate of the mouse lens epithelial cell line,
a lower confluency was favoured. Therefore, the cells were seeded so that they would be roughly
50% confluent at the time of transfection (1-2 x 105 cells / well for a 6-well plate, seeded 24
hours before transfection - see 2.9.4). The optimised transfection protocol involved transfecting
2.5pg of DNA into cells using 6pl of Lipofectamine 2000. Both the 2.5ug of DNA and the 6pl
of Lipofectamine 2000 were each diluted in 250pl Opti-MEM I Reduced Serum Media. The
diluted Lipofectamine 2000 was incubated at room temperature for 5mins and then mixed with
the diluted DNA, and incubated for a further 20mins at room temperature. The entire 500pi of
DNA/Lipofectamine mix was then added to a well in a 6-well plate, which contained 3ml of
fresh antibiotic free DMEM media. The cells were then left to incubate at 37°C for 48 hours,
although the medium was replaced with fresh medium after 24 hours transfection.
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2.10 Protein methods.
Acrylamide (Bio-Rad) 30% Stock Acrylamide/Bis Solution,
37.5:1 Acrylamide: A,/V'-methylenebisacrylamide
Blocking Buffer 5% w/v Fat free powdered milk (Marvel),
0.2% v/v Tween 20,
in PBS,
Make up fresh and store at 4°C
Laemmli Running Buffer 125mMTris,
(5x Stock) 1.25M Glycine,
0.5% (v/v) SDS,
Store at 4°C
Laemmli Sample Buffer 10% (v/v) Glycerol,
(2x Stock) 4% (w/v) SDS,
60mM Tris, pH 6.8,
0.1% (w/v) Bromophenol Blue,
Add 200mM (dithiothreitol) DTT immediately
before use.
Ponceau S Stain 0.2% (w/v) Ponceau S,
in 3% (v/v) Glacial acetic acid.
Running Gel (10%, 12%, 18%) 10%, 12% or 18% Acrylamide/Bis Solution,
375mM Tris, pH 8.8,
0.1% SDS,
0.1% (w/v) Ammonium persulphate (APS),
Typically made up to lOmls with dH20,
4pl TEMED.
Overlaid with dH20, allowed to set in plates
(~30mins)
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Stacking Gel (5%) 5% Acrylamide/Bis Solution,
125mM Tris, pH 6.8,
0.1% SDS,
0.1% (w/v) APS,
Typically made up to 3mls with dH20,
3pl TEMED.





Wash Buffer (TBS+ Tween) lOmM Tris-HCl, pH 7.5,
150mM NaCl,




SDS-polyacrylamide gel electrophoresis was performed using the Bio-Rad Mini-PROTEAN® 3
cell. The Bio-Rad Mini-PROTEAN 3 cell instruction manual is comprehensive in its explanation
of how to assemble and pour SDS-polyacrylamide gels and can be downloaded from the Bio-
Rad website at http://www.biorad.com/cmc upload/Literature/44432/4006 l57B.pdf. Separating
and stacking gels were prepared as described in the instruction manual using the recipes given
above. Although a 5% stacking gel was always used, a range of separating gels (10%-18%) was
made to resolve protein bands of various sizes. High percentage separating gels were used to
separate proteins with small molecular weights and vice versa. Protein samples were prepared by
mixing protein lysate with an equal volume of 2x Laemmli sample buffer (containing ImM
DTT) and boiling at 100°C for 5mins. The reduced protein samples were then loaded into the
wells of the stacking gel along with the correct markers. 2 types of markers were routinely used:
Full Range Molecular Weight Rainbow Markers RPN800 (Amersham Pharmacia), lOpl
commonly run on low percentage separating gels; and Low Molecular Weight Rainbow Markers
RPN755 (Amersham Pharmacia), prepared in Laemmli sample buffer and then lOpl loaded on
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high percentage separating gels. The gel was submerged in lx Laemmli running buffer and
electrophoresis performed at 150 volts for 1-2 hours. Progress of the migrating protein was
monitored by the progress of the rainbow markers.
2.10.2 Electrophoretic Transfer to Hybond-P.
Electrophoretic transfer of protein was performed using the Bio-Rad Trans-Blot Semi-Dry
Electrophoretic Transfer Cell. The Bio-Rad Trans-Blot SD cell instruction manual is
comprehensive in its explanation of how to assemble a 'transfer sandwich' and can be
downloaded from the Bio-Rad website at http://www.biorad.com/cmcupload/Literature/12490/
M1703957B.pdf.
Following SDS-PAGE (see 2.10.1), the gel was equilibrated in transfer buffer for 15mins. An
appropriately sized piece of polyvinylidene difluoride (PVDF) Hybond-P membrane (Amersham
Pharmacia Biotech) was pre-wetted in methanol for lOsecs, rinsed in distilled water and then
was also incubated in transfer buffer for 15mins. A 'transfer sandwich' was then assembled on
the Trans-Blot SD Transfer Cell, which was run at 15 volts for 1 hour. Following transfer it was
ascertained whether protein had successfully been transferred by staining the Hybond-P
membrane with Ponceau S. The membrane was stained with Ponceau S for lOsecs and then the
protein bands were visualised by washing 3 times in dH20. The membrane was then incubated
overnight in blocking buffer at 4°C in preparation for western blotting (see 2.10.3).
2.10.3 Western Blotting.
Following overnight incubation in blocking buffer at 4°C, the membrane was then incubated
with the appropriate primary and secondary antibodies (see Tables 2.9 and 2.10 respectively).
The volume of blocking buffer that was used to dilute the primary antibody was 0. lml/cm2
membrane. The membrane was then sealed into a plastic pocket and incubated for 2 hours with
end over end mixing at 4°C. The membrane was then removed from the plastic pocket and
rinsed 3 times with wash buffer, followed by lx 50ml wash for 15mins and 2x 50ml washes for
5mins each. Then the appropriate HRP-conjugated secondary antibody was diluted in 20ml of
blocking buffer and incubated with the membrane at room temperature for 90mins. Finally the
membrane was washed as before and then the signal was detected using ECLplus (Amersham
Biosciences), according to the manufacturer's instructions. When ECL detection was used,
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MACO-X-RAY HS90 medical film (Scientific Laboratory Supplies, SLS) was exposed and
developed using a Hyper Processor (Amersham Life Science).
Name. Antibody. Company. Dilution.
C' PAX6 Rabbit anti-PAX6 polyclonal antibody Chemicon International 1:1000
GST Goat anti-GST polyclonal antibody Amersham 1:4000
FLAG Mouse anti-FLAG® M2 Monoclonal antibody Sigma 1:1000
PAX6 Cocktail of 4 PAX6 antibodies:
Chick PAX6 aa 1-223 antibody DSHB* 1:100
Human PAX6 aa 1 -206 Sera AD 2.35.8 Dieter Engelkamp 1:50
Human PAX6 aa 1-206 Sera AD 2.3.7B Dieter Engelkamp 1:50
Human PAX6 aa 1-206 Sera AD 2.38.9B Dieter Engelkamp 1:50
Table 2.9 Primary antibody dilutions.
This table shows the primary antibodies that were used. The PAX6 cocktail is a mix of 4
different antibodies: An antibody from the Developmental Studies Hybridoma Bank (DHSB)
designed against the first 223 amino acids of chick PAX6; 3 different monoclonal antibodies
made by D. Engelkamp against the first 206 amino acids of human PAX6 (Engelkamp et ai,
1999).
Name. Antibody. Company. Dilution.
C' PAX6 anti-rabbit HRP conjugated DAKO 1:5000
GST anti-goat HRP conjugated DAKO 1:10 000
FLAG anti-mouse HRP conjugated Sigma 1:80 000
PAX6 anti-mouse HRP conjugated Sigma 1:80 000
Table 2.10 Secondary antibody dilutions.
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2.10.4 Large scale protein preparation from cells.
Lysate Buffer 150mM NaCl,
50mM Tris, pH 7.5,




Add lx protease inhibitors before use.
Protein was isolated from the lens epithelium cell lines (see Table 2.8) so that they could be used
as positive controls when Western Blotting with PAX6 antibodies. The method used to isolate
protein was very similar to that routinely used as part of the immunoprecipitation protocol. A
T75 flask of each cell type was grown until fully confluent (see 2.9.1), washed with 12ml V3
media and detached from the flask in the normal way using 12ml T:V media (see 2.9.2). 6ml of
the dissociated cells were then combined with 24ml of DMEM full media and spun for 5mins at
750xg. The supernatant was then removed, the cell pellet resuspended in 250pl of Lysate Buffer
and the mixture sonicated on ice for 5mins to reduce the viscosity of the cells. The sample was
then boiled for 5mins and spun at 12 OOOxg for 5mins, and the supernatant was removed to a
fresh 1,5ml eppendorf. The protein concentration was determined using the Bio-Rad DC protein
assay (see 2.10.5) and the protein was stored in aliquots at -70°C.
2.10.5 Quantification of protein by use of the Bio-Rad DC Protein Assay.
Protein concentrations were determined using the Bio-Rad DC Protein Assay detection kit, as
per the manufacturer's instructions. Briefly, 5pl sample was mixed with 25pl Reagent A, 200pl
Reagent B and then incubated for 15mins. The absorbance at 750nm was read using a UV
spectrophotometer. A BSA (bovine serum albumin) standard curve was generated each time the
assay was performed by plotting absorbance values obtained from a range of BSA dilutions from
0-1.5mg/ml, and was used to determine the concentration of protein samples.
2.10.6 Subcellular Proteome Extraction Kit (Calbiochem®).
This kit was used to extract 4 subcellular fractions from an 80% confluent T25 flask of mouse
lens epithelium cells (mv+, see Table 2.8). The 4 subcellular fraction contained: cytosolic
proteins; membrane and organelle proteins; nucleic proteins; and cytoskeletal matrix proteins.
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The subcellular proteome extraction kit protocol was followed exactly for adherent cells, as mv+
cells are adherent cells, and as recommended in the protocol when the cells began to detach after
incubation with extraction buffer I the suspension cell protocol was followed from then on.
Samples were prepared for analysis by SDS-PAGE by combining 15pl of each subcellular
fraction with an equal volume of 2x Laemmli sample buffer (containing ImM DTT) and boiling
at 100°C for 5mins. lOpl of each sample was then loaded onto a 12% SDS-polyacrylamide gel
(see 2.10.1).
2.10.7 In vitro translation of 35S radioactively labelled protein.
35S radioactively labelled protein was produced from QIAquick cleaned PCR amplified DNA
and control vector DNA using the TnT® Coupled Reticulocyte Lysate System (Promega). In
vitro translation reactions were initially made up to a volume of 23pi with nuclease free water
and: 2pl of TnT reaction buffer; lpl of T7 RNA polymerase; lpl of amino acid mixture minus
methionine (ImM); lpl of RNasin ribonuclease inhibitor (40U/pl); and either 0.5pg of control
vector DNA (0.5pg/pl) or approximately 200ng of sample PCR DNA (~20ng/pl). The reaction
was then transferred to a fume hood and 2pl of 35S methionine (20pCi of Amersham Pharmacia
Redivue™ L-[35S]methionine) was added to the reaction with adequate radioactive shielding.
The total reaction volume was then made up to 50pl by adding 25pl (50% v/v) of TnT rabbit
reticulocyte lysate with adequate radioactive shielding. The in vitro translation reaction was then
incubated at 30°C for 90mins and then stored overnight at -20°C before being used in the
Matchmaker co-IP kit (see 2.11.5).
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2.11 Co-lmmunoprecipitation.
Lysis Buffer (1% NP-40) 150mM NaCl,
50mM Tris, pH 8,
1% NP-40 (Non-idet P),
Store at 4°C,
Complete Protease Inhibitor Cocktail 1 tablet (Roche),
(25x Stock) Dissolved in 2ml dH20.
Store at -20°C for up to 4 weeks.
2.11.1 Cell Lysis.
After 48 hours transfection (see 2.9.5) the cells were washed in 1ml of room temperature PBS.
The transfected cells were then treated with 250ul of chilled lysis buffer containing Ix protease
inhibitors (PI), and incubated on ice at 4°C for 30mins, with occasional rocking. The cell lysate
was then transferred to a chilled 1.5ml eppendorf and spun at 10 OOOxg for lOmins at 4°C. The
supernatant was then removed to a fresh 1.5ml eppendorf. At this stage lysate was either used for
pre-clearing and immunoprecipitation (see 2.11.3 and 2.11.4) or alternatively 15pl of lysate was
added to 15pl of 2x Laemmli sample buffer (containing ImM DTT), boiled for 5mins and then
lOpl was analysed by SDS-PAGE and Western Blotting (see 2.10.1 to 2.10.3).
2.11.2 Preparing protein G.
Protein G sepharose fast flow beads were used in immunoprecipitation, as protein G is able to
facilitate the purification of specifically tagged proteins. Protein G can bind to a certain antibody
that recognises the tagged protein, and then this complex can be purified from a complex
mixture of proteins using centrifugation and washing steps. The protein G sepharose was
supplied in 20% ethanol and so needed to be washed 3 times in lysis buffer + PI before use.
2.11.3 Pre-clearing Lysate.
To reduce non-specific background bands, the cell lysate was first pre-cleared by incubating
with protein G beads only. 200pl of the cell lysate was mixed with 50pg of protein G and made
up to 500pi with lysis buffer + PI. A negative control that only contained lysis buffer + PI and
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protein G was also always included. The pre-cleared lysates were then incubated at 4°C for 1
hour with end over end mixing.
2.11.4 Immunoprecipitation.
After the pre-clearing step the samples were spun at 10 OOOxg for lmin at 4°C. The supernatant
was then poured into a fresh 1.5ml eppendorf and combined with 15pg of protein G and 0.1 ug
of goat anti-GST polyclonal antibody (Amersham). The samples were then incubated at 4°C for
2 hours with end over end mixing. It is vital at this stage that the experiment be kept chilled to
reduce the amount of background bands. Therefore, the immunoprecipitation samples were spun
at 10 OOOxg for lmin at 4°C and washed with 1ml of chilled lysis buffer + PI. The washing step
was repeated 4 times so that the beads were thoroughly washed to remove any unbound protein.
After the washing steps the protein G beads were suspended in 30pl of 2x Laemmli sample
buffer (containing ImM DTT) and boiled for 5mins to remove the bound protein from the
protein G beads. The sample was then spun at 10 OOOxg and lOpl of the supernatant was
analysed by SDS-PAGE and Western Blotting (see 2.10.1 to 2.10.3).
2.11.5 Matchmaker Co-IP Kit (BD Biosciences).
The Matchmaker co-immunoprecipitation kit was followed exactly as outlined in the BD
Biosciences protocol. In vitro translated (see 2.10.7) protein was used to perform in vitro
co-immunoprecipitation; however the specific details of proteins used in these reactions can be
seen in Chapter 8.9. In brief 35S radioactively labelled bait and library proteins were incubated
together to allow interaction, and then either the cMyc or HA antibody was added to purify the
proteins. Negative controls were also included to identify if there was non-specific binding of
the incorrect antibody and epitope (i.e. cMyc purifying library protein containing the HA
epitope). Protein A beads were then added to isolate the co-immunoprecipitation antibody
complex and then a series of washes were performed. The washed beads were then combined
with 2x Laemmli buffer, boiled and analysed by SDS-PAGE (see 2.10.1). After electrophoresis
the gel was fixed and amplified and then dried at 80°C under constant vacuum. The gel was then
exposed to X-ray film (same as in western blot, see 2.10.3) for up to 11 days at room
temperature.
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Chapter 3 Defining the C terminal region of PAX6
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3.1 Introduction.
As already discussed in the main introduction (see 1.76 and 1.8) it has been inferred from
examining several mutations and from amino acid alignments that the C terminal portion of the
PST domain seems to be very important for the normal function of PAX6. Therefore, the main
goal of my PhD has been to investigate this C terminal end of PAX6.
3.2 BLAST searches.
At the start of my project the C terminal region of PAX6 was uncharacterised in terms of
structure and function and so my first task was to define this C terminal region. This problem
was addressed by performing BLASTP searches of the protein sequence database using the PST
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Figure 3.1 The PAX6 protein and C terminal peptides.
This shows the amino acid sequence of the PAX6 protein. The paired domain (PD) and the
homeodomain (HD) are highlighted in blue and red boxes respectively. Also the first 4 amino
acids of each of the 4 truncated C-terminal PAX6 peptides are marked. The blue ASNT peptide
corresponds to the whole PST region; the green SYSC peptide corresponds to part of the PST
region (containing a small beta sheet); the red MQTH peptide corresponds to a shorter portion of
the PST region (without this beta sheet); and the yellow TTST peptide is part of the PST region
that has been defined as the C terminal region of the PAX6 protein on the basis of secondary
structure information and sequence alignments. Purple lines indicate (3-sheets in the PST region.
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The purpose of this search was to look for highly conserved amino acid motifs within the PAX6
PST domain of different organisms. Highly conserved regions of amino acid sequences often
indicate areas of functional importance within a protein (Johnson and Lehtonen, 2000). The
preliminary BLAST search showed that there was a conserved region within the last 42 amino
acids of PAX6. This sequence was entered into another BLAST search to further investigate this
region. This second search revealed that there was a very highly conserved region at the C
terminus of PAX6 that was common between humans and very diverse organisms including
axolotl (Ambystoma mexicanum), amphioxus (Branchiostoma lanceolatum) and common sea
urchin (Paracentrotus lividus). To better illustrate this conserved region multiple protein
sequences were aligned using the CLUSTAL program. This resulted in a clear indication of the
most highly conserved region of the PAX6 C terminus - the "GLISP" motif (illustrated by the
stars underneath the aligned sequences in Figure 3.2).
CLUSTAL TJ (1. 74) multiple sequence alignment.
cavefish2 HNSQSMATSGTTSTGLISPGV3VPVQVPGSEPDH3- QYWPRLQ
sebrafi3h2 HNSQSHAASGTTSTGLISPGVSVPVQVPGSEP DMS - QYWPRLQ
chick2 MNSQPHGTSGTTSTGLISPGVSVPVQVPGSEPDHS- QYIJPRLQ
human2 MNSQPMGTSGTTSTGLISPGVSVPVQVPGSE P DMS - QYWPRLQ
inouse2 MNSQPMGTSGTTSTGLISPGVSVPVQVPGS E P DMS - QYWPRLQ
xenopus2 MNSQPMGTSGTTSTGLISPGVSVPVQVPGSE P DMS - QYWPRLQ
axolot12 MNSQSMGTAGATSTGLISPGVSVPVQVPGS E P DMS- QYWPRLQ
medaka2 MNSQSMTTSGTTSTGLISPGVSVPVQVPGSE P DMS- QYWSRLQ
urchin2 HMTJSACNNGL ISPGVSVPVQVPGSS PADTHP SHQY¥PRIQ
amphioxus2 PGHSHMSHANGGSAGLISPGVSVPVQVPGAVTEEM-TSQPYWPRIQ
squid2 MTPHSTNGASTGL ISPGVSVP IQVPGGGPQDM- -STHHMSS—
J m
Figure 3.2 Alignment of terminal 42 amino acids of human PAX6.
This shows a CLUSTAL alignment of the terminal 42 amino acids of human PAX6 and PAX6
from other species. The stars underneath the alignment indicate invariant amino acids, whereas
indicates that the substitution is highly similar and indicates that the substitution is only
moderately similar.
Although this conserved GLISP peptide had been identified there was still some doubt as to
where the cut off for the C terminal region should be. Therefore the amino acid sequence of the
GLISP motif was put through a secondary structure predicting program called JPRED. This
showed that this region contained a single predicted beta sheet (see Figure 3.3).
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Figure 3.3 GLISP secondary structure prediction.
This shows the secondary structure as predicted by JPRED. The single beta sheet can be seen
represented as the red arrow. The human PAX6 amino acid sequence is on the top line indicated
by 'YourSeq.'
However, when the ASNT peptide was put through this program it was seen that there were
actually 2 beta sheets at the GLISP region, one in the 'SVPVQ' peptide and one in the 'GLISP'
peptide. This suggested that amino acids just N terminal of GLISP were required to seed the
(3-sheet. By gradually increasing the size of the GLISP peptide, in the N terminal direction, I

























Figure 3.4 TTST secondary structure prediction.
This shows the secondary structure as predicted by JPRED. This shows that 2 beta sheets
(represented by red arrows) are predicted when the sequence of PAX6 is extended 4 amino acids
back from the conserved region. The human PAX6 amino acid sequence is on the top line
indicated by 'YourSeq.'
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Therefore on the basis of sequence conservation and secondary structure prediction, I have
classed this TTST peptide as representing the C terminal domain of PAX6.
3.3 Conservation of the C terminal domain over evolution.
The discovery that the C terminal amino acids of the PST domain have been conserved over
evolution was an interesting result, and the classification of the peptide starting with the amino
acids TTST as this C terminal domain was valid when taking into consideration the results of the
secondary structure prediction.
However, as an interesting aside I investigated the hypothesis that the C terminal region of
PAX6 is important due to the retention of this specific secondary structure over evolution. To
investigate this I took all of the sequences from the CLUSTAL alignment and put them through
the JPRED secondary structure prediction program.
Unsurprisingly, the majority of the sequences had almost identical secondary structures
predicted due to them only varying from human PAX6 by 1 or 2 amino acids. However, the
sequence of amphioxus (Branchiostoma lanceolatum), California market squid (Loligo
opalescens) and common sea urchin (Paracentrotus lividus), which are the most distantly related
to the human PAX6 protein in evolutionary terms, are roughly 35% different within the region
classified as the C terminal domain. However, it is interesting to see that even though the
sequence is quite different the secondary structure is retained (see Figures 3.5 to 3.7).
I realise that in fact it is the highly conserved region of the C terminal domain that gives rise to
the characteristic secondary structure and that this will therefore, be conserved over evolution.
Even though the sequence surrounding this very highly conserved region has obviously altered
during evolution, this has not altered the secondary structure. This retention of sequence and
secondary structure conservation, therefore, gives even more strength to the explanation of a C
terminal domain in PAX6. It is tantalising to think that the conservation of these amino acids is
due to the C terminal domain having a specific function.
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Figure 3.7 California market squid secondary structure.
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Chapter 4 Construct Cloning
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4.1 Introduction.
Having defined the C terminal region of the PAX6 protein the next stage of my research was to
make constructs that would be interesting to study. Although the specifics of each cloning
strategy that I will outline are particularly varied there are many aspects that are very similar.
Therefore, rather than repeating the same explanations for each cloning strategy, I will outline
these commonalities first.
4.1.1 Common cloning strategies.
Subcloning steps in all of my cloning strategies were generated in one of two ways: either by
ligation of compatible restriction digested DNA; or by generating specific DNA fragments by
PCR. The DNA of all the clones produced by ligation was prepared using the Qiagen Miniprep
kit and simply verified by diagnostic restriction digest. However, fragments that were generated
by PCR were first cloned into pGEM-T (see 2.4.8) and insert-containing clones were identified
by a P-Gal assay. The DNA of these clones was then prepared using the Qiagen Miniprep kit
(see 2.2.1) and the presence and correct orientation of the PCR fragment was confirmed by
diagnostic restriction digest. The clones were then verified by sequencing using T7 and SP6
sequencing primers (see Table 2.7) and Big Dye kit (see 2.7.1) to ensure that there were no PCR
generated errors.
The DNA of all the verified clones was prepared using the Qiagen Midiprep kit (see 2.2.2) and
glycerol stocks (see 2.6.5) were made for each subcloning stage product as well as the final
complete clone.
4.2 Cloning truncated PAX6 into pDBLeu.
I decided to make 4 PAX6 constructs in the pDBLeu expression vector. This vector is used to
clone a cDNA sequence of interest in frame with the GAL4 DNA binding domain for use in the
yeast 2-hybrid system. Constructs that correspond to the PST region of PAX6 and the newly
defined C terminal domain were made and used to screen a cDNA library using the yeast
2-hybrid system (see Chapter 5).
I also decided to prepare 2 other clones containing the green SYSC and the red MQTH peptides
(see Figure 3.1). These were to be used in pairwise interactions with the isolated interactors from
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the yeast 2-hybrid screen. These truncated peptides were chosen due to a combination of patches
of conserved sequence seen around the SYSC and MQTH regions of the sequence in the BLAST
search against the PST region and secondary structure information. The SYSC peptide was
chosen as it contains the 3' end of the PST domain, which contains a small predicted beta sheet.
The MQTH peptide is even further towards the 3'end of the PST region but does not contain this
small beta sheet (see Figure 3.1)
Having decided on these initial PAX6 clones, I then cloned the corresponding PAX6 cDNA
fragments into the pDBLeu expression vector using the following cloning strategy.
PCR primers were designed to produce the relevant truncated PAX6 cDNA fragments with a Sail
restriction site at the 5' end and a Notl site at the 3' end (see Table 2.3). The correctly sized PCR
fragments were cloned into pGEM-T and, following sequence verification, were cut with Sail
and Notl and sub-cloned into pDBLeu.
Construct Produced. Description. Schematic Diagrams.
pDBLeu_ASNT_normal PAX6 PST domain only. C_3 I I
pDBLeu_SYSC_normal Patches of conserved sequence.
pDBLeu_MQTH_normal Patches of conserved sequence. CZ3D
pDBLeu_TTST_normal PAX6 C terminal domain only. CZ20
Table 4.1 pDBLeu constructs.
This table shows the 4 different truncated proteins that were cloned into pDBLeu. The pDBLeu
vector produces a protein coupled to the GAL4 DNA Binding Domain, which is illustrated in the
schematic diagram. The GAL4 DNA binding domain is shown as a yellow oval. The C terminal
domain is shown as an orange rectangle. Blue, green and red rectangles represent the PST
domain, the SYSC peptide and the MQTH peptide respectively.
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4.3 Cloning full length PAX6 into pDBLeu.
In addition to these truncated proteins I also cloned full length PAX6 into the pDBLeu
expression vectors as a control for pairwise comparisons (see Chapter 6).
Full length PAX6 was cloned into pDBLeu by a combination of subcloning and PCR.
Specifically, the majority of full length PAX6 was cut out of a construct containing the full
length PAX6 cDNA (-5a isoform) in pBluescript® SK+/- (clone EE4, no.53, a gift from Dieter
Engelkamp), using NheI and Notl double digest and ligated into pDBLeu cut with the same
restriction enzymes. The most 5' portion of PAX6 was created by PCR, using EE4 as template
DNA, producing a fragment that extends from an artificially inserted 5' Sail site up to the Nhel
site within the PAX6 paired domain. The sequence verified PCR clone was then inserted into the
previously created clone using a Sail and Nhel double digest. The missing 300bp of PAX6 was
then cut out of the EE4 clone, by cutting with Nhel, and then inserted into the intermediate clone
to generate the final confirmed pDBLeu full length PAX6 clone.
Construct Produced. Description. Schematic Diagram.
pDBLeu_PAX6_Full
Corresponds to the entire
-5a PAX6 isoform. C ^IMBM HD
Table 4.2 Full length PAX6/pDBLeu construct.
This table shows the full length PAX6 protein that was cloned into pDBLeu. The schematic
diagram illustrates the GAL4/PAX6 fusion protein showing its various domains. PD, paired
domain; HD, homeodomain. Other domains as in Table 4.1.
4.4 Cloning the Q422R PAX6 mutant into pDBLeu.
Substitution of the C terminal amino acid (Q422R) of PAX6 causes eye malformations including
aniridia and uveal ectropion (Azuma and Yamada, 1998; Singh et ai, 2001). The Q422R
mutation was incorporated into the truncated pDBLeu constructs (see Table 4.1) to investigate
any differences between normal and mutated PAX6. The cloning procedure to create these
constructs was exactly the same as for the normal constructs (see 4.2); however a different 3'
PCR primer was used to incorporate the A to G nucleotide change at position 1682 (see Table
2.3).
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pDBLeu_ASNT_mutant PST domain with Q422R substitution.
pDBLeu_SYSC_mutant Containing Q422R substitution.
pDBLeu_MQTH_mutant Containing Q422R substitution.




Table 4.3 Q422R mutant pDBLeu constructs.
This table shows the 4 different Q422R mutant truncated proteins that were cloned into pDBLeu.
The different shading of the C terminal domain in the schematic diagram (compared to the
normal shading in Table 4.1) is meant to illustrate the single amino acid change at the very C
terminus of the PAX6 protein. Other domains are as in Table 4.1.
4.5 Cloning WHEDA and REMAR mutant truncated PAX6 into
pDBLeu.
2 interesting C terminal mutations have been identified in aniridia patients called WHEDA and
REMAR. WHEDA has the mutation 1615del 10 (Heyman et al., 1999) and REMAR has the
mutation X423L (Sisodiya et al., 2001). Both these mutations alter the reading frame of PAX6 at
the C terminus, causing read through of the normal stop codon into the 3' untranslated region of
PAX6. The details of these mutations have already been discussed in the introduction (see 1.7.6).
pDBLeu constructs corresponding to the PST domain (ASNT) and C terminal domain (TTST)
were prepared from the mutant and normal alleles of WHEDA and REMAR. The nested
RT-PCR method (see 2.4.5) was used to generate all the TTST mutant and normal fragments and
the ASNT WHEDA mutant fragments using the following second set of PCR primers: The SalI
conjugated 5' primer used to amplify the TTST truncated protein was also used for the TTST
mutants (ST004, see Table 2.3); A 5' primer that corresponds to the Nde\ site in PAX6 was used
for the ASNT mutant (ST015, Table 2.3); and a 3' primer, containing a Noil site, that was
designed about 350bp downstream of the stop codon of PAX6 was used for both TTST and
ASNT mutants (ST013 for TTST and ST031 for ASNT, Table 2.3). Poly (A) addition (see 2.4.7)
was carried out on these PCR fragments, which were then processed as normal. The mutant and
normal fragments were identified by sequence analysis and then the verified PCR fragments
were cloned into pDBLeu using a Sail and Notl digest for all the TTST mutant and normal
constructs and a Ndel and Noil digest for the ASNTWHEDA mutant construct.
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The remaining ASNT clones were generated by the following method: the wild type REMAR
and WHEDA constructs and mutant REMAR constructs were created by transferring a MluNl
and Notl cut fragment from the TTST clones into pDBLeu_ASNT_normal (see Table 4.1) also
cut with MluNl and Notl.
Construct Produced. Description Schematic diagrams.
pDBLeu_TTST_WHmut
pDBLeu_ASNT_WHmut
C ter domain with WHEDA
mutant allele 1615dell0.






C ter domain with REMAR
mutant allele X423L.
PST domain with REMAR
mutant allele X423L. C ^ RM>
pDBLeu_TTST_WHwt
pDBLeu_ASNT_WHwt
C ter domain with WHEDA
wild type allele.






C ter domain with REMAR
wild type allele.
PST domain with REMAR
wild type allele.
dn
Table 4.4 WHEDA and REMAR mutant pDBLeu constructs.
This table shows pDBLeu constructs corresponding to the PST domain (ASNT) and C terminal
domain (TTST) that were prepared from the mutant and normal alleles of WHEDA (WH) and
REMAR (RM). The arrow boxes in the schematic diagrams of these constructs illustrate the
predicted elongated proteins due to the read through of the normal PAX6 stop codon. The
schematic diagrams for the wild type constructs are exactly as the corresponding normal PAX6
constructs in Table 4.1, as there will be no translation past the normal stop codon even though
the 3' UTR sequence is included.
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4.6 Cloning a minus C terminal domain PAX6 construct.
This method was used to make a pDBLeu_ASNT_normal construct (equivalent to the PST
domain of PAX6) that was lacking the C terminal domain of PAX6. This construct was created
as a control to investigate any differences in pairwise interactions with the isolated interacting
proteins. It was hypothesised that this construct would cement the importance of the C terminal
domain in the functioning of PAX6.
This construct was created by ligating a synthetic linker into pDBLeu_ASNT_normal construct,
which had already been made (see Table 4.1). The annealed oligos (see 2.5.2) were diluted 1:100
and 4pl of this (~60ng linker) used to ligate into 35ng of Ndel, Notl cut pDBLeu_ASNT_normal
(see 2.2.10) and transformed into XLl-Blue Subcloning-Grade Competent Cells (see 2.6.1).
Construct Produced. Description. Schematic Diagram.
PDBLeu_ASNT-TTST PST domain without the C terminal domain. CZ3
Table 4.5 Minus C terminal domain PAX6 construct.
This table shows the minus C terminal domain PAX6 construct and this is illustrated by a
schematic diagram. Domains as in Table 4.1.
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Chapter 5 Yeast 2-hybrid screening
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5.1 Introduction.
Having successfully completed the cloning of the PAX6 PST (pDBLeu_ASNT_norm) and C
terminal domain (pDBLeu_TTST_norm) constructs (see Table 4.1), the next step was to use
these pDBLeu constructs to investigate interactions with other proteins. This was done by using
the yeast 2-hybrid system to screen a mouse brain cDNA library (see 2.8.1).
5.1.1 Preparing the mouse brain cDNA library.
The cDNA library was prepared as described in the materials and methods section (2.8.1). The
concentration of the resulting double stranded plasmid DNA was then quantified using
spectrophotometric measurements (2.2.3) and the DNA diluted and stored in lpg/pl aliquots. As
a further control a Notl and Sail double digest was performed (2.2.4) on lpg of the cDNA
library DNA to release the cDNA inserts from the vector. Therefore, if the correct DNA has
been prepared then a pPC86 vector band of 7kb as well as a smear of DNA (which represents the






















Figure 5.1 Mouse brain cDNA library confirmation.
The cDNA library DNA (lpg) was cut with Notl and Sail and run out on a 0.8% agarose gel.
500ng of uncut cDNA library DNA and A. x Hindlll Marker were also run out. A, This clearly
shows the smear of the cDNA library fragments in the double digest lane. B, This gel has been
run slightly further and clearly shows the 7kb pPC86 vector band in the double digest lane.
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5.1.2 The yeast 2-hybrid system.
The yeast 2-hybrid system (see 2.8) utilises the DNA binding transcriptional activator, GALA
The pDBLeu constructs that have been made produce truncated PAX6 proteins that are coupled
to a GALA DNA binding domain (see Table 4.1), whereas the proteins produced by the cDNA
library will be coupled to a GALA activation domain. Therefore, in the yeast 2-hybrid system,
the GALA-PAX6 fusion protein expressed from the pDBLeu construct will bind to the GALA
binding site upstream of a reporter gene. However, unless there is interaction between the
GALA-PAX6 fusion protein and a protein from the cDNA library, there will be no expression of
the reporter gene because a functional transcription factor will not be formed. This is outlined in
the diagram below (see Figure 5.2).
Yeast cell expressing both the GAL4 DB-X fusion protein
and the GAL4 AD-Y fusion protein.
X and Y do not interact.
The GAL4 AD-Y fusion protein cannot localize to the promoter
to activate transcription.
Yeast cell expressing both the GAL4 DB-X fusion protein
and the GAL4 AD-Y fusion protein.
X and Y do interact.




Figure 5.2 Illustration of the 2-hybrid
system.
This shows how the 2-hybrid system works.
My fusion proteins (X) are attached to a GAL4
DNA binding domain (GAL4 DB) and the
cDNA library proteins (Y) are attached to a
GAL4 activation domain (GAL4 AD).
Therefore, there will only be reporter gene
expression if proteins X and Y interact (from
ProQuest 2-hybrid instruction manual).
5.2 Yeast 2-hybrid library screen.
In the yeast 2-hybrid system the first reporter gene that is utilised to screen the cDNA library is
HIS3. However, before the mouse brain cDNA library was screened, the pDBLeu constructs
were optimised for use with this reporter gene. As described in the materials and methods (see
2.8.4) a 3AT screen was performed on the pDBLeu constructs to eliminate any background
self-activation of the HIS3 reporter. This resulted in a 3AT concentration of 7.5mM for the
pDBLeu_TTST_norm construct and lOmM for the pDBLeu_ASNT_norm construct required to
eliminate basal levels of HIS3 reporter gene expression.
The yeast 2-hybrid system was then used to screen the mouse brain cDNA library with the
pDBLeu_TTST_norm and pDBLeu_ASNT_norm constructs, which correspond to the C
terminal and PST domains of PAX6 respectively (see Table 4.1).
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The cDNA library was screened 3 times using the C terminal domain construct (reasoning
behind this discussed in 5.2.2) and screened once using the PST domain construct. For each
library screen, it was estimated that lxlO7 to lxlO8 yeast 2-hybrid library clones were screened.
In the C terminal domain screens it was recorded that small numbers (10-50) of HIS3 positive
colonies grew within 3 days incubation at 30°C after replica cleaning and the position of these
colonies were marked. However, when the plates were incubated for longer thousands of HIS3
positive colonies began to develop. In the PST domain screen the case was even more severe.
Even before replica cleaning, 60 HIS3 positive colonies had developed, whose position was
marked, but on further incubation after replica cleaning although these 60 colonies re-grew,
thousands of new HIS3 positive colonies developed.
I could not discount the thousands of HIS3 positive colonies but likewise could not spend
endless amounts of time screening them all using the full screen. Therefore, I decided that it
would be pertinent to randomly pick 475 of the thousands of HIS3 positive colonies and test
them using an X-gal assay (2.8.8). This would utilise the lacZ reporter gene and allow quick
identification of lacZ and HIS3 positive colonies due to the colour change (white to blue) that is
central to the X-gal assay (see Figure 5.3).
Figure 5.3 High throughput screening ofHIS3 positive colonies.
A, This is the template used to screen large numbers of HIS3 positive colonies using an X-gal
assay. The first 5 positions were the 5 yeast controls (A-E) followed by 95 HIS3 positive
colonies. B, This is one of the plates used to screen HIS3 positive colonies from the PST domain
library screen. The transactivation ability of the whole PST domain is clearly recognisable as the
lacZ reporter gene is constitutively expressed. C, This shows screening of HIS3 positive colonies
from the C terminal domain library screen, which does not show constitutive transactivation of
the lacZ reporter gene. In both B and C, colonies that first developed the positive blue colour in
the X-gal assay are ringed.
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The results of these high throughput X-gal assays were very interesting. Not only did they
confirm that the majority of these later developing colonies were false positives but also with the
HIS3 positive colonies from the PST domain screen it was seen that all of the colonies developed
a faint blue colour, suggesting that the PST fusion protein had innate transactivation activity.
This is immediately noticeable when comparing the X-gal assay on HIS3 positive colonies from
the PST domain (B, Figure 5.3) and C terminal domain (C, Figure 5.3) screens as the colonies
from the PST domain almost all have a positive blue colour. This transactivation ability of the
PST domain, whilst already having been described (Tang et a/., 1998) and tested by other
authors (Singh et al., 1998), was investigated further and my results can be seen in Chapter 7.
Although the main function of this high throughput technique was to confirm that the majority of
the later developing colonies were false positives, 2% of the tested HIS3 positive colonies from
the C terminal domain screen and 12% of those from the PST domain screen showed lacZ
reporter gene expression in the X-gal assay. The HIS3 positive colonies that first developed the
positive blue colour in the X-gal assay (circled in Figure 5.3 panels B and C) were taken on to be
screened using all 3 reporter genes. The amount of HIS3 positive colonies, from the library
screens and lacZ and HIS3 positive colonies from the high throughput X-gal test plates that were
taken on for further screening using the 3 reporter genes are outlined in Table 5.1.
Library Screen. HIS3 positive. LacZ and HIS3 positive.
PST domain f M 60 56
CT domain ^ ^~| 95 9
Table 5.1 Number of colonies investigated further using all 3 reporter genes.
This table outlines how many positive colonies were taken on for further screening using all 3
reporter genes. There are 2 categories; HIS3 positive, those HIS3 positive colonies that grew on
the screen plates before replica cleaning in the PST domain screen and within the first 3 days
after replica cleaning in the C terminal (CT) domain screen; LacZ and HIS3 positive, the lacZ
and H1S3 positive colonies that were identified by the high throughput X-gal assay.
5.2.1 Further investigation using all 3 reporter genes.
As outlined in the materials and methods section (2.8.7) further characterisation of the HIS3
positive colonies was carried out using the 3 reporter genes HIS3, URA3 and lacZ that are
integrated into the yeast genome in this system. This allows 4 tests to be carried out on each
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positive colony: 2 are simple replacement of essential amino acids (histidine and uracil) due to
HIS3 and URA3 reporter gene expression, allowing growth of positive colonies on plates
deficient of these amino acids; the X-gal assay which easily identifies positive colonies as they
activate lacZ reporter gene expression and initiate a colorimetric change (white to blue); a test
for weak interactions using repression of growth of yeast due to URA3 reporter gene activation
by positive colonies which converts 5F0A into toxic 5-fluorouracil.
Single colonies of the HIS3 and HIS3 and lacZ positive colonies from the main library screens
were first obtained from glycerol stocks and master plates were set up (see 2.8.7). As illustrated
in the materials and methods section, each master plate contained: 5 positive colonies that were
to be tested plated in quadruplicate; a negative control that tests for self activation of reporter
gene expression; and a full range of control yeast strains (A to E) which show increased
activation of the various reporter genes.
The results obtained from this screening using all 3 reporter genes were then compared to the
expected results as outlined in Table 5.2.
-His lacZ -Ura 0.2% 5FOA Easily-Interpreted Phenotypes
no growth False positive/background
growth blue no growth no growth Interactor, probably weak
growth blue growth no growth Interactor
growth white no growth growth Non-interactor
-His lacZ -Ura 0.2% 5FOA One Inconsistent Phenotype
growth blue growth growth Probable interactor
Possible mixed population*
growth white growth no growth Probable interactor (check lacZ expression using CPRG assay)
-His lacZ -Ura 0.2% 5FOA Two Inconsistent Phenotypes
growth blue no growth growth Possible non-interactor
Possible weak interactor (look carefully for any inhibition on 5FOA)
Possible mixed population*
growth white growth growth Possible interactor (check lacZ expression using CPRG assay)
Possible mixed population*; look carefully for inhibition on 5FOA
growth white no growth no growth Probable weak interactor (check tacZ expression using CPRG
assay; confirm 5FOA phenotype)
'Mixed populations can result from numerous causes. Examples Include: More than one AD-Y in the cell resulting in one population
that contains AD-Y interacting with DB-X (no growth on 5FOA), and another population that contains AD-Y that does not interact with
DB-X, giving rise to growth on 5FOA; mutations or instability in DB-X, AD-Y or URA3 reporter or promoter; carry over of cells from the
-His+3AT plate that do not contain interacting DB-X:AD-Y.
Table 5.2 Possible phenotypes from full screen.
This table shows the entire spectrum of phenotypes that are possible from screening the positive
colonies with the 3 reporter genes. Takenfrom ProQuest 2-Hybrid system manual (Gibco-BRL).
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5.2.2 C terminal domain full screen results.
The following table (Table 5.3) summarises the information obtained from screening the 95
HIS3 positive colonies and the 9 HIS3 and lacZ positive colonies isolated from the C terminal
domain library screen, using the full range of 3 reporter genes. The table is laid out to represent
the table from the ProQuest 2-hybrid system manual (see Table 5.2).
H L u 5F Phenotype CT CR Seq
NG False positive 16 - -
G B NG NG Interactor, probably weak 12 8 4
G B NG Interactor 2 1 1
G W 1 G Non-interactor 50 - -
G B G G Probable interactor or mixed population 2 - 2
G W G NG Probable interactor 4 1 3
G B _Oz G Possible non-interactor, weak inter or mixed pop. 5 - -
G W G G Possible interactor or mixed population 6 - 4
G w NG NG Probable weak interactor 7 6 1
Table 5.3 Full screen of C terminal domain positive colonies.
This table shows the combined full screen results of all 3 of the C terminal domain library
screens. The coloured boxes and phenotype descriptions refer to Table 5.2. G, growth identified
as red; NG, no growth identified as green; B and W, blue and white colour in X-gal assay. CT,
the number of positive colonies that correspond to each phenotype. CR, Some colonies could not
be recovered from the first library screen (see main text). Seq, this shows the number of colonies
in which the cDNA insert was sequenced. H, HIS3\ L, lacZ\ U, URA3\ 5F, 0.2%5FOA (see
2.8.7).
I have presented the data from the C terminal domain full screens in combined form but there are
certain discrepancies that need to be explained. When performing the first C terminal domain
library screen, glycerol stocks were not made of the HIS3 positive colonies and therefore some
possibly interesting positive colonies were lost (hence Couldn't Recover column in Table 5.3).
Therefore, this is the reasoning for performing another C terminal domain library screen. I
screened the mouse brain cDNA library a further two times to recover more positive colonies
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with phenotypes corresponding to interactors. As is demonstrated in Table 5.3 the only positive
colonies that I did not mark for sequencing were those whose phenotype corresponded to
non-interactors.
5.2.3 PST domain full screen results.
The following table (Table 5.4) summarises the information obtained from screening the 60
HIS3 positive colonies and the 56 HIS3 and lacZ positive colonies isolated from the PST domain
library screen, using the full range of 3 reporter genes. The table is laid out to represent the table
from the ProQuest 2-hybrid system manual (see Table 5.2).
HIfl U 5F Phenotype PST HTX Seq
False positive - - -
G B NG NG Interactor, probably weak 1 3 4
G B NO Interactor 32 22 52
G W NG G Non-interactor 4 - -
G B G G Probable interactor or possible mixed pop. - 1 -
G W G NG
■BBI
Probable interactor 5 31 5
G B NG Poss. non-interactor, weak inter or mixed pop. - 1 -
G W o a Poss. interactor or mixed population 1 10 1
G W m*wni Probable weak interactor - 5 -
Table 5.4 Full screen of PST domain positive colonies.
This table shows the results of the PST domain library screen. The coloured boxes and
phenotype descriptions refer to Table 5.2. G, growth identified as red; NG, no growth identified
as green; B and W, blue and white colour in X-gal assay. PST, the number of HIS3 positive
colonies that correspond to each phenotype. HTX, the number of HIS3 and lacZ positive
colonies that correspond to each phenotype. Seq, this shows the number of colonies' DNA that
was sequenced. H, HIS3\ L, lacZ\ U, URA3; 5F, 0.2%5FOA (see 2.8.7).
As previously described for the C terminal library screen, by combining data from the H1S3
positive colonies and the HIS3 and lacZ positive colonies, certain discrepancies occur that need
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to be further explained. In the PST domain full screen results the disparity occurs when
considering which positive colonies I marked for sequencing. Therefore, I have separated the
results of these full screens into 2 groups, the HIS3 positive colonies identified by the main PST
domain library screen and the HIS3 and lacZ positive colonies that were identified from the high
throughput X gal assay (see Table 5.4). In this way it can be clearly seen that HIS3 positive
colonies that correspond to interactors or probable interactors were marked for sequencing,
although I was unable to isolate the DNA of 2 interactors. However, due to the large number of
samples that were already marked for sequencing when the results of the HIS3 and lacZ positive
colonies were obtained, only the unequivocal interactors and weak interactors were marked for
sequencing.
5.3 Summary of fully characterised positive colonies.
The mouse brain cDNA library was screened 3 times using the C terminal domain construct
(pDBLeu_TTST_norm) and once with the PST domain construct (pDBLeu_ASNT_norm). The
detailed results of the individual screens can be seen above, however, a more condensed version
is shown in the table below (see Table 5.5).
Library Screen. Colonies to be fully screened Number sequenced
PST domain 116 62
CT domain 95 15
Table 5.5 Condensed yeast 2-hybrid screening results.
This table summarises the results of the yeast 2-hybrid library screens. For both the PST domain
and C terminal (CT) domain library screens this table shows: the number of positive colonies
that were further characterised using the full screen (utilising all 3 reporter genes); and the
number of fully screened positive colonies' DNA that was taken on to be sequenced.
In total 77 positive colonies were identified as being interesting to investigate further, 62 from
the whole PST domain screen and 15 from the C terminal domain screen. The positive colonies
were re-grown and cDNA library plasmid DNA was made from the yeast cultures as outlined in
the materials and methods section 2.8.9.
To try and ascertain the identity of the positive colonies a simple Notl and Sail double digest
was performed on isolated DNA of the 77 positive colonies. This produced a range of DNA
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sized bands, which were useful once the colonies had been sequenced to check whether the
nucleotide sequence that was pulled out of the database was roughly the same length as that of
the cDNA fragment in the library. Obviously this is not foolproof as the cDNA in the library
could be a fraction of the clone in the database or vice versa.
The resultant plasmid DNA was then sequenced using the specific sequencing primers for the
pPC86 vector (see Table 2.7). The resulting DNA sequence traces were then checked and edited
so that the pPC86 vector sequence was removed and only unambiguous nucleotide sequence
remained. The trimmed DNA sequence was then used to search nucleotide databases using the
BLASTN program (see 2.1.1). This revealed the following information.
5.4 Isolated Interactors.
The DNA sequence of 72 out of the 77 positive colonies identified entries in the nucleotide
databases when searched using BLASTN. It was found that: the nucleotide sequence of 7
colonies aligned to various RIKEN cDNA clones of unknown identity from thymus, pancreas,
lung, small intestine, brain and 2 from whole embryo; the sequence of one colony aligned to the
mouse mitochondrial genome and the sequence of another colony aligned to the GAL4 vector.
However, the majority of the nucleotide sequences of the positive colonies aligned to nucleotide
sequences that encode proteins: the sequence of 3 colonies aligned to ribosomal RNA genes; the
sequence of 7 colonies aligned to nucleotide sequences that encode hypothetical proteins; 20
sequences each aligned to sequences that encode known proteins (see Table 5.6); 5 proteins were
each encoded by the nucleotide sequence of 2 positive colonies (see Table 5.7); and there were 3
proteins that were encoded by the nucleotide sequence of three or more colonies (see Table 5.8).
Due to the nature of a PhD, it was impossible to further investigate all of these proteins in detail;
therefore I decided to only follow up those proteins identified 3 or more times.
The 3 proteins that were isolated from the library screens 3 or more times are called Homer3,
Dncll (Dynein cytoplasmic light chain T) and Triml 1 (Tripartite motif protein family member
11). More information about the different clones that have been isolated for each of these
proteins will be discussed in more detail in section 5.5 as well as information about the known
structure and function of these proteins in section 5.6.
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Isolated from the C terminal domain library screen
Gstml Glutathione S transferase mu 1
Isolated from the PST domain library screen
Arl6ip5 ADP-ribocylation like factor 6 interacting protein 5.
Snn Aligned to the Stannin gene.
Nsg2 Neuron specific gene family member 2.
Bcap37 B cell receptor associated protein 37.
Arnt Aryl hydrocarbon receptor nuclear translocator.
Tm9sf2 Transmembrane 9 superfamily member 2.
Atp6f Vacuolar proton-translocating ATPase 21kDa subunit.
Trb Aligned to traube mRNA
ZfRbp Zinc finger RNA binding protein
Vim Vimentin is an intermediate filament cytoskeletal element expressed in brain, and also in
retina and lens. Vim null mutations in mice do not affect mouse development.
Fbfl Structural protein with sequence similarity to plectin. May interact with CD95/Apo-l/Fas.
Pdcd6 Programmed cell death 6 protein.
Cytb Cytochrome b from mitochondrial genome.
Fth Ferritin heavy chain is a transport cargo protein that is cytoplasmic and expressed in brain.
mTRIP-Brl TRIP-Br are a novel family of PHD zinc finger and bromodomain interacting proteins.
Tapl Similar to transient receptor protein 4 (Trp4) associated protein.
Dncicl Cytoplasmic dynein intermediate chain IB.
T-plastin Similar to plastin 3 precursor, T plastin.
Mcmd7 Mini chromosome maintenance deficient 7.
Table 5.6 Interactors isolated once that correspond to known proteins.
The table above shows the proteins that were isolated once from the C terminal domain screen
and the PST domain screen.
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Interactor Description
Rabl
Member of ras superfamily and possibly involved in the regulation of
membrane vesicle targeting and fusion during organelle assembly and transport
(Zahraoui et al., 1989).
Coxl Cytochrome C oxidase subunit in mitochondrial genome.
Similar to
KIAA1816




In humans TRIM7 is derived from GNIP which is a novel protein that binds
and activates glycogenin and may represent a novel participant in the initiation
of glycogen synthesis (Skurat et al., 2002).
Ppia
Peptidylprolylisomerase A or cyclophilin A to be involved in protein folding
and/or intracellular protein transport (OMIM 123840).
Table 5.7 Interactors isolated twice in the PST domain library screen.
The following table outlines the interactors that were isolated twice in the PST domain library
screen. The table gives the names and a very brief description of the proteins aligned to the
sequence of positive colonies.
Interactor No. of clones Isolated in library
homer3 7 pst domain C_3 II
clllld evhi Cc 6 C terminal domain CZ70
DNCL1 2 pst domain C_3 11
m i 2 C terminal domain C_2U
trim 11 6 pst domain C 31 tH
0 C terminal domain CZ30c r B Cc spry
Table 5.8 Interactors isolated more than twice in the yeast 2-hybrid screens.
The following table specifies the 3 interactors that were isolated more than twice in the yeast
2-hybrid screens. The table illustrates each of the isolated interactors including known domains
(Cc, coiled coil domain, R, RING finger domain, B, B-box domain, EVH1 and SPRY see 5.6)
coupled to the GAL4 activation domain (purple oval). The table also outlines the number of
times each interactor was isolated from either the PST domain (ASNT) or the C terminal domain
(TTST) yeast 2-hybrids screens (These constructs are also represented by schematic diagrams,
see Table 4.1 for details).
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5.5 Isolated Clone Information.
For each of the isolated clones that were identified for Homer3, Dncll and Trimll the first thing
that I looked at was whether these proteins would be expressed in the yeast 2-hybrid system.
That is to say whether the coding regions for these proteins are in frame with the GAL4 DNA
activation domain. It was confirmed that all of the 23 clones that encode these 3 proteins were in
frame with this domain.
5.5.1 Homer3.
6 of the Homer3 clones were isolated from the TTS screens: 4 from the first screen as 'probably
weak interactors' and 2 from the third screen as 'possible interactors or mixed populations'. 7 of
the Homer3 clones were isolated from the ASN screen: 6 as 'interactors' (2 of which were from
the high throughput X-gal assay) and one as a 'probable interactor'. When sequenced all the
clones aligned to the sequence for the mouse, similar to Homer, neuronal immediate early gene,
3 (BC005773, IMAGE: 3602414). When the clones were compared 12 clones were exactly the
same starting at nucleotide 334 and one clone (T24) contained an extra 3 nucleotides and started
at nucleotide 331 in the published sequence of Homer3.
In the published sequence of Homer3, the normal starting methionine is at nucleotide position
120 and so the isolated clones do not code for the first 72 amino acids of Homer3 (T24 missing
only the first 71 amino acids). Sequencing of the entire clones enabled me to discover that there
was only a single nucleotide change in the coding region of the isolated clones from the
published sequence and that this difference does not equate to an amino acid change. The stop
codon of Homer3 is at position 1188 in the published sequence and all of the sequenced clones
retain this stop codon in the correct reading frame. All the clones extend up to the poly(A)
stretch in the published sequence of Homer3, but the T24 clone has a slightly different end as the
sequence AAATG is inserted into the beginning of this poly(A) stretch at nucleotide position
2373.
The isolated clones were shown to be missing the first 71/72 amino acids of the Homer3 protein,
which corresponds to the N terminal half of the EVH1 domain (see 5.6.1) of the full length
Homer3 protein. I was initially concerned that the clones devoid of these amino acids would
have a completely different structure. By using the secondary structure prediction program
JPRED (see 2.1.3) I showed that the missing N terminal 71/72 amino acids do not drastically
alter the secondary structure of the rest of the protein, and that the missing region is composed of
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(3 sheets bordered by 2 alpha helixes. Nevertheless, I decided that it would be beneficial to create
a full length Homer3 cDNA (see 6.2) to investigate any difference to the truncated Homer3
protein in pairwise interactions with PAX6 (see Chapter 6).
5.5.2 DncM (Dynein cytoplasmic light chain 1).
2 of the Dncll clones were isolated from the second TTS screen high throughput X-gal assay as
'possibly weak interactors'. The remaining 2 Dncll clones were isolated from the ASN screen as
'interactors'. The sequence alignment of these 4 clones was to the nucleotide sequence for the
mouse dynein, cytoplasmic light polypeptide clone (BC008106, IMAGE: 3158148). In this
sequence of Dncll the normal starting methionine is at nucleotide position 99 and the stop codon
at position 366. The coding region of the 4 isolated clones is exactly the same as the published
sequence as is the 3' UTR which extends for a further 273 nucleotides before the poly(A)
stretch.
However, there is slightly more variability between the clones in the 5' UTR. One clone (XT31)
is exactly the same as the published nucleotide sequence with an extra 98 nucleotides before the
starting methionine; one clone (A13) only has an extra 71 nucleotides before the start codon; one
clone (XT84) has an extra 56 nucleotides before the start codon; the final clone (A62) has the
same 56 nucleotides before the start codon as XT84, however, it has an additional 48 nucleotides
inserted 8bp before the start site of the protein. The inserted nucleotides of clone A62 begin with
the sequence GTGAGA that resembles the consensus splice donor sequence (GTAAGT)
(Krawczak et al., 1992) and so this clone could possibly represent a splice variant of Dncll.
5.5.3 Triml 1 (Tripartite motif protein family member 11).
All 6 of the Triml 1 clones were isolated from the ASN screen as 'interactors' (2 of which were
from the high throughput X-gal assay). When sequenced all the 6 isolated clones aligned to the
nucleotide sequence of the mouse tripartite motif protein 11 (Triml 1, AF220124). There are no
differences between the coding region of the isolated clones and the published nucleotide
sequence that has a starting methionine at position 125 and a stop codon at position 1526. All the
6 clones have the same 3' UTR as the published sequence which extends for a further 723
nucleotides after the stop codon before the poly(A) stretch. However, there is more variation in
the length of the 5' UTR; 2 clones (A3, A5) have 92 nucleotides; 3 clones (A23, A47, XA22)
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have 125 nucleotides, which is the same as in the published sequence; and 1 clone (XA3) has
143 nucleotides at the N terminus, which is 18bp more than in the published sequence.
5.6 interacting protein information.
In this section I have reviewed the current information about each of these potential novel and
interesting interactors. I have included information about the structure and function of each of
the proteins and at the end of each section have included some hypotheses of what role the
interactions with PAX6 may play in development. In the sections that follow (5.6.1 to 5.6.3) for
the sake of simplicity I will use generic lower case gene and protein names, even when I am
referring to the human gene or protein.
5.6.1 Homer3.
In Drosophila there is only a single Homer gene that encodes a single Homer protein, however,
in mammals there are three Homer genes, Homerl, Homer2 and Homer3, which encode for
several Homer protein isoforms (Xiao et al., 1998). The Homer3 gene is located on chromosome
19ql3.11 in humans and 8B3.3 (69.3cM) in mice. The human and mouse genes are thought to be
composed of 10 exons that encode a single protein isoform of 365 amino acid and 357 amino
acid proteins respectively (www.ensembl.orgI. There is no co-localisation between any
interesting disease phenotypes and the chromosomal location of Homer3 when investigating the
OMIM database and the mouse genome informatics (MGI) database (www.informatics.jax.org/).
The initial Homer protein that was characterised in humans was the Homerla isoform that is
highly up regulated by synaptic activation and is only composed of the N terminal EVH1
domain (Brakeman et al., 1997; Kato et al., 1998). However, the Homer3 protein, as well as
other isoforms such as Homerlb/c, and Homer2a/b are composed of 2 domains: the EVH1
domain encompassing the N terminal 186 amino acids in mice; and a coiled coil domain
produced from 2 leucine zipper motifs (Sun et al., 1998) within the C terminal 171 amino acids
in mice (see Table 5.8). The EVH1 domain is highly conserved between the members of the
Homer protein family, for example in the N terminal 120 amino acids of the EVH1 domain,
Homerla and Homer3 are 86% homologous (Xiao et al., 1998). However, this homology is
vastly reduced between the C terminal sequences of Homer3 and the long isoforms Homerlb/c
with only 22% homology, although even with this reduced homology the coiled coil secondary
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structure is retained between all of the Homer proteins (Xiao et al., 1998). Specifically in mice
and humans the Homer3 protein sequence is 88.6% identical.
The N terminal region of Homer proteins was initially thought to be homologous with a PDZ
domain, which is involved in protein-protein interactions and PDZ domain containing proteins
are known to be enriched in the post synaptic density (PSD) (Brakeman et al., 1997). The PSD is
a region subjacent to the postsynaptic membrane of excitatory synapses, predominantly found on
dendritic spines (specialised structures that protrude from the dendritic shaft), which often
contain smooth endoplasmic reticulum and translational machinery (Sala et al., 2001). However,
it has been suggested that there is a closer homology to the EVH1 domain (Kato et al., 1997).
The EVH1 domain was initially characterised due to its similarity to the Ena (Enabled), VASP
(vasodilator stimulated phosphoprotein) or WASP (Wiskott-Aldrich Syndrome homology
domain) protein domains (Kato et al., 1997) that are common to cytoskeleton interacting
proteins (De Bartolomeis and Iasevoli, 2003). EVH1 domains are found in proteins that range in
function from cell signalling, nuclear transport and cytoskeletal events (Xiao et al., 1998) and
this domain binds to a consensus polyproline motif, FPxxP (Ball et al., 2002). However, the
Homer EVH1 domain (from this point on merely referred to as the EVH1 domain) has been
proposed to be a novel functional subset of classical EVH1 domains, as crystallographic studies
revealed that this domain has a unique structure which allows binding to a different but specific
polyproline motif xPPxxF (Beneken et al., 2000).
The specific polyproline motif (xPPxxF) that is bound by the EVH1 domain of Homer3 is not
found in the PST domain sequence of Pax6 and although a PPMPSF sequence is in Pax6, when
compared to the specificity of the motif in other binding partners of Homer3 (Ball et al., 2002) I
would suspect that this does not represent a true Homer3 binding site. Furthermore, 3
surface-exposed aromatic side chains are vital for the recognition of proline rich sequences in
ligands by the EVH1 domain (Ball et al., 2002) and 2 of these are within the first 70 amino acids
of Homer3 which is missing in the Homer3 clones isolated from the yeast 2-hybrid screen. This
seems to suggest that Pax6 interacts with the coiled coil domain of Homer3, one of the few
interactions that have been reported associating with this region of the Homer3 protein.
Obviously more experimentation must be performed to elucidate the site of interaction between
Homer3 and Pax6 more specifically.
The coiled coil domain is produced by multimerisation of the 2 leucine zipper motifs within the
C terminal region of Homer3 (Sun et al., 1998). These leucine zipper motifs are known to
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promote self association; however it has been shown that this region can also facilitate
multimerisation between the coiled coil domains of different members of the Homer protein
family producing heteromeric clusters (Shiraishi et al., 2003).
The Homer family can be divided into 2 groups: the inducible form, Homerla that can be
induced by synaptic stimuli; and the constitutively expressed forms, Homerlb/c, Homer2 and
Homer3. The Homer3 protein has been shown to be expressed in the brain but more specifically
in the hippocampus and the cerebellum (Xiao et al., 1998) as well being found in the lung and
thymus (Xiao et al., 1998). Homer3 is located in the postsynaptic density, as well as being
distributed along the soma and into apical dendrites, but is not present in the cell nucleus (Xiao
et al., 1998). Interestingly it has been shown that Homer3 is expressed in discrete puncta along
the length of dendritic shafts in hippocampal neurons in mammals (Shiraishi et al., 2003) and
Drosophila (Diagana et al., 2002) and this expression pattern of Homer proteins overlap with
synaptogenesis in development. Therefore, it has been suggested that Homer proteins are
involved in the formation of synapses (Kato et al., 1998; Diagana et al., 2002) as well as
possibly being involved in long term potentiation in excitatory synapses with the possibility of
functioning in memory formation (Kato et al., 1997).
The EVH1 domains of Homer proteins, and more specifically Homer3, have been shown to
interact with the polyproline motifs of: type-I metabotropic glutamate receptors (mGluRs),
mGluRla and mGluR5 (Brakeman et al., 1997); inositol 1,4,5-trisphosphate receptors (IP3Rs)
(Tu et al., 1998); ryanodine receptors (RyRs) (Kato et al., 1998); and the scaffolding protein
Shank (Tu et al., 1999) (see Figure 5.4). However, it must be noted that until recently no
proteins have been reported that interact with the coiled coil domain of Homer proteins.
It has just been reported that the N terminus of the human S8 ATPase, which has a role in
proteasomal processing of proteins for degradation, interacts with the coiled coil domain of
Homer3 (Rezvani et al., 2003). Homer3 binds to the C terminal region of mGluRla, and
simultaneous binding of the S8 ATPase has been shown to be involved in Homer3 mediated
degradation of these receptors (Rezvani et al., 2003).
The EVH1 domain of Homer3 interacts with the C terminal tail of mGluRla and mGluR5 (Tu et
al., 1998), which have been linked to determining synaptic plasticity, neuronal development and
pathological conditions such as epilepsy or Parkinson's disease due to their involvement in
multiple transduction pathways (De Bartolomeis and Iasevoli, 2003). However, the EVH1
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domain of Homer3 interacts with the cytosolic N terminal regions of the lP3Rs and RyRs, which
are known to be involved in calcium release due to their link with the endoplasmic reticulum
(ER) (Tu et al., 1998). Therefore, due to the multimerisation via the coiled coil domain the
Homer3 protein is able to link these 2 types of receptor with the mGluRs (see Figure 5.4), which
has been functionally demonstrated with Homer3 co-precipitating with IP3R and mGluRla from
cerebellar lysates (Tu et al., 1998).
Figure 5.4 Role of Homer3 as a scaffolding protein in the PSD density.
This illustrates how the Homer proteins (Homer CC), including Homer3 multimerise through
their coiled coil regions and through their EVH1 domain interact with: type-I metabotropic
glutamate receptors (mGluRs), mGluRla and mGluR5; inositol 1,4,5-trisphosphate receptors
(IP3Rs); and the scaffolding protein Shank. The interaction between Homer CC and Shank
provides a link between the mGluRs and the N-methyl-D-aspartate receptors (NMDA-R) in the
post-synaptic density (PSD) (Thomas, 2002).
This scaffolding function of Homer3 as well as the other long Homer isoforms (i.e. those which
contain both EVH1 and coiled coil domains) is antagonised by Homer la in a dominant negative
way (Xiao et al., 1998) (see Figure 5.5). As already mentioned the expression of Homerla is
rapidly induced by synaptic activity (Brakeman et al., 1997; Kato et al., 1997; Ango et al., 2001)
and this disrupts the complex between Homer3 and both mGluRs and IP3Rs which results in an
alteration of the mGluR induced calcium release (Tu et al., 1998). The disruption of the complex
between Homer3 and mGluRla by Homerla has specifically been shown in cerebellar
homogenates (Xiao et al., 1998).
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synaptic cleft nmda-r
Figure 5.5 Scaffolding function of Homer3 antagonised by Homerla.
This illustrates how the scaffolding function of Homer proteins (Homer CC), including Homer3
is antagonised by Homerla. Homerla disrupts the complex between Homer CC and: type-I
metabotropic glutamate receptors (mGluRs), mGluRla and mGluR5; inositol 1,4,5-
trisphosphate receptors (IP3Rs); and the scaffolding protein Shank. Uncoupled mGluR* may
have agonist-independent activity (Thomas, 2002).
It has been shown that Homerla mRNA expression is induced in the cerebral cortex of
dark-reared rats 30mins after their first visual experience in the 3-5 postnatal weeks (Brakeman
et al., 1997). Also monocular deprivation by stopping the retinal activity of one eye means that
the mRNA levels of Homerla are rapidly reduced in the contralateral visual cortex (Brakeman et
al., 1997). Therefore, this provides an example of how physiological neuronal activity
dramatically regulates Homerla, which reinforces the suggestion that the Homer proteins are
involved in stimulating synapse formation (Brakeman et al., 1997).
It was also found that the mGluRla was able to produce agonist-independent activity when
Homer3 levels were decreased in cerebellar granule cells (Ango et al., 2001). This was
investigated further and it was found that the cessation of the constitutive activity of mGluRla
required not only the binding of Homer3 to the receptor but also the coupling of the receptor via
Homer3 to other synaptic proteins such as Shank (Ango et al., 2001). Therefore, this provides a
hypothesis in which the competitive interaction of Homerla with the receptors promotes the
constitutive activity of the mGluRla due to its uncoupling from the synaptic complex without
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receptor activation (Ango et al., 2001) (mGluR*, see Figure 5.5). This mechanism might be
utilised in situations such as synaptic plasticity or in seizures (Ango et al., 2001; Thomas, 2002)
where a delayed or long lasting signal is produced from an initially strong stimulus.
The interaction between the EVFI1 domain of Homer proteins and Shank proteins (see Figure
5.4) has been shown to occur in mammals (Tu et al., 1998) and in Drosophila (Diagana et al.,
2002) showing that this interaction is evolutionarily conserved, although a specific interaction
with Homer3 can only be alluded to due to EVH1 domain homology. It has been suggested that
an important function of Shank is to stimulate head expansion in dendritic spines and that this
role is reliant on the interaction between Homer and Shank (Sala et al., 2001; Ehlers, 2002). As a
consequence of this spine enlargement the occurrence of other synaptic proteins was increased,
most notably IP3Rs and F-actin, which have both been shown to interact with Homer (Xiao et
al., 1998; Shiraishi et al., 1999). It was suggested that Homer mediates their enrichment in the
PSD due to its interaction with Shank (Sala et al., 2001). Therefore, the Homer/Shank complex
seems to indicate that these proteins are perhaps involved in developmental and activity
dependant structural plasticity (Thomas, 2002), which has been suggested to underlie experience
dependant changes in the brain such as learning and memory (Ehlers, 2002).
As I have already mentioned Homer proteins function as scaffolding proteins within the PSD of
dendritic spines, interlinking proteins involved in synaptic transmission. Further evidence for
this has been shown as Homer proteins were colocalised with the NMDA receptor complex
during dendritic and synaptic differentiation in excitatory hippocampal neurons (Shiraishi et al.,
2003). This colocalisation has been suggested to be due to the interaction between Homer and
Shank, which seems to be part of a larger complex involving the binding of Shank and GKAP
and PSD-95 as well (Grant and O'Dell, 2001). It is thought that this complex may function to
make a functional bridge between mGluRs and NMDA receptors (see Figure 5.4) in neuronal
development and synaptic plasticity (Brakeman et al., 1997; Tu et al., 1999).
Drosophila mutants of the single Homer protein have been shown to be predominantly normal
with no abnormalities in axon pathfinding during development, no synaptic transmission
problems or general nervous system development problems and these mutant flies are viable,
fertile and can respond to visual stimuli (Diagana et al., 2002). However, it has been reported
that over expression of either Homerla or Homerlb/c in Xenopus optic tectal neurons resulted in
aberrant axon pathfinding due to a dysfunction of the signal transduction from cell surface
receptors to intracellular proteins (Foa et al., 2001). However, a gain of function Homer
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mutation in Drosophila did not show any axon guidance problems, which is consistent with the
finding that in Drosophila little or no Homer protein is detected in the axons of neurons, as the
expression is concentrated in the dendrites of neuronal cells (Diagana et al., 2002). Drosophila
Homer mutants showed defects in behavioural plasticity. They were unable to learn/memorise
mating conditioning. Also they showed defects in the control of locomotor activity, characterised
by higher levels of spontaneous locomotor activity (Diagana et al., 2002). Although these
Drosophila mutants did not confirm a role for Homer in synaptogenesis it was suggested that
Homer predominantly functions to alter the activity of neuronal circuits by regulating synaptic
functioning due to its control of mGluRs signalling (Diagana et al., 2002), backed up by the fact
that mice with a loss of function mutation of type-I mGluRs also develop learning problems as
well as movement problems (Aiba et al., 1994).
With the importance of the type-I mGluRs clearly evident in correct synaptic functioning it is
interesting to note that Homer is central to their function in protecting neurons from apoptotic
death (Rong et al., 2003). I have already mentioned how coupling of S8 ATPase to mGluRs via
Homer3 targets these receptors for degradation, however, it has recently been shown that the
activity of the mGluRs promoted the recruitment of a phosphoinositide 3-kinase enhancer
(PIKE-L) to the receptor due to its interaction with Homer. This has the effect of activating
phosphoinositide 3-kinase (PI3 kinase), which had the effect of preventing neuronal apoptosis
(Rong et al., 2003).
I have already explained how the interaction between Shank and Homer is central to the
formation of a complex that makes a functional bridge between mGluRs and NMDA receptors in
neuronal development and synaptic plasticity (Brakeman et al., 1997; Tu et al., 1999).
Furthermore, the activation of NMDA receptors stimulates mitogen-activated protein kinase
(MAPK), which results in long term potentiation (LTP). LTP and long term depression (LTD)
are both changes in the strength of synapses that are caused by changes in their activity and both
LTP and LTD have been implicated in memory and learning (Grant and O'Dell, 2001).
MAPK has been shown to be physically tethered to the NMDAR/PSD-95 complex and thought
to act on some immediate synaptic substrates, which allows LTP induction (Grant and O'Dell,
2001). MAPK has also been implicated in phosphorylating Pax6 and it has been suggested that
MAPK is involved in post-translational regulation of Pax6 after activation of MAPK signalling
cascade (Mikkola et al., 1999). Therefore, my discovery of an interaction of Pax6 and Homer3 is
intriguing as it is possible that this interaction establishes a physical proximity between Pax6 and
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MAPK in the PSD of neurons. Therefore, the activation of MAPK by NMDAR stimulation
could lead to a rapid phosphorylation of Pax6, which cause an increase in the transcriptional
activation by Pax6 (Mikkola et al., 1999). Therefore, it is possible that this increased
transcriptional activation may function in the LTP, learning, memory or even spine
morphogenesis in the developing brain to develop new synaptic connections.
A huge yeast 2-hybrid screen was performed by the CuraGen Corporation, which investigated
potential proteins interactions of the entire proteome of Drosophila melanogaster (Giot et al.,
2003). The results of the yeast 2-hybrid screen were then designated as being either 'high
confidence' interactions or 'other interactions' and can be searched at the Drosophila interaction
database (http://portal.curagen.com/cgi-bin/interaction/flyHome.pl?modeIn=Fistl. This revealed
that in Drosophila the Pax6-like protein eyegone (eyg) interacts with the Drosophila Homer
protein. The eyg protein appears to corresponds to Pax6 missing the NTS subdomain of the PD,
which is the equivalent of the +5a Pax6 isoform in vertebrates (Epstein et al., 1994).
5.6.2 DncM (Dynein cytoplasmic Mght chain 1).
The Dncll gene is located on chromosome 12q24.31 in humans and 5F (112.5cM) in mice and
the human gene is composed of 3 exons encoding a protein of 89 amino acids
(www.ensembl.orgl. There is 89% identity between the mouse and human nucleotide sequences
but the protein sequence is identical between mouse and humans as well as being 90-100%
conserved with homologous proteins from mammals, insects, nematodes and bacteria and
50-60% conserved in yeast and plants (Jacob et al., 2000). It is interesting to note that by looking
at the OMIM gene database it can be seen that the 12q22-q24.1 region co-localises with growth
and mental retardation, and the 12q24.1q31-q42 region co-localises with Schizophrenia. There is
no co-localisation with any interesting phenotypes when looking at the mouse genome
informatics (MGI) database (www.informatics.jax.org/1.
Whilst reading the literature on the dynein cytoplasmic light chain 1, I realised that there were
many synonyms for Dncll in the literature that included LC8, PIN, DLC1 and DLC8. However,
in an effort to simplify things I have chosen to merely use the synonym Dncll/ DNCL1.
Dncll is a component of the brain cytoplasmic dynein complex (King et al., 1996) (see Figure
5.6), which is a molecular motor involved in minus end directed movement along microtubules
i.e. in neurons this movement is from the synapse to the neuronal cell body (Jacob et al., 2000)
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(see Figure 5.7). Not only is Dncll thought to be a component of the dynein motor complex, but
there is also evidence that it is a component of an actin based molecular motor (Espindola et al.,
2000). A protein homologue of Dncll has been reported in chicken associated with the tail
domain of chicken brain myosin-Va (see Figure 5.6) which is a ubiquitously expressed actin
based molecular motor (Espindola et al., 2000). Therefore, Dncll is thought to be a subunit of
both a microtubule transport network involved in moving protein cargos large distances and an
actin transport network which is responsible for the local distribution of proteins within the cell
(Jacob et al., 2000).
Figure 5.6 Dncll incorporation in motor protein complexes.
This illustrates how Dncll (LC8) is incorporated into the actin based (Myosin V) and
microtubule based (Cytoplasmic dynein) molecular motor proteins (Vale, 2003). Nomenclature:
DIL represents the dilute domain; ELC is the essential light chain; LIC is the light intermediate
chain; and IC is the intermediate chain.
Dncll was originally described as being homogeneously expressed in the cytoplasm of cells
(Dick et al., 1996; Jaffrey and Snyder, 1996; King et al., 1996), however more recently it has
been reported that Dncll is present in both the nucleus and the cytoplasm (Crepieux et al., 1997;
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Herzig et al., 2000). This difference in the subcellular localisation of Dncl 1 has been ascribed to
differences in cell type and cell cycle phase (Kaiser et al., 2003).
0
Figure 5.7 Minus end directed movement of dynein along microtubules.
This illustrates how dynein binds to cargo proteins via Dncll and allows retrograde transport
from the growth cone or post-synaptic density to the nucleus (Vale, 2003).
Nuclear and cytoplasmic extracts of two mammalian cell lines showed that Dncl 1 was expressed
in both the nucleus and cytoplasm, which led to the hypothesis that Dncll may be involved in
intracellular trafficking of protein complexes (Crepieux et al., 1997). Furthermore, it has been
suggested that perhaps the binding of Dncll to proteins facilitates their nuclear export and
subsequent cellular distribution due to coupling to the microtubule organising centre (MTOC),
which is a perinuclear region from which the microtubule network radiates (Crepieux et al.,
1997). This hypothesis is based on the observation that Dncll has been shown to colocalise with
both IkBcx (Crepieux et al., 1997) and the African swine fever virus (ASFV) p54 protein
(Alonso et al., 2001) at the MTOC.
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Dncll has also been reported to occupy discrete regions of the nucleus colocalising with the
transcriptional repressor protein (TRPS1) (Kaiser et al., 2003) and the transcriptional activator
nuclear reparatory factor 1 (NRF1) (Herzig et al., 2000). This has led to the suggestion that
Dncll may be involved in the movement of proteins such as transcription factors from
interchromatin granules (storage or assembly structures for proteins involved in gene expression)
in the nucleus to sites of active gene expression (Herzig et al., 2000).
Dncll has also been shown to bind to specific sequences in the 3'UTR of mRNA of the
parathyroid hormone (PTH). It has been proposed that this interaction facilitates a specific
cytoplasmic localisation of the mRNA, due to its coupling to the microtubule associated dynein
motor complex, to produce a spatially restricted pattern of protein expression in the cell (Epstein
et al., 2000).
In situ hybridisation using Dncll cDNA showed that it was strongly expressed in the central
nervous system of Drosophila (Herzig et al., 2000) and high concentrations of Dncll mRNA
have been shown to be present in brain, heart, liver and kidney by Northern blot analysis in rat
(Wilson et al., 2001). Furthermore, it has been shown by immunofluorescence that Dncll is a
synaptic protein that is predominantly concentrated at the postsynaptic density (PSD) but is also
expressed in a punctate pattern along dendritic shafts (Naisbitt et al., 2000).
Dncll has also been shown under the synonym of pin (protein inhibitor of neuronal nitric oxide
synthase) to be an inhibitor of nNOS (neuronal nitric oxide synthase) (Jaffrey and Snyder, 1996).
It was reported that binding of the Dncll protein to nNOS destabilised the dimeric structure,
which is required for the enzyme's activity (Jaffrey and Snyder, 1996). However, more recently
this role of Dncll has been challenged and it has been proposed that the main function of Dncll
is in dynein and myosin motor complexes (Hemmens et al., 1998). This is further substantiated
as it has been demonstrated that Dncl 1 definitely binds to nNOS; however, it neither dissociates
the dimeric structure of the enzyme nor inhibits its function. Therefore, it is proposed that its
interaction merely facilitates the transport of nNOS along the microtubule network (Rodriguez-
Crespo etal., 1998).
Not only has Dncll been shown to bind to nNOS (Rodriguez-Crespo et al., 1998) but it has also
been shown to bind to the guanylate kinase domain-associated protein (GKAP) (Naisbitt et al.,
2000). In both cases Dncll has been proposed to function in coupling these proteins to
cytoplasmic dynein and so facilitating their axonal transport. Interestingly, the post-synaptic
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density (PSD), a dynamic structure where proteins are transient and stoichiometrically variable
(Sheng and Kim, 2002), has been shown to include both nNOS and GKAP coupled to NMDA
(A-methyl-D-aspartate) receptors through the PSD-95 family of scaffold proteins (see Figure
5.4) (Sheng and Kim, 2002). Therefore, it is possible that both nNOS and GKAP are transported
to the PSD and due to their interaction with Dncll are specifically localised within this region
via the myosin molecule, as it has also been shown that PSD-95, GKAP, Dncll and myosin-V
co-immunoprecipitate as a complex in rat brain (Naisbitt et al., 2000). This is fascinating as it is
possible that a similar function of Dncl 1 could be attributed to its interaction with PAX6 and that
Dncll is responsible for specifically localising PAX6 within the PSD in developing neurons.
The possible roles of the Dncll protein that I have mentioned so far have been in intracellular
transport and more specifically in axonal transport; however, other functions of the Dncll
protein have also been described including: regulation of the pro-apoptotic activity of Bim, a
Bcl2 family member (Puthalakath et al., 1999); and suppression of the transcriptional repression
function of TRPS1 (Kaiser et al., 2003). In the case of TRPS1 the suppression of transcriptional
repression is thought to be due to a possible conformational change due to the interaction of
TRPS1 and Dncll (Kaiser et al., 2003). However, the Bim protein is regulated as it is attached to
the microtubule associated dynein motor complex via Dncll. When activated by certain
apoptotic stimuli the Bim/Dncll complex dissociates from the dynein molecule and moves to the
Bcl2 protein where it interacts and stops the antiapoptotic effect of Bcl2 protein (Puthalakath et
al., 1999).
Loss of function mutations in Drosophila show embryonic lethality via the apoptotic pathway
(Dick et al., 1996); however, this is not surprising given that Dncll functions to sequester the
proapoptotic protein Bim onto the microtubule network (Puthalakath et al., 1999). Although
lethal this mutation is characterised by severe neuronal defects suggesting that Dncll may also
be involved in axon formation (Jacob et al., 2000).
Whilst reading the literature on Dncll I discovered that potential Dncll binding sites in the
interacting proteins had been ascertained in many cases. Therefore, I thought it would be
interesting to use matcher in EMBOSS (see 2.1.5) to identify any regions of similarity between
these Dncll binding sites and the sequence of the PST domain of PAX6. As I have illustrated in
Figure 5.8 there are potentially two Dncll binding domains within the PST domain of PAX6,
although this hypothesis is based on very weak regions of homology between previously isolated
Dncll binding sites.
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Figure 5.8 Alignment of Dncll binding domains to PAX6 sequence.
This shows the PAX6 amino acid sequence (345-407aa) as illustrated in Figure 3.1, as well as
the alignment to the published Dncll binding domains that have previously been reported: as
determined from pepscan technique (Pep) (Rodriguez-Crespo et al., 2001); in the African swine
fever virus (ASFV) protein p54 (Alonso et al., 2001); in the Mokola virus (Mok) P protein
(Jacob et al., 2000); and in the Rabies virus (Rab) P protein (Poisson et al., 2001). A red amino
acid indicates an identical residue whereas a blue amino acid indicates a similar residue. Two
possible Dncll binding regions in PAX6 have also been illustrated.
The two consensus sequences identified by Rodriguez-Crespo et al., (2001) using a pepscan
technique in Dncll interacting proteins are KSTQT and GIQVD, which correspond to Dncll
binding regions 1 and 2 respectively in Figure 5.8. The interacting proteins investigated in this
technique included some of the proteins I have already mentioned including the Bim protein
(Puthalakath et al., 1999), which has a KSTQT consensus sequence and nNOS and GKAP which
both utilise the GIQVD sequence to bind to Dncll (Rodriguez-Crespo et al., 2001). The
sequence in the p54 protein of the African swine fever virus (ASFV) that has been shown to
interact with Dncll shows similarity to Dncll binding region 1 (Alonso et al., 2001). Human
DNCL1 interacts with the phosphoproteins of 2 lyssaviruses: the rabies virus (Poisson et al.,
2001) and the Mokola virus (Jacob et al., 2000). The sequences in both these virus P proteins
that interact with Dncl 1 show similarity to Dncl 1 binding region 2.
Although the characterisation of these two potential Dncll binding regions in Pax6 was based on
very weak regions of homology with other identified Dncll binding domains it is encouraging to
see that the C terminal domain is potentially important in facilitating the interaction between
Pax6 and Dncl 1.
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5.6.3 Discussion of the interaction of Homer3 and DncM with Pax6.
Interestingly, it has been demonstrated that the localisation of the S8 ATPase in the dendrites of
Purkinje cells is dependant on the presence of mGIuRla, otherwise the S8 ATPase is found in
the nucleus of the neuron (Rezvani et al., 2003). This suggests that the scaffolding function of
Homer3 allows proteins that bind to the coiled coil domain of Homer3 to be specifically
sequestered in the postsynaptic density. Therefore, the interaction of Homer3 and Pax6 could
suggest that Pax6 is sequestered in the PSD until stimulus activation of Homerla causes the
dissociation of the Homer scaffolding proteins, including Homer3, so that Pax6 could translocate
to the nucleus. Alternatively, stimulation of receptors in the postsynaptic membrane might also
activate MAPK, as I have already mentioned, which could potentially activate Pax6 before the
PSD complex of Homer3 and Pax6 dissociates.
It is even more intriguing to then include Dncll in this picture, so that the release of activated
Pax6 from the PSD scaffold allows Pax6 to be translocated to the nucleus specifically by its
interaction with Dncll. This would mean that PAX6 could travel along the actin cytoskeleton
first until it reached the microtubule network as Dncl 1 has been shown to interact with both
Myosin-Va and Dynein motor complexes. This provides a possible hypothesis for how the
stimulation of synapses by extracellular cues that are detected by cell-surface receptors could
lead to changes in gene expression within the cell nucleus of developing neurons, which could
have implications for synapse function such as synaptic plasticity or long term potentiation.
Obviously this is only hypothetical and the interactions need to be definitively confirmed.
5.6.4 Triml 1 (Tripartite motif protein family member 11).
The Triml J gene is located on chromosome lq42.13 in humans and 11B1.3 (59.6cM) in mice.
The human and mouse genes are thought to be composed of 6 exons that encode 482 amino acid
and 467 amino acid proteins respectively (www.ensembl.org). which show 90.5% similarity
(86.6% identity). It is interesting to note that by looking at the OMIM gene database it can be
seen that the Iq31-q42 region co-localises with Alzheimer's disease 4, whereas region lq42.1
co-localises with schizophrenia and more specifically the DISCI and DISC2 genes. There is no
co-localisation with any interesting phenotypes when looking at the mouse genome informatics
(MGI) database (www.informatics.iax.org/').
Triml 1 is a member of the mouse tripartite motif protein family (also known as the RBCC
family), and contains the characteristic structural motifs of this protein family: a RING finger, a
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B-box zinc finger, and a coiled coil domain, as well as a B30.2 domain (also termed a SPRY
domain) that is in many but not all Trim proteins (Reymond et al., 2001).
The expression of Trimll in mouse E12.5 embryos is ubiquitous, however, there is a stronger
signal in the CNS, more specifically in the dorsal root ganglia, the telencephalon, the
mesencephalon, and the external layers of the cerebellar primordium (Reymond et al., 2001).
Trimll has a diffuse nuclear and cytoplasmic localisation and is not localised to specific cell
compartments like other Trim proteins (Reymond et al., 2001).
The RING finger is a 40 to 60 amino acid domain that is thought to be involved in
protein-protein interactions (Saurin et al., 1996). In acute promyelocyte leukaemia the
promyelocyte leukaemia protein (PML) is fused to the retinoic acid receptor due to a
chromosomal translocation (Topcu et al., 1999). The PML protein is also a RBCC/TRIM protein
and has been shown to form macromolecular complexes in the nucleus, called nuclear bodies
(Saurin et al., 1996) which are disrupted if the RBCC/TRIM domain (Borden, 2000) or more
specifically, the RING domain (Saurin et al., 1996) is mutated. This suggests that the RING
domain is important in protein interactions and this is further supported by the observation that
the RING domain of PML binds to a specific 65 amino acid sequence in the transcriptional
repressor proline rich homeodomain (PRH) protein (Topcu et al., 1999). The binding of the
RING domain of PML increases the transcriptional repression of PRH, which suggests that this
domain may be linked to a role in transcriptional repression. This is corroborated as the RING
domain of the RBCC/TRIM protein KAP1 has been shown to bind to the KRAB domain of the
transcriptional repressor KOX1 and regulate transcriptional repression through this interaction
(Borden, 2000).
The RING domain is also thought to be involved in protein ubiquitination and function as an E3
ubiquitin ligase (Borden, 2000). It has been suggested that the RING domain is vital for the
targeting of the E3 ubiquitination complex to proteins that have been marked for degradation
(Borden, 2000). Although I have described the involvement of the RING finger domain in
transcriptional repression and ubiquitination, it is likely that these domains are involved in far
more cellular processes. However, the common theme that has been suggested for RING domain
proteins is that they form large macromolecular scaffolds which enable proteins to be correctly
positioned in biological processes (such as ubiquitination) and may also act as molecular
modifiers, altering the specificity of these processes (Borden, 2000).
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The B-box zinc finger is a 40 amino acid domain and is found in transcription factors,
ribonucleoproteins and proto-oncoproteins but it does not have a clearly defined function
(Borden, 1998). The B-box and RING finger motif in the RBCC/TRIM protein PML has been
shown to be essential for the assembly and possible targeting of large macromolecular
complexes, which I have already mentioned (Borden et al., 1996). The coiled coil region is also
important in forming high molecular weight complexes although the function of this domain has
been shown to allow the self association of the Triml 1 (Reymond et al., 2001).
The B30.2 domain is a 160-170 amino acids domain, which is found in nuclear and cytoplasmic
proteins, as well as transmembrane and secreted proteins, although the function of the domain is
not known (Henry et al., 1998). The SPRY domain is of unknown function but was named after
the SPla and Ryanodine receptors which mediate calcium release from the sarcoplasmic or
endoplasmic reticulum (Ponting et al., 1997).
Other members of the Trim protein family have been implicated in development, cell growth and
identifying cell compartments although the specific function of Triml 1 was speculated to be in
the identification of cell compartments (Reymond et al., 2001). However, it has recently been
shown that Triml 1 interacts with Humanin, which is a protein that was initially isolated from a
cDNA library of an Alzheimer's disease patient's brain and was shown to stop neurotoxicity
(Niikura et al., 2003). Humanin has been shown to be expressed in neurons of the occipital lobe
and glial cells of Alzheimer's disease brains but not in age matched controls (Tajima et al.,
2002). The interaction between Humanin and Triml 1 is reliant on the coiled coil and B30.2
domains of Triml 1 with the coiled coil domain instigating self association of Triml 1 so that
there is sufficient interaction of the B30.2 domain with Humanin (Niikura et al., 2003).
It has also been shown that the expression of Triml 1 negatively regulates Humanin expression,
which is consistent with the function of the RING finger domain of Triml 1 in protein
ubiquitination and transcriptional repression (Niikura et al., 2003). However, this report
concludes that the regulation of Humanin levels is through ubiquitin-mediated protein
degradation pathways due to the isolation of increased ubiquitinated Humanin protein in the
presence of Triml 1 (Niikura et al., 2003).
Therefore, it is interesting to speculate that the interaction of Triml 1 with Pax6 in regions of the
brain may allow the specific regulation of Pax6 protein expression levels. Another related
hypothesis is that Triml 1 allows the formation of large macromolecular complexes and that the
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interaction of Triml 1 and Pax6 means that Pax6 is positioned correctly so that it can carry out its
normal function. Disruption of these complexes due to mutation of either Pax6 or Triml 1 may
then lead to dysregulation of the protein components of the complex leading to human disease.
5.7 Expression Studies.
By looking at the UniGene website (see 2.1.6) I could quickly investigate the expression pattern
of these genes. This revealed that all of the interactors have similar expression patterns to PAX6,
with them all being represented by EST (Expressed sequence tagged) sequences from the eye
and brain.
5.7.1 Expression of the interactor genes in the cDNA library.
As the genes encoding the potential interacting proteins, Homer3, Dncll and Triml 1 had been
isolated from the yeast 2-hybrid system several times each then a concern was that these genes
were highly represented in the mouse brain cDNA library and therefore more likely to be pulled
out in the library screens.
I decided to quantify the amount of DNA that was present in the cDNA library for each of the
interacting proteins as well as Pax6 and 2 controls: Glyceraldehyde 3-phosphate dehydrogenase
(Gapdh) gene, a housekeeping gene which has high expression (Patel et al., 2002); and Atp5al,
the alpha subunit gene of ATP synthase, which has strong expression in the brain (Personal
communication, B. Pickard). This was done by performing a PCR (see 2.4.2) with the correct
PCR primers (see Table 2.4) at increasing number of cycles (20 to 35 cycles) to amplifying the
relevant DNA bands from the mouse brain cDNA library. One tenth of the PCR product was
then run out on a 0.8% agarose gel (see 2.2.7) as shown in Figure 5.9.
This showed that the Pax6, Homer3, Dncll and Triml 1 genes were all equivalently expressed in
the mouse brain cDNA library and showed lower expression than the two highly expressed
controls. Therefore, this verified that the interacting proteins were not pulled out of the mouse
brain cDNA library screens multiple times merely because they are more prevalent in the cDNA
library.
Page 124
PAX6 protein-protein interactions Yeast 2-hybrid screening
Pax6 Atp5al Gapdh
-| r n r
« > o ir, o 'r, gOTiom > o o in . ,Q> i rt rt m tn i N rt cn w T n rt co cn <P bp
Trimll Dncll Homer3
n r 1 r
u ^ > oino in ^oinoin' ' > o «n © in , .bp $ I NNWW I Nrtmcn T MNCO CO $ bp
Figure 5.9 Quantitation ofPax6 and the three interactors in the cDNA library.
Amount of cDNA that represents Pax6 (600bp band) and the Homer3 (485bp band), Dncll
(485bp band) and Trimll (609bp band) was estimated by performing PCR and varying the
number of cycles from 20 to 35. Two controls, AtpSal (415bp band) and Gapdh (450bp band),
which represent highly expressed proteins in the brain, were also included. One tenth of the PCR
was run on this 0.8% agarose gel along with 4>x marker.
5.7.2 Expression of the interactor genes in relevant cell lines.
Although it was encouraging that the three interactor genes were expressed in similar regions as
determined by looking at EST sequences, I wanted to specifically investigate whether these
genes were expressed in a mouse and a human lens epithelium cell line (mv+ and H36CE2
respectively, see Table 2.8). These were known to express the PAX6 protein (Veronica van
Heyningen, personal communication). The primers in Table 2.4 were designed against the
exonic sequences of the mouse and human Homer3, Dncll, Trimll and PAX6 genes and these
were used to performing RT-PCR (see 2.4.4) on the RNA (see 2.3.1) of the mouse (mv+) and
human (H36CE2) PAX6 expressing cell lines.
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Table 5.9 Expression of PAX6 and interactors in lens epithelial cell lines.
This table estimates the level of expression of PAX6 and the three interactors (Homer3, Dncll
and TrimlT) by RT-PCR in mouse (mv+) and human (H36CE2) lens epithelial cell lines.
This was very encouraging as the results of the RT-PCR (see Table 5.9) showed that PAX6 and
Homer3, Dncll and Trimll are all expressed in the mouse and human lens epithelium cell lines.
This experiment does not confirm that the proteins are expressed in these cells or that they
interact in vivo, but the mRNA is expressed in the same cells which made me optimistic of a true
interaction.
5.7.3 Sub-cellular localisation of PAX6.
The three novel and interesting interacting proteins that I have isolated are all predominately
cytoplasmic in expression and it is known that PAX6 is mainly nuclear in its expression pattern.
However, as discussed in section 1.3.3 there is a minus paired domain isoform of PAX6 (-PD
PAX6), which has been shown to have a cytoplasmic localisation (Carriere et al., 1995) and has
also been shown to be highly expressed in the mouse brain by RT-PCR (Mishra et al., 2002).
Therefore, it is possible that the interacting proteins may associate with this isoform of PAX6 in
vivo.
The subcellular localisation of PAX6 was investigated in mouse lens epithelium cells (mv+)
using the subcellular proteome extraction kit (see 2.10.6). The resulting subcellular fractions
were then run out on a 12% SDS-polyacrylamide gel (see 2.10.1), transferred to Hybond-P (see
2.10.2) and western blotting (see 2.10.3) carried out using the C terminal PAX6 antibody (see
Table 2.9) and the HRP conjugated anti-rabbit secondary antibody (see Table 2.10). The results
are shown in Figure 5.10.
It is interesting to discover that using this protocol the cytosolic protein fraction not only
contains the -PD PAX6 isoform (24.3kDa) but also contains the -5a PAX6 isoform (46kDa),
whereas only the +5a PAX6 isoform (48kDa) was located in the nucleic protein fraction. The
results of this experiment confirm that the -PD PAX6 isoform is predominantly expressed in the
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Figure 5.10 Subcellular localisation of PAX6.
This shows that there are 2 bands in the cytosolic protein fraction: -5a PAX6 at 46kDa; and -PD
PAX6 at 24.3kDa. The nucleic protein fraction contains a single band representing +5a PAX6 at
48kDa. mv+ is protein extracted from mouse lens epithelial cells. The FLAG -PD PAX6 lane
contains lysate isolated from mv+ cells that have been transfected with p3XFLAG-PD_PAX6
(see Table 8.3) that represents the 27kDa FLAG tagged -PD PAX6 produced. Autorad has been
exposed for 2mins of an immunoblot probed with the C terminal PAX6 antibody (see Table 2.9)
and the HRP conjugated anti-rabbit secondary antibody (see Table 2.10).
The fact that the +/- 5a PAX6 isoforms have different subcellular localisation with the +5a
isoform being nuclear and the -5a isoform being cytoplasmic is also interesting. If this result is
true then the -5a PAX6 isoform could potentially interact with these 3 interactors like the -PD
PAX6 isoform.
It has been shown from experiments on quail Pax6 (Carriere et al., 1995) that there are
potentially two nuclear localisation signals (NLS) in the Pax6 protein. One of these, which is
contained within exon 6 (see Figure 1.3), is thought to function in localising the paired domain
containing Pax6 isoforms (i.e. +/- 5a Pax6) to the nucleus. The other NLS, which is thought to
function in the -PD Pax6 isoforms, is located just before the homeodomain (LKRKLQR, aa
206-212, see Figure 3.1) and is similar to a SV40 nuclear localisation signal (Zhang et al., 1998).
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However, even these two NLS are not sufficient to direct non-nuclear proteins into the nucleus,
and it is speculated that another region is required for correct nuclear localisation (Carriere et al.,
1995). It was shown by deletion studies that a region between amino acids 271-342 in Pax6
might also be involved in nuclear localisation, and this region shows similarity to a proposed
bipartite nuclear signal (266-276) at the end of the homeodomain which might also have an
involvement in nuclear localisation (Carriere et al., 1995). However, even with the
characterisation of these possible NLS it was still noted that a small proportion (7%) of
transfected quail neuroretinal cells had a cytoplasmic localisation of the -5a Pax6 isoform
(Carriere et al., 1995), which suggests that there is potentially another mechanism that partitions
Pax6 between the nucleus and the cytoplasm.
It has also been speculated that there might be a region within the PST domain that is required
for cytoplasmic retention (Zhang et al., 1998). As the PST domain contains several potential
phosphorylation sites then it is possible that the subcellular localisation of Pax6 could be
regulated by protein phosphorylation, which is already known to control nuclear transport (Jans
and Hubner, 1996). Therefore, this is particularly interesting as I have already proposed the
possibility of a link between MAPK (mitogen-activated protein kinase) and Pax6 due to the
interaction between Pax6 and Homer3, and this could potentially be involved in the nuclear
localisation of Pax6 isoforms.
However, it is also possible that the subcellular localisation of Pax6 could be modulated by the
binding of other proteins that could potentially mask nuclear localisation signals. This has
specifically been shown in cerebellar granule cells, as a protein called mDia binds to Pax6 in the
nucleus (Tominaga et al., 2002). This is sufficient to reduce the transcriptional activity of Pax6
by dissociating it from DNA and also alter its subcellular localisation making it more cytosolic
(Tominaga et al., 2002). Although not specifically characterised it is proposed that mDia binds
across the Pax6 homeodomain, which is thought to contain a potential NLS, and it could
potentially be this masking of the NLS that localises Pax6 to the cytoplasm.
Furthermore, recent work has determined that there is variability in the subcellular localisation
of Pax6 even within a single cell type of a normal chicken retina (Shin et al., 2003). It was
shown that although Pax6 was nuclear in ganglion cells and the inner nuclear retinal layer, it was
localised in the intercellular space and the cytoplasm in the outer nuclear retinal layer (Shin et
al., 2003). Therefore, this suggests that the subcellular localisation of the PAX6 protein is
variable, and can fluctuate in different cell types (Shin et al., 2003).
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The +/- 5a isoforms of PAX6 are known to have unique functions during development (Mishra
et al., 2002), but the importance of the +5a Pax6 isoform in lens development is illustrated by
the observation that transgenic mice that have a loss of function (Singh et al., 2002) or an
overexpression (Duncan et al., 2000) of this isoform develop lens defects. As the +5a PAX6
isoform has been shown to be specifically important in lens development then it is very
interesting that I found that this isoform is nuclear whereas the -5a PAX6 and -PD PAX6
isoforms are cytoplasmic. It is interesting to hypothesise that in this cell type the -5a and -PD
PAX6 isoforms are either sequestered in the cytoplasm by a cytoplasmic retention factor or are
unable to translocate to the nucleus due to masking of their potential NLS.
Although this is an intriguing result for lens epithelial cells, this subcellular localisation of Pax6
isoforms cannot be assumed for every cell type and it is possible that it could be different in
brain neurons. Therefore, it is feasible that any of the PAX6 isoforms could be cytoplasmic
before being translocated into the nucleus to elicit their individual gene expression pattern and
that the selection of which isoform is re-located is cell type specific.
5.7.4 The next step.
Having provided more in vivo evidence that the expression of PAX6 and the three identified
interactors overlap, another important question needed to be answered. "Could the interaction
between these three interacting proteins and PAX6 be re-confirmed using the yeast 2-hybrid
system in a pairwise manner?" This is discussed in chapter 6.
Page 129
PAX6 protein-protein interactions Pairwise Interaction
Chapter 6 Pairwise Interaction
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6.1 Introduction.
As described in chapter 5, the yeast 2-hybrid library screens using the C terminal and PST
domain constructs (pDBLeu_TTST_norm and pDBLeu_ASNT_norm respectively) isolated
three potentially novel and interesting interactors of PAX6 several times from the mouse brain
cDNA library. However, to add weight to the argument that PAX6 does indeed interact with
these 3 interactors, I needed to confirm these interactions in a pairwise manner i.e. PAX6 and
each of the 3 interactors specifically introduced into yeast cells to investigate interactions.
As all the isolated Homer3 clones were devoid of the first 72 amino acids of the protein (see
5.5.1), I also decided to clone the full length Homer3 (see 6.2) and use this to further
characterise the interaction with PAX6. I also decided to investigate the effect on these
interactions with full length PAX6 (see Table 4.2) and to investigate the role of the C terminal
domain of PAX6 on these interactions. Therefore, I screened the 3 interactors with the C
terminal mutant forms of PAX6 (see 1.7.6 and Tables 4.3 and 4.4) and the minus C terminal
domain PAX6 construct (see Table 4.5).
6.2 Cloning full length Homer3 into pPC86.
The Homer3 clone that was isolated from the yeast 2-hybrid screen was found to be missing the
first 72 amino acids of the published IMAGE clone sequence. Therefore, a full length Homer3
clone was created to investigate any differences with the truncated Homer3 clone in its
interaction with PAX6. A full length Homer3 IMAGE clone was identified by BLAST searches
(IMAGE: 3602414). The clone was ordered and DNA was prepared (see 2.5.3). The missing 70
amino acids were then PCR amplified from the IMAGE clone DNA using PCR primers that
were designed with a 5' Sail site and a 3' EcoRl site (see Table 2.3). The restriction sites used in
this cloning strategy were chosen so that the PCR generated fragment could be easily added to
the pPC86 Homer3 clone using a Sail site within the polylinker and a convenient EcoRl site near
the 5' end of the pPC86 Homer3 insert. The sequence verified PCR product was then cut with
Sail and EcoRl and ligated into the pPC86 Homer3 clone that had been cut with the same
restriction enzymes to generate the full length Homer3 clone (see Table 6.1).
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Construct Produced. Description. Schematic Diagram.
pPC86_Homer3_Ful1
Corresponds to the entire Homer3
cDNA sequence.
^ Ml Cc
Table 6.1 Full length Homer3 in pPC86.
The pPC86 vector produces a protein coupled to the GAL4 activation domain (purple oval). This
table shows the artificially constructed full length Homer3 construct that was created, which is
also illustrated as a schematic diagram (Domains as in Table 5.8).
6.3 Investigating pairwise interactions.
Interactions were tested by first transforming yeast with a relevant pDBLeu PAX6 construct and
one of the pPC86 interactor constructs (see 2.8.3). These pairwise interactions were then
analysed using the full screen with an optimised 3AT concentration of lOmM 3AT that was
sufficient to eliminate basal growth between interactors and PAX6 constructs.
6.3.1 Controls included in pairwise screens.
Apart from the transactivation ability of the whole PST domain constructs which will be
discussed in Chapter 7, none of the remaining pDBLeu PAX6 or pPC86 interactor constructs
had any transactivation potential when included in the yeast 2-hybrid system along with the
corresponding empty vector, e.g. pPC86_Homer3 included with empty pDBLeu vector was not
able to activate reporter gene expression. In addition to these controls the pPC86 interactor
constructs were also tested against random pDBLeu constructs, which encoded SIX1, SIX3,
Synip and Grg5. This showed that none of the interactor clones interacted with these
non-specific proteins. PST domain and C terminal domain constructs containing the wild type
alleles from patients REMAR and WHEDA (see Table 4.4) were also included as controls in
these pairwise interactions. These wild type constructs contain part of the 3'UTR but are
expected to form the normal C terminus of PAX6 and hence behave like normal PAX6
constructs. This was confirmed by the pairwise interactions full screens as these constructs did
not behave differently from the normal PST or C terminal domain constructs (Data not shown).
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6.3.2 Quantification of pairwise interaction results.
The full set of results obtained from this pairwise screening between pDBLeu PAX6 constructs
and each of the pPC86 interactor constructs is illustrated in Table 6.2. By comparison to the 5
yeast control strains A to E which have increasing reporter gene expression (A, lowest and E,
highest expression) I attempted to quantify the pairwise interactions so that the results could be
interpreted more readily. By combining this level of reporter gene expression with the predicted
colony phenotype, using Table 5.2, I quantified the interactions from ZZZ as the strongest
interaction to * which shows no interaction and no reporter gene expression. The interactions
that have been termed 'weak' are those interactions where the reporter gene expression is very
low when compared to the control yeast strains and would normally be characterised as a Z or
however, there is one inconsistent reporter gene phenotype.
It is clearly illustrated (see Table 6.2) that the whole PST domain has been confirmed to interact
with Homer3 (full and truncated constructs), Trimll and Dncll. Although there is innate
transactivation ability of the PST domain construct (pDBLeu_ASNT_norm), its interactions with
Homer3, Dncll and Trim 11 causes a higher amount of reporter gene expression when compared
to the yeast control strains A to E than only the PST domain construct. Therefore, it can be
concluded that the PST domain of PAX6 and these 3 interactors really do interact in this system
and that it is not just an artifact of the transactivation ability of the PST domain.
The confirmation of the interactions between the C terminal domain PAX6 construct and
Homer3 and Dncll was more problematic. In the full screen of HIS3 positive colonies isolated in
the C terminal domain library screen, these colonies showed low level URA3 and lacZ reporter
gene expression, indicating a weak interaction. However, when the pairwise interaction full
screen was performed only the test for low level reporter gene expression was affected. This
showed very slight inhibition of colony growth on plates containing 0.2% 5FOA (see 2.8.7), but
there was no expression of the lacZ reporter gene. This result was not affected by repeating the
full screen with freshly transformed yeast cells. I can only conclude that the reporter gene
expression in these pairwise experiments is so low that it isn't sufficient to give a colour change
in the lacZ assay, and only slightly affects the 5FOA result. Therefore, due to the inconsistency
of the reporter gene expression I cannot confirm the pairwise interaction between the C terminal
domain PAX6 construct and the pPC86 Homer3 or Dncl 1 constructs with this system.
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pPC86 constructs ■M
Construct Name Dncll Trim 11
nSSB 1 ill l
Normal pDBLeu constructs mmmmmwgm
■HHBHIHniflHHHHHMIi
\rPAX6 Full C | y. - >| J X A X X
ASNT norm c—y—n yyy // // yy
SYSC_norm CZZZXH yy X X //
MQTH_norm CZ3D Weak X X X
TTST_norm CZX1 X X X X
Q422R mutant pDBLeu constructs
ASNT_mut c—3 11 y V yy
SYSCjnut CZXB y X X yy
MQTH_mut CZZ2$] X X X X
TTST_mut CZ33 X X X X
X423L (REMAR) mutant pDBLeu constructs
ASNT_RMmu t ^^— 11 ^ y X Weak ✓V
TTST_RMmut CH20H^ X X X X
1615dell0 (WHEDA) mutant pDBLeu constructs
ASNT_WHmut >i—n > Weak X X yy
TTST_WHmut C=3E==> X X X X
Minus C terminal pDBLeu construct
ASNT-TTST c—T~\ Weak X X yy
Table 6.2 Pairwise interaction results.
This table shows the results of all the pairwise interactions between the various PAX6 constructs
and the interactor constructs. A schematic diagram illustrates each construct. The interaction is
quantified with yyy being a definite interactor and * being a definite non-interactor and 'weak'
indicating that there is low or no reporter gene expression, but that there is one inconsistent
reporter gene phenotype. Schematic diagrams of pDBLeu PAX6 constructs as in Chapter 4 and
pPC86 interactor constructs as in Tables 5.9 and 6.1.
Also of concern was the finding that full length PAX6 was shown not to interact with the 3
interacting proteins in this system. It could potentially be argued that as these 3 interactors do
not interact with full length PAX6 then this weakens the proposal that the interactions occur in
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vivo. However, in the yeast 2 hybrid system, the GAL4 DNA binding domain is coupled to the N
terminus of the fusion protein when expressed, which could potentially alter the structure of the
full length PAX6 protein. The GAL4 DNA binding domain is in fact roughly the same size as
the paired domain (about 150 amino acids in length) and when coupled to the N terminus of the
paired domain could sufficiently alter the conformation of PAX6 so that interaction with the 3
interactors is not possible. Furthermore, as the 3 interactors are predominantly cytoplasmic and a
potential minus paired domain isoform of PAX6 (see 1.3.3) is also mainly cytoplasmic in
expression, then interactions may occur due to the specific conformational arrangement of this
-PD isoform. However, the characterisation of the -PD isoform and the interactors was not
investigated using this yeast 2-hybrid system.
It is also interesting to note that although only the whole PST domain of PAX6 interacts with
Dncll, the interaction of Homer3 and Trimll also occurs with the more truncated PAX6
construct pDBLeu_SYSC_norm, although this interaction is reduced with Homer3 and does not
occur with full length Homer3. This potentially indicates that the interaction site of Homer3 and
Triml 1 with PAX6 may well occur more towards the C terminus of the PST domain than Dncll.
However, in the case of Homer3 this does not take into account the results of the C terminal
mutant PAX6 construct interactions which will be discussed further in section 6.3.4.
6.3.3 Triml 1 interaction site in PAX6.
Trimll interacts specifically with the whole PST domain PAX6 construct and the more N
terminally truncated construct pDBLeu_SYSC_norm. The PST domain constructs that either
include the C terminal mutations (Q422R, X423L and 1615dell0, see Figure 1.18) or lack the C
terminal domain (see Table 4.5) do not alter this interaction (see Table 6.4 and Figure 6.1),
which implies that the site of Trimll interaction with PAX6 may be tentatively suggested. The
interaction between Triml 1 and PAX6 is not altered by the removal of the N terminal 75 amino
acids of the PST domain (difference between the ASNT and SYSC constructs, see Figure 3.1)
but there is no interaction between Triml 1 and the pDBLeu_MQTH_norm construct. Therefore,
I speculate that Trimll interacts with PAX6 in the region illustrated in Table 6.3 around the
SYSC motif of the PST domain (green box, see Figure 3.1). The amino acid sequence of PAX6
immediately surrounding this SYSC motif shows weak homology over evolution and may
suggest a specific region for interactions. Mutational studies would be interesting to further
characterise the interaction site between PAX6 and Triml 1 in this region.
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Table 6.3 Illustration of possible Trim 11 interaction site in PAX6.
This table highlights the possibility that Trimll may bind to PAX6 in a specific region indicated
by the vertical stippled box. This is based on the different interacting potentials of the truncated
PAX6 constructs. The GAL4 DNA binding domains (yellow oval) in previous schematic
diagrams have been removed so that the interacting site can be clearly illustrated. Other domains
of the schematic diagrams as in Table 4.1.
6.3.4 C terminal influence on pairwise interactions.
As already described, the interaction between the three proteins Homer3, Dncl 1 and Trim 11 and
the PST domain of PAX6 was confirmed but the interaction with the C terminal domain was not.
These results are consistent with Triml 1 only being isolated from the PST domain library screen
but Homer3 and Dncll were isolated from both library screens and I was concerned that I could
not re-confirm their interaction with the C terminal domain construct. Although I have already
mentioned that the interaction between Homer3 and Dncll and the C terminal domain of PAX6
could be extremely weak (see 6.3.2), I was reassured when I discovered that the C terminal
domain plays an important role in these interactions (see Table 6.4).
Although there is an interaction between the PST domain of PAX6 and Homer3 or Dncll, this
interaction is severely affected by the removal of the C terminal domain (see Table 6.4 and
Figure 6.1). In the case of full length Homer3 and Dncll the interaction with PAX6 seems to be
dependent on the C terminal domain even though the interaction with the C terminal domain
itself is very weak. Therefore, it is feasible to speculate that the interaction of the C terminal
domain and the PST domain may generate a specific conformation that cannot be achieved
without the intact C terminal domain.
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Even more tantalising are the results that the interaction between Homer3 or Dncll and PAX6 is
reduced or abolished due to C terminal mutations that are known to cause eye malformations in
patients (see Table 6.4).















Table 6.4 Pairwise interaction results with various PAX6 mutants.
This table shows the affect that PST domain constructs including the PAX6 C terminal mutants
(see 1.7.6) or lacking a C terminal domain have on the interaction between PAX6 and the 3
isolated interactors Homer3, Dncll and Triml 1. Schematic diagrams as in Chapter 4.
















Figure 6.1 Alteration of lacZ expression due to altered C terminus of PAX6.
This figure shows how the interaction of Homer3, Dncll, Triml 1 and PAX6 is altered due to
changes at the C terminus of PAX6, as shown by changes in lacZ reporter gene expression. The
alterations of the C terminus of PAX6 are the 3 C terminal mutations (see 1.7.6) and a PST
domain devoid of the C terminal domain (see Table 6.4 for schematic diagrams). For
comparison, a control panel is included showing the yeast control strains A-E and their
increasing expression of the lacZ reporter gene.
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It has been shown for both Homer3 (full and truncated) and Dncl 1 that the various C terminal
mutations have an increasingly detrimental effect on the interactions: the Q422R mutation has
the mildest effect and reduces the interaction with both Homer3 (full and truncated) and Dncll;
the X423L (REMAR) mutation reduces the interactions with both Homer3 and Dncll even
further, abolishing the interaction with full length Homer3; and the 1615del 10 (WHEDA)
mutation has the most severe effect with the interaction with Homer3 (full and truncated) and
Dncll being abolished (see Table 6.2 and Figure 6.1).
6.4 Discussion.
The Q422R mutation changes the very last amino acid of PAX6 and is found in patients showing
either mild aniridia characterised by uveal ectropion (Azuma and Yamada, 1998) or more
classical aniridia with foveal hypoplasia (Singh et al., 2001).
The X423L (REMAR) mutation occurs in several patients all showing aniridia. The mutation is
an insertion of a T nucleotide into the normal stop codon of PAX6. The amino acid sequence of
the PAX6 protein up to the normal stop codon is not altered but the mutated protein encodes a
further 35 amino acid extension into the 3'UTR (untranslated region). This mutation has also
been associated with the incorrect formation of brain structures such as the anterior commisure
and neuronal connections to the olfactory bulb. In one case the mutation was also linked with
brain anomalies that were manifested by autistic type behaviour (Chao et al., 2003).
The 1615del 10 (WHEDA) mutation is found in a family suffering from classical aniridia as well
as an atypical neurobehavioural phenotype, namely impaired social understanding and verbal
inhibition (Heyrnan et al., 1999). This mutation causes the deletion of 10 nucleotides just before
the normal stop codon of PAX6 and so the final 5 amino acids of the normal PAX6 protein are
altered and the protein is elongated by a further 103 amino acid extension into the 3'UTR.
It is interesting to see that as more of the C terminal domain of PAX6 is altered by the various C
terminal mutations (see Figure 1.18) then the interaction with Homer3 or Dncll decreases (see
Table 6.4 and Figure 6.1). I have already suggested that a potential function for these proteins is
in neurogenesis, hypothesising that PAX6 could be sequestered in the post-synaptic density due
to its interaction with Homer3 and upon activation of the post synaptic density by extracellular
stimuli, MAPK activated PAX6 could then be transported to the cell nucleus (due to its Dncll
interaction) to alter cell gene expression (see 5.6.3).
Page 138
PAX6 protein-protein interactions Pairwise Interaction
The finding that the mutations that alter the largest amount of the C terminal domain of PAX6
(1615dell0, WHEDA) cause a more severe brain phenotype is intriguing. It is possible that the
neurobehavioural phenotype of these patients may be due to incorrect neuronal connections in
specific regions of the brain that may in part be caused by the inability of PAX6 to interact with
HOMER3 and/or DNCL1. In a patient with the X423L mutation the defect in olfactory function
was suggested to be due to incorrect neuronal patterning between the brain and the intact
olfactory bulb (Sisodiya et al., 2001). More intriguing for this mutation is the discovery that 2
patients with this mutation both developed polymicrogyria, which is a rare brain defect that is
thought to be caused by disruption of neuronal migration (Mitchell et al., 2003). Furthermore, it
was noted that one of these patients also suffered from epilepsy, which may also allude to
incorrect neuronal patterning of the brain, which made this patient more susceptible to seizures.
Conversely, it is interesting to note that the phenotype produced by the Q422R mutation, which
only affects the final amino acid of the C terminal domain has not been reported to cuase any
brain or behavioural abnormalities. This may be simply due to the fact that the brain phenotype
was not investigated or it could be that as this mutation does not abolish interactions between
PAX6 and HOMER3 or DNCL1, then normal brain development can occur.
It has already been suggested that the expression of PAX6 in the brain is required to provide
local navigational information to developing axons (Mastick et al., 1997). Therefore, these
PAX6 mutations could alter or disrupt the normal gradient of PAX6 that occurs in regions of the
developing brain (see 1.5.2) resulting in the associated brain abnormalities of these aniridia
patients.
However, it is interesting to note that Homer mutants result in axon pathfinding errors in
Xenopus optic tectal neurons (Foa et al., 2001) suggesting that there may be a possible link
between these scaffolding proteins and proteins that govern axon trajectories. Although my
suggestion of the function of the interactions between PAX6 and Homer3 and Dncll is in axonal
trafficking from the dendrites to the cell nucleus, it is possible that these interactions could be
involved in axon guidance due to the activation of genes that may be involved in axonal
guidance during brain development (Meech et al., 1999).
Therefore, the reduced or disrupted interaction of the mutant PAX6 and these interacting
proteins perhaps suggests that as the mutation of the C terminus of PAX6 becomes more severe
then either PAX6 is not sequestered in the post-synaptic density by Homer3 or is not able to be
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transported to the nucleus by Dncll to alter gene expression. This may mean that the gradient of
PAX6 is not set up correctly causing changes in axon guidance or the altered gene expression
may cause problems in neuronal patterning that are evident in patients that contain these PAX6
mutations. However, at this stage this is only a hypothesis attempting to link my findings with
the phenotype of patients with these PAX6 mutations, and it must be remembered that these
phenotypes may have an alternative explanation.
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Chapter 7 Transactivation
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7.1 Introduction.
It was noticed that when the PST domain HIS3 positive colonies were screened using the X-gal
assay (see 5.2), the majority of these colonies as well as the pDBLeu_ASNT_norm only control
had a positive blue colour. This indicated that the innate transactivation ability of the entire PST
domain (Tang et al., 1998; Mikkola et al., 1999) was functioning in the yeast 2-hybrid system
and was capable of activating reporter gene expression.
Therefore, this transactivation ability of the PST domain was investigated further and the
transactivation ability of constructs that contained the various C terminal mutations was
examined.
7.2 Yeast 2-hybrid reporter gene expression.
Figure 5.2 shows an illustration of how the yeast 2-hybrid system works to activate reporter gene
expression. The PST domain pDBLeu construct produces a GAL4 DNA binding domain
coupled protein that will bind to the DNA binding site and the empty pPC86 vector will produce
the uncoupled GAL4 activation domain. However, the first question that I wanted to answer was
"Is the transactivation of the reporter genes by the PST domain dependant on the GAL4
activation domain in this system?"
7.2.1 PST domain and the GAL4 activation domain.
I answered this question by transforming the PST domain construct (pDBLeu_ASNT_norm) into
yeast cells with and without the empty pPC86 vector that encodes the GAL4 activation domain. I
also did the same for the C terminal domain construct (pDBLeu_TTST_norm) to confirm that
this construct has no transactivation ability. It must be remembered that the transformed yeast
cells lacking pPC86 do not have the ability to synthesise tryptophan since pPC86 carries the
TRP1 gene. Therefore, the plates used in the reporter gene assays (see 2.8.7) had to include
tryptophan to allow growth of these yeast cells. The full range of reporter gene assays were then
performed as normal and the results are represented in Figure 7.1.
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Figure 7.1 Assessing transactivation ability without the GAL4 activation domain.
This figure shows the results of all the reporter gene assays. Each panel illustrates the various
plates containing selective media and each plate has the same layout as illustrated for the X-gal
assay plate. Two concentrations of 3AT were used: 7.5mM for the C terminal construct and
lOmM for the PST domain constructs. For more details about this full screen see 2.8.7.
This confirmed that the C terminal domain construct was unable to activate the reporter genes,
even at low levels (tested by inhibition of growth on 5FOA containing plates) irrespective of
whether the GAF4 activation domain was present or absent. However, it was clearly shown that
there is transactivation of all the reporter genes with the PST domain construct and this
expression is identical with and without the GAF4 activation domain. I also tested the more
truncated PAX6 constructs (see Table 4.1) as well as full length PAX6 (see Table 4.2) as part of
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the pairwise interaction experiments (see 6.3) and all these constructs had no transactivation
ability. Therefore, only the PST domain construct has been shown to have transactivation ability
and this is independent of the GAL4 activation domain. Initially this caused some concern, as I
was worried that the pairwise results with the PST domain might result from its transactivation
ability. However, as I've already mentioned in Chapter 6 (see 6.3.2) the results of the pairwise
interactions with Homer3, Dncll and Trim 11 all produced higher reporter gene expression than a
PST domain only control when compared to the yeast control strains A to E.
7.2.2 Effect of C terminal mutations on transactivation.
Having ascertained that only the PST domain construct was capable of activating the reporter
genes in the yeast 2-hybrid system, I wanted to investigate what effect altering the C terminus of
the PST domain would have on this transactivation ability. Therefore, I transformed the pDBLeu
PAX6 constructs that were lacking the C terminal domain (see Table 4.5) or that contained the C
terminal mutations (see Tables 4.3 and 4.4) with the empty pPC86 vector into yeast cells. I then
ran a full screen on the resultant transformed colonies and the interesting results are shown in
Table 7.1.






Table 7.1 Varying transactivation of PST domain constructs.
This table shows the varying transactivation ability of the PST domain constructs including the
PAX6 C terminal mutants (see 1.7.6) or lacking a C terminal domain (see Table 4.5). Schematic
diagrams as in Chapter 4.
I also included PST domain constructs containing the wild type alleles from patients REMAR
(X423L) and WHEDA (1615del l0, see Table 4.4) as controls. These constructs should produce
normal PST domain proteins that terminate at the normal stop codon of PAX6. The results of the
reporter gene assays showed that these wild type constructs behaved exactly the same as the
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Although the PST domain construct was shown to have transactivation ability it was very
interesting to see that the constructs encoding the C terminal mutations caused a change in this
transactivation, as is illustrated by the X-gal assay results in Figure 7.2.
Figure 7.2 PST domain transactivation of lacZ reporter gene.
This shows how the transactivation ability of the PST domain is altered due to the various C
terminal PAX6 mutations. X-gal assay on 7 test samples in quadruplicate and A-E control yeast
strains in duplicate showing varying amounts of lacZ reporter gene expression. Construct names
as in Chapter 4: ASNT refers to the PST domain; ASNT_mut contains the Q422R mutation;
WHmut and WHwt are constructs that contain the WHEDA (1615dell0) mutant and wild type
alleles respectively; likewise RMmut and RMwt are constructs that contain the REMAR
(X423L) mutant and wild type allele respectively.
The Q422R mutation changes just the final amino acid of the normal PAX6 protein; however,
the inclusion of this mutation in a PST domain construct (pDBLeu_ASNT_mut) was sufficient
to substantially reduce reporter gene activation. The transactivation ability of this construct was
sufficient to cause inhibition of growth in the 5FOA assay (a test for low levels of URA3
expression), but was insufficient to allow growth on plates lacking uracil (a test for high levels
of URA3 expression).
Although the Q422R mutant construct still retained a very weak transactivation ability, the PST
domain constructs that contained the run on mutations 1615dell0 (WHEDA) and X423L
(REMAR) and produce elongated PAX6 proteins, had absolutely no transactivation ability. The
PST domain construct that was lacking the C terminal domain was also sufficient to stop
activation of reporter genes (see Table 7.1).
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As I mentioned in the previous section I was concerned that the pairwise interaction results (see
6.3.2) between the PST domain PAX6 constructs and the interacting proteins (Homer3, Dncll
and Trim 11) could be an artefact of the transactivation ability of the PST domain. Furthermore,
the validity of the pairwise interactions between the mutated PST domain constructs and
Homer3 or Dncll could also be questioned, as the reduced interactions due to these mutations
could feasibly be accounted by the reduction in the transactivation ability of the mutant
constructs themselves. However, this theory can be discounted because even though the PST
domain constructs with an altered C terminal domain do not show any transactivation ability, the
interaction between these constructs and Trimll is the same as with the normal PST domain
construct. This therefore, goes some way in validating the interactions between the various
PAX6 constructs and the three interactors and subsequent loss of interactions in some cases due
to these C terminal mutations.
7.3 Transaotivation due to a specific conformation?
Previous investigation into the functioning of the transactivation domain of PAX6 has shown
that the entire PST domain is required to produce its transactivation ability (Tang et al., 1998;
Mikkola et al., 1999). More specifically it has been shown that the C terminal 79 amino acids of
PAX6 has a potent transactivation function (Czerny and Busslinger, 1995) and that the
cooperation between the N (amino acids 271-331) and C (amino acids 380-416) terminal regions
of the PST domain are needed for it to carry out its function as a transcriptional activator
(Carriere et al., 1995).
My results have substantiated these findings and demonstrate that the C terminal domain of
PAX6 is vital in maintaining the transactivation ability of the PST domain. It is possible that the
cooperation of the N and C terminal regions of the PST domain produce a specific conformation
that instigates the transactivation potential. This would explain why there is no transactivation
with only the C terminal domain of PAX6 or with the PST domain lacking the C terminal
domain. A similar explanation was proposed by Mikkola et al., (1999) who suggested the large
size of the PST domain provided a potential interaction surface for protein interactors involved
in the transcriptional machinery. Therefore, the specific conformation set up by the interaction of
the N and C terminal regions of the PST domain could potentially be a site for the interaction of
other proteins. Only when the specific conformation produces this correct interface can PAX6
interact with the correct set of proteins to carry out its function.
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However, the most interesting results are that specific C terminal mutations that have been
identified in patients with eye disease and some related brain anomalies (see 1.7.6) are sufficient
to reduce or abolish the transactivation ability of the PST domain. Fitting this into the hypothesis
that the PST domain forms a specific conformation suggests that these mutations alter this
conformation. In the case of the Q422R mutation perhaps the effect of this mutation is less
severe on the conformation of the mutated PAX6 as a limited amount of transactivation is still
possible. However, the elongated proteins of 1615dell0 and X423L are sufficient to completely
alter the conformation of the PST domain and abolish transactivation ability. Therefore, if the
proteins containing this missense mutation and these run on mutations are produced then the
alteration to the conformation of the PST domain of PAX6 will mean that PAX6 cannot elicit its
normal function.
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Chapter 8 Immunoprecipitation
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8.1 Introduction.
Three novel and interesting protein interactors of PAX6 have been identified, Homer3, Dncll
and Trimll. These interactions have been confirmed using the yeast 2-hybrid system in a
pairwise manner (see Table 6.2) and it has been shown that these interactions are specifically
affected by mutating the C terminal domain of PAX6 (see Table 6.4).
The next step of my PhD was to try and confirm these interactions using another method other
than the yeast 2-hybrid system. To increase the validity of these interactions my aim was to
confirm the interactions by in vivo or in vitro co-immunoprecipitation.
8.2 In vivo co-immunoprecipitation.
In vivo co-immunoprecipitation is a purification technique, which is used to determine whether
two proteins are able to interact in cells. First the GST tagged interactor protein is expressed in
mouse lens epithelium cells (mv+, see 2.9.5) and then a specific anti-GST antibody is added to
the cell lysate (see 2.11.1). The antibody-protein complex is then pelleted using protein G
sepharose beads (see 2.11.2), which binds to the GST antibody. If native PAX6 binds to the GST
tagged interactor proteins then this will also be pelleted due to the interaction. Then
identification of the proteins in the pellet can be determined by SDS-PAGE (see 2.10.1) and
western blot (see 2.10.3).
Failing this, my next idea was to use specifically tagged interactor protein (GST tagged) and
PAX6 protein (FLAG tagged -PD isoform) to see if this could be recovered using a similar
co-immunoprecipitation technique.
8.3 Cloning interactors into pDEST27.
The GATEWAY cloning system (Invitrogen) was used to make constructs that would express
Homer3, Triml 1 and Dncll coupled to an N-terminal GST molecule. These constructs were
created in an attempt to confirm the interaction with the PAX6 protein in vivo.
DNA of the appropriate pPC86 clone was cut with Sail and Notl, and the cDNA insert was
sub-cloned into the GATEWAY entry vector pENTR3c (also cut with Sail and Notl). The LR
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Recombination Reaction was then used to transfer the appropriate pPC86 derived fragments
from the pENTR3c clones and into a GATEWAY destination vector pDEST27 (see 2.5.1).
A negative control was also generated by removing the negative selection ccdB gene from the
pENTR4 GATEWAY entry vector with an EcoKl digest. The pENTR4 vector was used to
generate this construct instead of the pENTR3c entry vector due to technical difficulties that
meant that the ccdB gene could not be removed from the pENTR3c vector. The pENTR4 vector
has a different polylinker region; otherwise it is identical to the pENTR3c vector. The LR
Recombination Reaction was then used to transfer the empty cassette from the pENTR4 clone
into the pDEST27 vector to generate the pDEST27-ccdb construct (see Table 8.1). Therefore,
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Table 8.1 pDEST27 constructs.
The pDEST27 vector produces N terminal Glutathione S-transferase (GST, red oval) fusion
proteins, which are capable of high-level expression in mammalian cells. This table shows the
various pDEST27 constructs that were created.
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When the Homer3 constructs, which are illustrated in Table 8.1, are expressed in vivo the full
length and two truncated Homer3 proteins will be attached to an N terminal GST tag via a linker
region of 12 amino acids, which is produced from the pDEST27 vector. However, the situation
for the Dncll and Trimll constructs (see Table 8.1) is different because these cDNAs contain
5'UTR as well as the protein coding region. In both cases the 5'UTR did not contain an in frame
stop codon and so the GST tagged constructs will therefore, have an elongated linker region (see
Table 8.2) between the GST tag and the encoded protein. However, it must be remembered that
these linker regions would also have been present in the yeast 2-hybrid system attaching the
Dncll and Trimll proteins to the GAL4 activation domain. Therefore, the elongated linker
regions between these proteins and the GST tag do not interrupt their interaction with PAX6.
Construct GST tag Linker Coded Protein Total kDa Size
pDEST27_Homer3_T2 224aa 12aa 285aa 521aa 57.3kDa
pDEST27_Homer3_T24 224aa 12aa 286aa 522aa 57.4kDa
pDEST27_Homer3_Full 224aa 12aa 357aa 593aa 65.2kDa
pDEST27_Triml 1_XA3 224aa 59aa 467aa 750aa 82.5kDa
pDEST27_Triml 1_A47 224aa 42aa 467aa 733aa 80.6kDa
pDEST27_Dncl 1_XT31 224aa 44aa 89aa 357aa 39.3kDa
pDEST27_Dncl 1_A62 224aa 46aa 89aa 359aa 39.5kDa
Table 8.2 Sizes of the expressed interactor protein constructs.
This table shows the sizes in amino acids (aa) and kDa of the expressed GST tagged interactor
protein constructs (see Table 8.1). The table breaks down the expressed proteins into the GST
tag, a linker region and the encoded interactor protein and gives sizes in amino acids (aa) for
each.
8.4 Cloning minus paired domain PAX6 into p3XFLAG.
In mouse and quail a PAX6 isoform has been identified that is reported to be cytoplasmic and is
lacking the paired domain (see 1.3.3). This could explain how PAX6 interacts with the 3 isolated
interactors, which are all predominantly cytoplasmic in their expression patterns. The start of the
minus paired domain (-PD) protein is in exon 8 of PAX6 at the amino acid sequence MRL
(M202, see Figure 3.1).
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The start of the -PD protein was created by PCR so that when inserted into p3XFLAG it will
form an inframe protein with an N terminal FLAG tag. The EE4 PAX6 cDNA construct was
used as the template DNA and the -PD fragment was PCR'd producing a fragment that extends
from an artificially inserted 5' Notl site and up to the Ncol site in exon 11 of PAX6 (see Figure
1.3).
The remainder of the cloning strategy included many subcloning steps. Firstly, the entire PAX6
cDNA coding region was cut out of the EE4 construct with EcoRl and cloned into pBluescript II
SK+ to create pBluescipt_EE4-RI. The pBIuescipt_EE4-RI construct was then cut with Notl and
Ncol to drop out the 5' part of the coding region including the paired domain, which was then
replaced with the confirmed -PD PCR fragment. The final step included cutting the entire
fragment that corresponds to the -PD PAX6 clone and transferring it from pBluescript into
p3XFLAG-CMV™-7.1 (Sigma) cut with Notl and EcoRI.
Construct Produced. Description. Schematic Diagram.
p3XFLAG-PD_PAX6 Minus paired domain isoform of PAX6. HD
Table 8.3 Minus paired domain PAX6 isoform.
The p3XFLAG-7.1 expression vector produces N terminal FLAG fusion proteins, which are
capable of transient intracellular expression in mammalian cells. This table shows the -PD PAX6
p3XFLAG-7.1 construct that was created, illustrated by a schematic diagram.
8.5 Controls for in vivo co-immunoprecipitation.
So that the results of the in vivo co-immunoprecipitation experiments (see 8.6) could be
accurately determined it was necessary that I include sufficient controls, which I will discuss in
this section.
An aliquot of untransfected mv+ cell lysate was always included to ascertain any cross reactivity
with the western blot antibodies. Also a sample of cell lysate from cells transfected with the
relevant pDEST27 construct was always run alongside the co-immunoprecipitation reaction to
make sure that transfection had occurred. In addition I transfected cells with the pDEST27-ccdb
construct (see Table 8.1) and used the resulting cell lysate to check that the expected 28kDa
protein was being expressed.
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To check that the electrophoretic transfer (see 2.10.2) and western blotting (see 2.10.3) was
adequate to transfer and detect the relevant proteins, I always included a GST or a PAX6 control
where applicable. As a GST control I used a commercially available 26kDa GST protein
(Sigma) and for a PAX6 control I used an aliquot of purified mv-t- protein (see 2.10.4).
Two negative controls were also always included when performing the co-immunoprecipitation
reactions. A co-immunoprecipitation reaction was carried out using the cell lysate of cells
transfected with the pDEST27-ccdb construct, which should purify only the N terminal GST tag.
I also included a co-immunoprecipitation reaction that used no cell lysate to determine any
non-specific banding caused by the co-immunoprecipitation protocol.
8.6 Results using the GST antibody.
The first thing that I needed to confirm was that the GST tagged interactor proteins (see Table
8.1) were being expressed in the mouse lens epithelium cell line (mv+). Therefore, the DNA of
each of the interactor constructs was individually transfected (see 2.9.5) into this cell line and the
resulting cell lysates analysed by SDS-PAGE (2.10.1) and western blot (2.10.3).
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Figure 8.1 Transfection and expression of GST tagged interactor constructs in vivo.
This shows the resulting bands after 2.5pg of DNA transfected into mv+ cells. lOpl samples of
lysate run on a 12% acrylamide gel. Autorad has been exposed for 5 seconds of an immunoblot
with the anti-GST antibody.
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The lysate was run out on a 12% SDS-polyacrylamide gel with appropriate size markers (see
2.10.1) and controls. The gel was then transferred onto Hybond-P membrane and western blotted
using the anti-GST primary antibody (see Table 2.9) and appropriate secondary antibody (see
Table 2.10). The 5 second autorad clearly shows each of the interacting proteins at the predicted
protein sizes (see Table 8.2). This proved that the pDEST27 interactor constructs were being
expressed in the mouse lens epithelial cells and that the cell lysis method (see 2.11.1) was
sufficient to release these expressed proteins from the cells so that they could be identified by
SDS-PAGE and western blot.
My next step was to use co-immunoprecipitation to investigate whether I could isolate the GST
tagged interactor proteins bound to the native PAX6 protein from the mv+ cell line. However,
the absence of a preclearing step (see 2.11.3) in my initial experiments meant that there was high
cross reactivity with the western blot antibodies meaning that no results could be deciphered.
Even with the inclusion of the preclearing step, although the bands corresponding to the purified
GST tagged HOMER3 protein could be seen when probed with the anti-GST antibody there was
still a smear of signal on the autorads between approximately 20-50kDa. It was discovered that
this was because too much anti-GST antibody was being used in the co-immunoprecipitation,
and this was causing cross reactivity with the western blot antibodies. By titrating the antibody
concentration used in the co-immunoprecipitation of pDEST27_HOMER3_T2 transfected cell
lysate I determined that the original 20ug concentration was far too high and that a concentration
of 0.1 pg was more appropriate (see Figure 8.2).
The autorad in Figure 8.2 clearly shows that the extent of the cross reactivity with the anti-GST
antibody light and heavy chains (23kDa and 55kDa respectively) was proportional to the amount
of antibody that was used in the co-immunoprecipitation reaction. By using a concentration of
O.lpg of anti-GST antibody in the co-immunoprecipitation reaction, this almost completely
eradicated the 55kDa heavy chain cross reactivity band when analysed by western blot.
However, even with the antibody titration there was still a protein smear between 20-30kDa,
which must be caused by cross reactivity with more than just the co-immunoprecipitation
antibody light chain.
I decided that some of the 28kDa protein G (Akerstrom et al., 1987), used to bind the Fc region
of the co-immunoprecipitation antibody, was contaminating the samples and causing this protein
smear when analysed by western blot. I attempted to minimise the transfer of the protein G
sepharose beads by spinning them 3 times after they had been boiled in 2x Laemmli sample
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buffer (see 2.11.4). Obviously this method was insufficient to completely remove the protein G
from the samples and therefore when analysed by SDS-PAGE and western blot the protein
smear persisted whether probed with the anti-GST antibody (see Figure 8.2) or the N terminal
PAX6 antibody (see Figure 8.3).
Nevertheless, it is encouraging to see that apart from the cross reactivity with the
co-immunoprecipitation antibody subunits and protein G, that the 58.2kDa GST tagged
Homer3_T2 fusion protein was purified from non-specific bands (see Figure 8.2) using this







Figure 8.2 Co-immunoprecipitation of Homer3.
mv+ cells transfected with pDEST27_Homer3_T2. 200pl of cell lysate was precleared and then
co-immunoprecipitated using 0. lpg, 0.5pg and 5ug of anti-GST antibody (see Table 2.9). Lysate
and IP samples run on a 12% acrylamide gel. Autorad has been exposed for 10 seconds of an
immunoblot with the anti-GST antibody.
Having optimised the amount of antibody that was to be used in future co-immunoprecipitations
(O.lpg anti-GST antibody), I transfected mv+ cells with either pDEST27_Homer3_T2,
pDEST27_Dncll_XT31 or pDEST27_Triml 1_XA3 and used the resulting cell lysates in
co-immunoprecipitation reactions. These samples were then prepared as before to minimise the
transfer of protein G beads and then analysed by SDS-PAGE and western blot.
X) X5
<! x> <!
v on <u <! <o ao <u
-4—» _J -+—» -4_> -4—>
a ,5- c3 00 c3 3
cn If) cn «■? — —1
58kDa Homer3
• 55kDa Ab Heavy Chain
- 30kDa protein G
- 23kDa Ab Light Chain
Page 155



















































Figure 8.3 Co-immunoprecipitation of all the interacting proteins.
mv+ cells transfected with pDEST27_Homer3_T2, pDEST27_Dncl 1_XT31 and
pDEST27_Triml 1_XA3. 200pl of cell lysate was precleared and then co-immunoprecipitated
using the anti-GST antibody at a concentrations of 0.1 pg (see Table 2.9). Lysate and IP samples
were run on 12% acrylamide gels. GST autorad exposed for 4mins and PAX6 autorad exposed
for 50mins of an immunoblot with the anti-GST antibody and PAX6 N terminal antibody
cocktail respectively. The protein G and Ab light chain smear has been removed from the GST
antibody autorad picture.
It can be seen from the top panel of Figure 8.3 that GST tagged interactor proteins could be
purified from the crude cell lysate using the anti-GST antibody. There is still some cross reaction
with other proteins including protein G and antibody light and heavy chains. Although the
protein smear between 20-30kDa was still present when western blotted using the N terminal
PAX6 antibody (see Table 2.9) the autorad picture clearly demonstrates that there is no
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interaction between the GST tagged interactor proteins and full length PAX6 using this
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Figure 8.4 Optimised co-immunoprecipitation of Homer3 and Trimll.
Co-immunoprecipitation of Homer3_T2, Homer3_T24, Homer3_Full and Trimll_XA3
transfected mv+ cells. 200|xl of cell lysate was precleared and then co-immunoprecipitated using
O.lpg of the anti-GST antibody (see Table 2.9). Lysate and IP samples run on 12% acrylamide
gels. GST autorad exposed for lmin and PAX6 autorad exposed for 5mins of an immunoblot
with the anti-GST antibody and PAX6 N terminal antibody cocktail respectively.
In previous experiments the pDEST27 constructs (see Table 8.1) were transfected into 95%
confluent mv+ cells (see 2.9.5); however, after 48hrs incubation at 37°C these cells were often
overgrown and in some cases had begun to apoptose (die) and detach from the plate. Therefore, I
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decided to transfect the cells at a lower density (50% confluent cells) with the Homer3_T2,
Homer3_T24, Homer3_Full and Triml 1_XA3 pDEST27 constructs (see Table 8.1). The normal
co-immunoprecipitation protocol was then followed and the resulting samples analysed by
SDS-PAGE and western blot (see Figure 8.4).
Although there is still some cross reactivity with the antibody heavy chain and the protein smear
between 20-30kDa is still evident, it can be clearly seen that all of the Homer3 proteins and the
Triml 1 protein are purified. However, it can be seen by looking at the western blot with the N
terminal PAX6 antibody that there is no interaction with full length PAX6.
8.7 Results with C terminal PAX6 antibody.
The co-immunoprecipitation was optimised over the previous set of experiments and using the N
terminal PAX6 antibody probing it was identified that using this system none of the GST tagged
interacting proteins, when expressed in lens epithelium cells, interacted with native full length
PAX6.
The next step of my PhD was to identify whether co-immunoprecipitation could be used to show
that these GST tagged interacting proteins would be able to interact with the minus paired
domain (-PD) isoform of PAX6, that has been demonstrated to have a cytoplasmic localisation
(see Figure 5.10) (Carriere et al., 1995; Zhang et ai, 1998). This involved performing the
co-immunoprecipitation reactions (see 2.11) on mv+ cells transfected with the GST tagged
interacting proteins and the subsequent western blot would be performed using the C terminal
PAX6 antibody (see Table 2.9) which is able to detect the -PD PAX6 isoform (see Figure 5.10).
2.5pg of each of the pDEST27 constructs Homer3_T2, Homer3_Full, Dncll_XT31 and
Triml 1_A47 (see Table 8.1) were transfected into 50% confluent mv+ cells and the resulting
cell lysate was precleared and then co-immunoprecipitated (see 2.11) using O.lpg of anti-GST
antibody. The co-immunoprecipitation samples, transfected cell lysate and relevant controls
were then analysed by SDS-PAGE and western blotting using the anti-GST antibody or the C
terminal PAX6 antibody (see Table 2.9) and the relevant secondary antibodies (see Table 2.10).
At first the co-immunoprecipitation samples were run out on a 12% SDS polyacrylamide gel
which meant that due to the recurrent protein smear between 20-30kDa that the 24kDa -PD
PAX6 band, if present in these samples, was obscured (Data not shown). Therefore, this
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experiment was repeated and the resulting samples were run out on an 18% SDS polyacrylamide
gel (Data not shown). Although this meant that the smaller sized protein bands were better
resolved on the gel, after western blot the 24kDa -PD PAX6 band was still obscured in the
middle of the protein smear between 20-28kDa, caused by the protein G and antibody light
chain.
In an attempt to minimise the transfer of protein G and avoid this protein smear the
co-immunoprecipitation reactions were repeated in mini-spin columns (Sigma). When the
co-immunoprecipitation reactions were analysed by SDS-PAGE and western blot it was seen
that the GST tagged interactor proteins were purified from the crude cell lysate (as in Figure
8.3). However, once again there was severe cross reactivity with the protein G and antibody light
chain causing a protein smear between 20-30kDa meaning that I was still unable to asses
whether there was any interaction between these GST tagged interactor proteins and the -PD
PAX6 isoform (Data not shown).
8.8 Results with FLAG tagged -PD PAX6.
I decided to perform this experiment in an attempt to confirm a specific interaction between the
3 interacting proteins (GST tagged, see Table 8.1) and the minus -PD isoform of PAX6 (FLAG
tagged, see Table 8.3). However, this experiment is highly contrived as I am over expressing 2
artificially generated fusion proteins in the lens epithelial cell line.
The FLAG tagged -PD PAX6 fusion protein can be expressed in the mouse lens epithelium cell
line and can be detected in the cell lysate by western blot using the C terminal PAX6 primary
antibody (see Figure 5.10) or the FLAG primary antibody (data not shown, see Tables 2.9 and
2.10) with the correct secondary antibodies. However, the co-immunoprecipitation reactions
using this FLAG-PD PAX6 protein were only very preliminary (data not shown) as it was
quickly identified that in these reactions the 27kDa FLAG-PD PAX6 fusion protein band would
be masked by the smear between 20-30kDa that is caused by the protein G and the antibody light
chain (smear illustrated in Figure 8.2).
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8.9 In vitro co-immunoprecipitation.
Due to the problems that were encountered as a result of performing co-immunoprecipitation in
vivo, I decided to investigate the interaction between the PST domain of PAX6 and the
interacting proteins Homer3, Dncll and Trimll using an in vitro radioactively labelled protein
co-immunoprecipitation technique (see Figure 8.5).
Figure 8.5 Overview of the BD
Matchmaker Co-IP Kit.
pDBLeu constructs (DNA-BD/bait) are
attached to a cMyc epitope tag and
pPC86 constructs (AD/Library) to a
HA epitope tag (see 2.4.6). These
constructs are then translated into 35S
radioactively labelled protein in vitro
(see 2.10.7) and the interaction between
Homer3, Dncll or Trimll with the
PAX6 PST domain is investigated
using the Matchmaker Co-IP kit (see
2.11.5).
8.10Cloning Matchmaker co-immunoprecipitation constructs.
In order to be able to use the Matchmaker co-immunoprecipitation system to re-confirm the
protein-protein interactions identified in the yeast 2-hybrid system, I needed to modify
constructs that represented: the PST domain of PAX6 (pDBLeu_ASNT_norm, see Table 4.1);
and each of the interacting proteins Homer3 (pPC86_Homer3_T2), Dncll (pPC86_Dncl 1_A62)
and Trimll (pPC86_Triml 1_A47).
The DNA of these constructs was used in touchdown PCR (see 2.4.6) with the specifically
designed primers (see Table 2.5) that will amplify the cDNA inserts as well as introduce an
upstream T7 promoter and relevant epitope tag (see Table 8.4). The PCR products generated by
the touchdown PCR were checked by running on an agarose gel (2.2.7) and then the remainder
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of the PCR was cleaned using the QIAquick PCR purification kit (see 2.2.6). However, when
visualising the pDBLeu_ASNT_norm PCR product by agarose gel electrophoresis it was
discovered that 2 differently sized PCR products were generated. This was caused by a T7
promoter in the pDBLeu vector, which meant that the forward touchdown PCR primer (ST048)
mis-primed causing the additional PCR product. Therefore, the correctly sized PCR product was
cut out and purified from the agarose gel (see 2.2.8).
These modified constructs were then translated using the TnT coupled reticulocyte lysate system
(see 2.10.7) to generate a radioactively labelled PST domain PAX6 protein with an N terminal
cMyc tag and interactor proteins with an N terminal HA tag (see Table 8.4).
Modified Construct Size (aa) kDa Size Schematic Diagrams




3I0aa 33.9kDa EVH1 Cc
148aa 16.3kDa
533aa 58.6kDa R g Cc SPRY
Table 8.4 Radioactively labelled in vitro translated proteins.
For each of the in vitro translated proteins the size in amino acids (aa) and kDa is given for the
total protein. The schematic diagrams illustrate the N terminal cMyc or HA antibody tags
(orange and green oval respectively) and the domain structure of each protein (see Table 4.1 for
PAX6 domains and Table 5.8 for interactor protein domains). The Dncll and Triml 1 proteins
are also illustrated with a linker region (34aa or 41aa respectively) due to the translation of the
5'UTR included in these constructs.
8.11 in vitro Matchmaker co-immunoprecipitation.
The 35S radioactively labelled proteins were then used in the matchmaker co-IP kit (see 2.11.5)
along with the cMyc tagged murine p53 and HA tagged SV40 large T antigen positive controls,
to investigate in vitro protein-protein interactions (see Figure 8.6).
Page 161
PAX6 protein-protein interactions Immunoprecipi tation
Page 162
PAX6 protein-protein interactions Immunoprecipitation
The modified PCR products are successfully translated into the predicted antibody tagged
proteins (see Table 8.4) and the cMyc labelled PST domain of PAX6 and the HA labelled
interactor proteins can be successfully purified using the corresponding antibody (cMyc and HA
respectively) in the co-immunoprecipitation technique (see Figure 8.6).
To check whether there was any cross reactivity, negative controls were performed in which the
cMyc tagged PST domain protein was incubated with the HA antibody and the HA tagged
interactor proteins were incubated with the cMyc antibody to investigate if these non functional
co-immunoprecipitation reactions resulted in the purification of the incubated protein. Each of
the HA tagged interacting proteins are not purified with the cMyc antibody. However, it can be
seen that the cMyc tagged PAX6 protein (PST) always cross reacts with the HA antibody (see
Figure 8.6).
Therefore, when the cMyc tagged PAX6 protein (PST) is mixed with each of the HA tagged
interacting proteins and co-immunoprecipitated with the HA antibody it is unsurprising that the
result resembles a confirmed interaction. However, due to the cross reactivity of the cMyc
tagged PAX6 protein (PST) with the HA antibody it is presumably not a true interaction. This is
backed up by the result of incubating the mixed proteins with the cMyc antibody as none of the
interactions between the cMyc tagged PAX6 protein (PST) and the HA tagged interacting
proteins are re-confirmed (see Figure 8.6).
The strong interaction of the tumour suppressor protein p53 with the SV40 large T antigen
(D'Orazi et al., 2002) is used as a positive control in the matchmaker co-immunoprecipitation
(see 2.11.5). The cMyc tagged p53 protein can be purified using the cMyc antibody and the HA
tagged large T antigen can be purified using the HA antibody. However, when the p53 and T
antigen are incubated with the antibody that does not correspond to the proteins epitope tag, it
can be seen that there is cross reactivity and weakly purified p53 and T antigen bands are present
(see Figure 8.6). This therefore casts doubt as to the validity of the positive interaction seen
when the p53 and T antigen proteins are mixed and co-immunoprecipitated with either the cMyc
or HA antibody (see Figure 8.6).
This in vitro co-immunoprecipitation technique does not re-confirm the interactions between the
PST domain of PAX6 and the interacting proteins Homer3, Dncl 1 and Trim 11 as was hoped. A
possible explanation for why could be that these interactions are not strong enough to be
identified by this technique, unlike the strong interaction between the p53 protein and the SV40
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large T antigen, which is used as a positive control (D'Orazi et al., 2002). Furthermore, the
validity of this technique is questionable due to the cross reactivity that occurs in the positive
control. Even the confirmation of the known interaction of p53 and the large T antigen is
problematic using this technique. However, insufficient time meant that I could not investigate
this technique further in an attempt to resolve these problems and confirm possible interactions
between PAX6 and Homer3, Dncl 1 or Triml 1.
8.12 Future Studies.
The in vivo co-immunoprecipitation has illustrated that the interacting proteins Homer3, Dncll
and Triml 1 do not interact with full length PAX6 using this system. Due to technical difficulties
that have already been described in this chapter, it was not possible to determine whether the 3
interacting proteins interact with a minus paired domain isoform of PAX6 in vivo or with the
PST domain of PAX6 in vitro. One way to overcome this problem in vivo would be to increase
the size of the translated tagged -PD PAX6 fusion protein by adding a larger tag than the FLAG
tag (see 8.4). Therefore, if isolated by co-immunoprecipitation the resulting band of the -PD
PAX6 fusion protein would be larger than the smear between 20-30kDa caused by the cross
reactivity of the protein G and antibody light chain with the western blot antibodies.
8.12.1 Matrix assisted laser desorption/ionisation (MALDI) technique.
The MALDI technique utilises a mass spectrometer (MS) to identify unknown proteins by
peptide mass fingerprinting. This technique can be used to investigate the identity of the proteins
between 20-30kDa that correspond to the protein smear seen when a co-immunoprecipitation
reaction is run out on an SDS polyacrylamide gel and western blotted. It will then be possible to
determine whether this protein smear contains not only the protein G and antibody light chain
contaminants but also the -PD PAX6 isoform isolated due to its interaction with the GST tagged
interactor protein in the co-immunoprecipitation reaction.
8.12.2 Ciphergen's SELDI ProteinChip System.
Another future experiment involves using the SELDI ProteinChip system (Ciphergen, http://
www.ciphergen.com/). As for a normal co-immunoprecipitation the mv+ cell line would be
transfected with the relevant GST tagged interactor protein. However, instead of performing the
co-immunoprecipitation as described in section 2.11.4 the anti-GST antibody would be
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covalently coupled to a pre-activated surface of a ProteinChip array. Then the transfected cell
lysate would be applied directly to this ProteinChip array and unbound proteins washed off after
a short incubation time to allow interaction of the GST tagged proteins with the coupled
antibody. The ProteinChip array would then be analysed using a mass spectrometer and this will
hopefully detect not only the antibody and purified GST tagged protein, but also a PAX6 protein
isoform. Therefore, this is another possible technique to confirm the interaction of Homer3,
Dncl 1 and Trim 11 with PAX6.
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9.1 Discussion.
PAX6 is known to be a developmental transcription factor that is specifically involved in
controlling a series of crucial steps in eye development, but has also been shown to be involved
in the correct patterning of the brain, including cortical patterning (Bishop et al., 2000), cortical
neurogenesis (Heins et al., 2002), specification of neuronal subtypes (Takahashi and Osumi,
2002), and axon guidance (Mastick et al., 1997).
I have shown in Chapter 3 that the final 32 amino acids of the PAX6 PST domain are distinct
from the rest of the PST domain in having a highly conserved amino acid sequence and a
specific secondary structure. I have therefore, classified this region as a separate domain, the C
terminal domain. At the time of undertaking this work I was unaware that similar
characterisation had already been performed (Mikkola et al., 1999). However, it is reassuring
that the same region has already been described and the same secondary structure predicted
although this is the first time that this region has been specifically described as a separate
domain. The question that needed to be addressed in light of the description of this evolutionary
conserved C terminal domain was "Does the C terminal domain of PAX6 have a specific
function?"
This question led to the discovery that the PST domain of PAX6 interacts with three proteins
Homer3, Dncll and Triml 1, as determined by yeast 2-hybrid screening of a mouse brain cDNA
library, and this is the first report of an interaction between the PST domain of PAX6 and other
proteins. More intriguing is the fact that two of these interactions (with Homer3 and Dncll) are
specifically dependent on the newly characterised C terminal domain of PAX6.
This has been the first systematic screen for proteins that interact with PAX6. Although protein
interactions with the PAX family of transcription factors have been found, including several
interactions between Pax and Sox proteins, these have not been uncovered by systematic library
screens. As there seems to be a possible functional link between the PAX and SOX protein
families (Chi and Epstein, 2002), then it is possible that there could be a link between PAX
proteins and either the HOMER or TRIM protein families or subunits of the dynein motor
complex. Therefore, these interactions may influence the regulation and distribution of these
transcription factors in development and mutation may result in human disease caused by an
inability of these proteins to carry out their normal functions.
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It is interesting to hypothesise about a possible reason for the interaction between Homer3,
Dncll, Trimll and PAX6. In the sections that follow (9.1.1 to 9.3) for the sake of simplicity I
will use generic lower case gene and protein names, even when I am referring to the human gene
or protein.
9.1.1 Trim11.
The function of Triml 1 is still unclear although it is possible that it may regulate the expression
of Pax6 either by specific ubiquitin-mediated degradation of the protein due to Trimll
association (Niikura et al., 2003) or by correctly positioning Pax6 in a macromolecular complex
(Borden, 2000) so that it functions normally. As the PST domain of Pax6 is involved in the
transactivational role of Pax6 then it is possible that Trimll, due to its interaction around the
SYSC motif in Pax6 (green box, see Figure 3.1), allows the correct positioning of the
components of the transcriptional machinery, allowing Pax6 to execute its normal function.
However, due to the prior link of the Triml 1 proteins with ubiquitination (Niikura et al., 2003)
then it is more likely that the interaction of Triml 1 with Pax6 could potentially interfere with its
transcriptional activity and couple the Pax6 protein to ubiquitin degradation pathways. In this
way the levels of Pax6 could be regulated by Triml 1 in the brain.
9.1.2 Dncll.
Dncll has been shown to be a component of microtubule (King et al., 1996) and actin
(Espindola et al., 2000) based molecular motors and is thought to be involved in the coupling of
proteins to these motors and their subsequent movement around the cell. This is very important
when considering the interaction between Dncll and Pax6 as it suggests a mechanism of how
Pax6 is translocated throughout the cell. Dncll has also been shown to bind to nNOS
(Rodriguez-Crespo et al., 1998) and GKAP (Rodriguez-Crespo et al., 2001) and it is thought
that Dncll, due to its association with cytoplasmic dynein, is involved in axonal transport of
these proteins. Interestingly, the post-synaptic density has been shown to include both these
proteins coupled to NMDA receptors through the PSD-95 scaffolding protein and so it is likely
that both nNOS and GKAP are transported between the PSD and the nucleus via the dynein
molecule, due to their interaction with Dncll. This is fascinating as it is possible that Dncll
specifically functions to transport Pax6 from a PSD location to the nucleus in developing
neurons.
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Lissencephaly causes severe brain defects due to problems in neuronal migration that produce
brains lacking the normal convoluted surface (Vallee et al., 2001). Although the most common
phenotype of these syndromes is the severe brain defect that results in mental retardation and
normally early death caused by uncontrollable seizures (Vallee et al., 2001), there are also
related eye defects that occur in type II lissencephaly. However, at present it is only
lissencephaly type I that is thought to result from mutations in the LIS1 gene, which cause
haploinsufficiency (Vallee et al., 2001). The LIS1 protein is known to interact with the
cytoplasmic dynein motor protein and it is thought that the brain defects seen in lissencephaly
might be caused by a malfunctioning of dynein regulation (Vallee et al., 2001). Therefore, it is
interesting to hypothesise that other dynein-interacting proteins may also be involved in brain
patterning and neuronal migration, and that mutant forms of these interactors (such as the Pax6
mutants described in 1.7.6) may cause specific brain defects.
Dncll mutations in Drosophila are lethal but are characterised by severe neuronal defects, which
has led to the suggestion that Dncll may be involved in axon formation (Jacob et al., 2000). It is
therefore interesting to consider that the interaction between Dncll and Pax6 may facilitate the
transport of Pax6 from the PSD to the nucleus in order to activate gene expression (Herzig et al.,
2000). Therefore, due to the mutation of Dncll, the function of Pax6 in neuronal development
will be undirected, possibly contributing to these severe neuronal defects of axon formation in
Drosophila Dncll mutants. However, it must be remembered that it is not surprising that the
Drosophila Dncll mutants cause severe neuronal defects as Dncll has been implicated in the
transport of many post-synaptic proteins which link post-synaptic receptors to intracellular
signaling cascades.
Although the characterisation of 2 potential Dncll binding regions in Pax6 was based on very
weak regions of homology with other identified Dncl 1 binding sites (see 5.6.2) it was intriguing
to consider this when analysing the results of the yeast 2-hybrid pairwise results. It can be seen
that the entire PST domain interacts with Dncll; however, the SYSC truncated peptide does not
interact with Dncll (see Table 6.2). Although the interaction between Dncll and the C terminal
domain could not be replicated, when the C terminal domain was removed from the entire PST
domain construct then there was again no interaction with Dncl 1.1 have already explained how I
think the conformation of the entire PST domain is important in carrying out its transaclivalion
function (see 7.3) and in interacting with other proteins. It is possible that this correct
conformation means that these 2 Dncl 1 binding regions are correctly positioned so that Dncl 1
and Pax6 can interact.
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It is intriguing to consider that an interaction also occurs between Dncll and the PST domain of
other PAX proteins, and could potentially provide a mechanism for their cellular distribution.
Therefore, mutations in the PST domain of PAX proteins that alter the Dncll binding sites
would cause these proteins to be incorrectly distributed within the cell, which may provide an
explanation for developmental defects or human disease.
9.1.3 Homer3.
Homer3 is located within the postsynaptic density (PSD) (Dick et al., 1996; Xiao et al., 1998)
and regulates the metabotropic glutamate receptors mGluRl and mGluR5 (Sheng and Kim,
2002) by binding to a proline rich motif in the C terminal tail of the receptors (Tu et al., 1998). It
has also been shown that Homer3 is central in producing a scaffold that can potentially link these
type-I mGluRs to the endoplasmic reticulum through IP3Rs and RyRs and has also been shown
to be involved in linking mGluRs with NMDA receptors due to a large complex involving
Homer3, Shank, PSD-95 and GKAP. To date there has only been one reported interaction with
the coiled coil domain of Homer3, other than with other Homer family members to facilitate
multimerisation, and this was with S8 ATPase, a protein proposed to be involved in Homer3
mediated degradation of mGluRs (Rezvani et al., 2003). When dissociated from the Homer3
scaffolding complex it was found that S8 ATPase translocated to the nucleus (Rezvani et al.,
2003). Therefore, it is interesting to speculate that Pax6 could be sequestered in the PSD due to
its interaction with Homer3 and then transported to the nucleus via its interaction with Dncll.
Activation of NMDA receptors stimulates mitogen-activated protein kinase (MAPK), which is
known to phoshphorylate Pax6 (Mikkola et al., 1999). Therefore, it is interesting to envisage a
situation where synaptic activation leads to the stimulation of the NMDA receptor which in turn
activates MAPK. As Pax6 is sequestered in the PSD due to its interaction with Homer3, then it is
feasible that the activated MAPK could phosphorylate Pax6, producing a modified protein that
has an increased transcription activity. As it is probable that synaptic activation would also cause
the upregulation of Homer la, a Homer protein that antagonises the scaffolding function of
Homer3, then the activated Pax6 could be released from the PSD and be transported to the
nucleus, due to its interaction with Dncll. The activated Pax6 could then be transported to sites
of active gene expression in the nucleus to allow transcription of Pax6 target genes. In this way it
is possible that the resulting transcriptional activation may be involved in the development of
proper synaptic connections, spine morphogenesis or neuronal migration in the developing brain.
In the adult brain it is possible that this same signalling cascade could be involved in maintaining
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normal synaptic function or in the production of long term potentiation, which is thought to be
involved in learning and memory.
Further evidence to back up this hypothesis comes from the investigation of Pax6 mutant rats,
which led the authors to suggest that Pax6 functions to regulate the cytoskeletal organisation
during polarisation and migration of CNS neurons (Yamasaki et al., 2001). In wild-type rats
Pax6 mRNA and protein are both expressed throughout differentiation and migration of
cerebellar granule cells in these cells (Yamasaki et al., 2001). Although Pax6 is not expressed in
mutant cells it was shown that the gene cascade required for granule cell differentiation was still
produced (Yamasaki et al., 2001). It was also shown that it was specifically the inability of Pax6
to carry out its gene expression function in the nucleus that causes problems in neuron migration
and cellular morphogenesis due to abnormal polarisation of the cerebellar granule cells.
Therefore, it was hypothesised that Pax6 acts as an intrinsic upstream factor that stimulates
downstream target genes involved in the elongation of bipolar axons and their orderly migration
in the developing brain (Yamasaki et al., 2001).
Specifically, it has been suggested that Pax6 could potentially be involved in the control of the
cytoskeletal networks during the polarisation of neural cells in the CNS and the role of Pax6
might be to activate gene expression of target genes that are involved in the organisation of
cytoskeletal proteins in granule cells (Yamasaki et al., 2001). It has been suggested that Pax6
might potentially be involved in sustaining the formation of bipolar processes in tangential
migration of the cerebellar granule cells, which arc guided, by the leading processes that contact
the axon fibres that have already formed (Yamasaki et al., 2001).
Therefore, it is possible that although these mutant rats seem to have the correct gene cascade
required for granule cell differentiation but are lacking Pax6, then perhaps the inability to
activate Pax6 dependent gene expression due to stimulation by extracellular cues in the
developing neurons, leads to the reported inability to reorganise the cytoskeleton and the
enlarged growth cones (Yamasaki et al., 2001). This report represented the first description of
how Pax6 functions in regulating neuronal morphogenesis and migration by altering the
cytoskeletal network (Yamasaki et al., 2001); however, I have now provided an additional link
to this hypothesis that suggests that the activation of this Pax6 mediated genetic cascade is
caused by extracellular cues, relayed through cell surface receptors.
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This function of Pax6 in the regulation of neurite outgrowth and cell migration has also been
proposed to be further regulated due to the inhibitory effects caused by the binding of a piotein
called mDia to Pax6 (Tominaga et al., 2002). Therefore, this shows how the stimulation of
neuronal cells can cause the activation of gene cascades that allow proper neuronal migration
and alteration of cellular morphogenesis and how this has to be negatively regulated so that the
cytoskeleton can be re-organised.
Due to this possible role of Pax6 in regulating the cytoskeletal network it is therefore interesting
to consider the lethal mouse mutant, dilute, which is characterised by a convulsive neurological
disorder (Petralia et al., 2001). These mice are lacking the myosin-Va transport protein, involved
in the organisation of the cytoskeleton, which has been tentatively suggested to be a potential
downstream target of Pax6 mediated gene activation (Petralia et al., 2001). In these mice it is
thought that the convulsive disorder is due to the lack of recruitment of IP3R laden endoplasmic
reticulum into the dendritic spines even though the distribution of mGluRs, Homer and Dncl 1 is
not affected (Petralia et al., 2001). This suggests that there is no calcium release from these
dendritic spines which is thought to affect the long term depression of these synapses leading to
the convulsive disorders (Petralia et al., 2001).
A specific aniridia patient that has the C terminal Pax6 mutation X423L, was also found to have
polymicrogyria, a rare brain defect thought to be caused by disruption of neuronal migration
(Mitchell et al., 2003), and suffered from epilepsy. It is interesting to assume that in this patient
the Pax6 mutation is sufficient to dysregulate the normal Pax6 mediated signalling cascade, due
to the inability of the mutant protein to interact with Homer3 and Dncll (see Table 6.4). This
would mean that due to the failure of Pax6 to activate gene expression that the production of
cytoskeletal organisation proteins such as myosin-Va could be reduced or abolished. Therefore,
the lack of myosin-Va could potentially explain the phenotype of epilepsy and seizures that is
found in this patient. Alternatively, the epileptic phenotype could be an associated phenotype
that is specifically caused by the improper neuronal patterning of the brain that results in the
polymicrogyria in this patient.
Although the research by Yamasaki et al., (2001) was focused on cerebellar granule cells it was
suggested that the regulation of migration by Pax6 may also involve other neuronal cells that
utilise leading processes in migration in the cerebellar system (Yamasaki et al., 2001). This fits
nicely with similar findings in Pax6 null mice, where late born cortical neurons show errors in
migration and accumulate to create an expanded ventricular zone (Mastick et al., 1997).
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Therefore, this inability of neurons that lack Pax6 to migrate could explain why there is no
innervation between the thalamus and the cortex in Pax6 null mice.
A similar problem in neuronal migration and incorrect neuronal connections due to the inability
of Pax6 to interact with Homer3 and/or Dncll could potentially explain the brain associated
phenotypes of aniridia patients with C terminal domain Pax6 mutations such as 1615dell0
(WHEDA) or the X423L mutation. The 1615dell0 mutation is associated with a
neurobehavioural phenotype (Heyman et al., 1999) and the X423L mutation has been associated
with a defect in olfactory function in one patient (Sisodiya et al., 2001) and polymicrogyria in 2
patients (Mitchell et al., 2003). Therefore, it is possible that all of these brain anomalies could be
caused by incorrect neuronal patterning or connections caused by the defect in the Pax6
mediated gene activation involved in neuronal migration and morphogenesis.
Although the above discussion focuses on the role of Pax6 and the isolated interactors in the
developing brain, there is still a connection to the eye. It has been shown that specific expression
of Pax6 is required for the correct direction of axons from the retina to the superior colliculus,
which mediates ocular functions (Baumer et al., 2002). Therefore, the combination of Pax6,
Homer3 and Dncll may influence the connection of the neuroretina to discrete regions of the
visual centres of the brain due to the combined function in regulating neuronal migration. In
addition, expression of Pax6 in the developing neuroretina is important for normal patterning
within the developing eye (Baumer et al., 2002). If the C terminal domain is mutated and the
normal interaction with Homer3 and Dncll is disrupted then normal patterning of the eye and
the visual centres of the brain may also be altered.
9.2 Interesting future studies.
Using the yeast 2-hybrid pairwise screens I showed that full length Pax6 (-5a Pax6 isoform) was
unable to interact with the three interacting proteins (see Table 6.2) or transactivate reporter gene
expression (data not shown). This could potentially be due to a conformational change caused by
the attachment of the large N terminal GAL4 DNA binding domain. Alternatively, the inclusion
of the DNA binding domains of Pax6 could themselves introduce a direct negative effect, as
already shown with inclusion of the homeodomain of Pax6 in transactivation potential
experiments resulting in the inhibition of the transactivation ability of fusion proteins (Tang et
al., 1998; Mikkola et al., 1999). It was proposed that this direct negative effect of the DNA
binding domains could be caused by interfering with the transactivation ability of the PST
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domain or by directing the protein to bind to other yeast chromosomal regions other than the
GAL4 promoter site (Mikkola et al., 1999).
However, it was also determined that Homer3, Dncll and Triml 1 do not interact with full length
Pax6 isoforms in lens epithelial cells, by means of in vivo co-immunoprecipitation. Therefore, it
is possible that these three proteins interact with the predominantly cytoplasmic -PD Pax6
isoform and it will be interesting to determine whether an interaction between this Pax6 isoform
and the 3 interactors can be confirmed using the yeast 2-hybrid system, although similar
technical problems as experienced with full length Pax6 may occur.
Following on from this, obviously the highest priority for future studies will be to positively
confirm an interaction between Pax6 and these three interactors Homer3, Dncll and Triml 1 in
vivo. I have already mentioned in Chapter 8 that one possible addition to the experiments that I
have already performed would be to increase the overall size of the -PD Pax6 fusion protein so
that co-transfection studies will avoid the problem of cross reactivity of the protein G and
antibody light chain with the western blot antibodies.
It is appealing to think that the -PD Pax6 isoform might have a specific function in neuronal
cells due to a possible interaction with Homer3, Dncll or Triml 1. It has already been shown in
Caenorhabditis elegans that only the ortholog of the -PD Pax6 isoform is expressed in ray cells
of the male tail and neurons in the preanal ganglion and during development this isoform
translocates from the cytoplasm to the nucleus possibly due to lineage specific or spatial cues
during differentiation of these cells (Zhang et al., 1998). Therefore, it is possible that if the -PD
Pax6 isoform does interact with Homer3 and Dncll then it may be that this specific isoform is
sequestered in the post-synaptic density until dissociation of the scaffolding network allows
transport to the nucleus via Dncll. A novel function of the -PD Pax6 isoform may be to cause
changes in gene expression related to synaptic development and activation, possibly indicating a
role in learning and memory.
I think it would also be worthwhile to investigate the in vivo co-immunoprecipitation of Pax6
and the three interacting proteins in various cell types including specific cell lines derived from
neural tissues such as the retina and the brain. The subcellular localisation of Pax6 isoforms has
already been proposed to be variable between cell types and so these experiments could be used
to specifically ascertain whether this hypothesis is true and if this affects the results of in vivo
co-immunoprecipitation.
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I think it is evident from the transactivation studies that a specific conformation is required for
Pax6 to produce its transactivation ability and that the C terminal domain is pivotal in producing
this structure. It is interesting to think that this interaction is not only important for the
transactivation ability of Pax6 but also that this same conformation could potentially be required
for the interaction of the PST domain with the three interacting proteins (see 7.3) and that both
transactivation and interaction with these interactors is altered by C terminal domain Pax6
mutations. Therefore, on confirmation of the interaction between these proteins and Pax6,
another potentially interesting follow up experiment would be to further characterise the region
within Pax6 that is responsible for its interaction with these proteins. This could be carried out
by utilising deletion analysis and site directed mutagenesis to determine the important amino
acids within the C terminal domain of Pax6 for the formation of the interaction complex.
Having investigated the literature on Homer3, I have found that it shows a punctate expression
pattern along developing neurons (Xiao et al., 1998; Diagana et al., 2002; Shiraishi et al., 2003).
It would therefore be interesting to perform fluorescent localisation studies in neuronal cells to
see if this characteristic punctate pattern of Homer3 is reproduced by Pax6. It would also be
interesting to confirm that Pax6 does indeed localise to the post synaptic density in neurons and
to further investigate which isoform of Pax6 localises to this region with Homer3.
It would also be interesting to see whether it is possible to observe the co-expression of Dncll
and Pax6 in developing neurons and to determine whether stimulation of neurons causes a
translocation of Pax6 from the PSD to the cell nucleus to confirm my hypothesis of the
functional significance of this interaction.
A possible interaction between Dncll and Homer3 is implied by the observation of a punctate
pattern of expression of Dncll in dendritic shafts (Naisbitt et al., 2000), which is similar to that
of Homer3 (Xiao et al., 1998; Diagana et al., 2002; Shiraishi et al., 2003). Furthermore, Dncll
has been reported to interact with other PDZ containing proteins such as GKAP and nNOS that
are localised within the PSD. Therefore, it would be interesting to see if there was an interaction
between Dncl 1 and Homer3 and determine whether Homer3 is transported between the PSD and
the nucleus due to its interaction with Dncll.
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9.3 Concluding remarks.
In conclusion, although speculative at present, it is exciting to think that the interaction of these
three proteins with the PST domain of Pax6 represents the first functionally significant protein
interactions with this region of Pax6. The importance of the C terminal domain of Pax6 in some
of these interactions justifies its description as a separate domain, which is involved in producing
a specific conformation. The function of Pax6 in combination with the isolated interactors has
been hypothesised to provide a model of how a neuron can change its pattern of gene expression
in response to receptor stimuli. Through these interactors Pax6 may regulate aspects of neuronal
development such as axon guidance and could also have a role in learning and memory.
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